AMENDMENT NO. _________ Calendar No. _______

Purpose: In the nature of a substitute.


S. 3799

To prepare for, and respond to, existing viruses, emerging new threats, and pandemics.

Referred to the Committee on ______________ and ordered to be printed

Ordered to lie on the table and to be printed

AMENDMENT IN THE NATURE OF A SUBSTITUTE intended to be proposed by ____________

Viz:

1 Strike all after the enacting clause and insert the following:

2  

SECTION 1. SHORT TITLE; TABLE OF CONTENTS.

(a) SHORT TITLE.—This Act may be cited as the “Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics Act” or the “PREVENT Pandemics Act”.

(b) TABLE OF CONTENTS.—The table of contents for this Act is as follows:

Sec. 1. Short title; table of contents.

TITLE I—STRENGTHENING FEDERAL AND STATE PREPAREDNESS

Subtitle A—Federal Leadership and Accountability
Sec. 102. Appointment and authority of the Director of the Centers for Disease Control and Prevention.
Sec. 103. Additional provisions related to the Centers for Disease Control and Prevention.
Sec. 104. Advisory Committee to the Director of the Centers for Disease Control and Prevention.
Sec. 105. Public health and medical preparedness and response coordination.
Sec. 106. Strengthening public health communication.
Sec. 107. Office of Pandemic Preparedness and Response Policy.

Subtitle B—State and Local Readiness

Sec. 111. Improving State and local public health security.
Sec. 112. Supporting access to mental health and substance use disorder services during public health emergencies.
Sec. 113. Trauma care reauthorization.
Sec. 114. Assessment of containment and mitigation of infectious diseases.
Sec. 115. Consideration of unique challenges in noncontiguous States and territories.

TITLE II—IMPROVING PUBLIC HEALTH PREPAREDNESS AND RESPONSE CAPACITY

Subtitle A—Addressing Disparities and Improving Public Health Emergency Responses

Sec. 201. Addressing social determinants of health and improving health outcomes.

Subtitle B—Improving Public Health Data

Sec. 211. Modernizing biosurveillance capabilities and infectious disease data collection.
Sec. 212. Genomic sequencing, analytics, and public health surveillance of pathogens.
Sec. 213. Supporting public health data availability and access.
Sec. 214. Epidemic forecasting and outbreak analytics.
Sec. 215. Public health data transparency.
Sec. 216. GAO report on public health preparedness, response, and recovery data capabilities.

Subtitle C—Revitalizing the Public Health Workforce

Sec. 221. Improving recruitment and retention of the frontline public health workforce.
Sec. 222. Awards to support community health workers and community health.
Sec. 223. Improving public health emergency response capacity.
Sec. 224. Extension of authorities to support health professional volunteers at community health centers.
Sec. 225. Increasing educational opportunities for allied health professions.
Sec. 226. Public Health Service Corps annual and sick leave.
Sec. 227. Assessing barriers to additional training.
Sec. 228. Leadership exchange pilot for public health and medical preparedness and response positions at the Department of Health and Human Services.
Subtitle D—Improving Public Health Responses

Sec. 231. Centers for public health preparedness and response.
Sec. 232. Vaccine distribution plans.
Sec. 233. Coordination and collaboration regarding blood supply.
Sec. 234. Supporting laboratory capacity and international collaboration to address antimicrobial resistance.
Sec. 235. One Health framework.
Sec. 236. Supporting children during public health emergencies.

TITLE III—ACCELERATING RESEARCH AND COUNTERMEASURE DISCOVERY

Subtitle A—Fostering Research and Development and Improving Coordination

Sec. 301. Research and activities related to long-term health effects of SARS–CoV–2 infection.
Sec. 302. Research centers for pathogens of pandemic concern.
Sec. 303. Improving medical countermeasure research coordination.
Sec. 304. Accessing specimen samples and diagnostic tests.

Subtitle B—Improving Biosafety and Biosecurity

Sec. 311. Improving control and oversight of select biological agents and toxins.
Sec. 312. Strategy for Federal high-containment laboratories.
Sec. 313. National Science Advisory Board for Biosecurity.
Sec. 314. Research to improve biosafety.
Sec. 315. Federally-funded research with enhanced pathogens of pandemic potential.

Subtitle C—Preventing Undue Foreign Influence in Biomedical Research

Sec. 321. Foreign talent programs.
Sec. 322. Securing identifiable, sensitive information and addressing other national security risks related to research.
Sec. 323. Duties of the Director.
Sec. 324. Protecting America’s biomedical research enterprise.
Sec. 325. GAO Study.
Sec. 326. Report on progress to address undue foreign influence.

Subtitle D—Advanced Research Projects Authority for Health

Sec. 331. Advanced Research Projects Authority for Health.

TITLE IV—MODERNIZING AND STRENGTHENING THE SUPPLY CHAIN FOR VITAL MEDICAL PRODUCTS

Sec. 401. Warm base manufacturing capacity for medical countermeasures.
Sec. 402. Supply chain considerations for the Strategic National Stockpile.
Sec. 403. Strategic National Stockpile equipment maintenance.
Sec. 404. Improving transparency and predictability of processes of the Strategic National Stockpile.
Sec. 405. Improving supply chain flexibility for the Strategic National Stockpile.
Sec. 406. Reimbursement for certain supplies.
Sec. 407. Action reporting on stockpile depletion.
Sec. 408. Provision of medical countermeasures to Indian programs and facilities.
Sec. 409. Grants for State strategic stockpiles.
Sec. 410. Study on incentives for domestic production of generic medicines.

TITLE V—ENHANCING DEVELOPMENT AND COMBATING SHORTAGES OF MEDICAL PRODUCTS

Subtitle A—Development and Review

Sec. 501. Advancing qualified infectious disease product innovation.
Sec. 502. Modernizing clinical trials.
Sec. 503. Accelerating countermeasure development and review.
Sec. 504. Third party test evaluation during emergencies.
Sec. 505. Facilitating the use of real world evidence.
Sec. 506. Platform technologies.
Sec. 507. Increasing EUA decision transparency.
Sec. 508. Improving FDA guidance and communication.
Sec. 509. GAO study and report on hiring challenges at FDA.

Subtitle B—Mitigating Shortages

Sec. 511. Ensuring registration of foreign drug and device manufacturers.
Sec. 512. Extending expiration dates for certain drugs.
Sec. 513. Unannounced foreign facility inspections pilot program.
Sec. 514. Combating counterfeit devices.
Sec. 515. Strengthening medical device supply chains.
Sec. 516. Preventing medical device shortages.
Sec. 517. Remote records assessments for medical devices.
Sec. 518. Advanced manufacturing technologies designation pilot program.
Sec. 519. Technical corrections.

1 TITLE I—STRENGTHENING FEDERAL AND STATE PREPAREDNESS

Subtitle A—Federal Leadership and Accountability

SEC. 101. COMPREHENSIVE REVIEW OF THE COVID–19 RESPONSE.

(a) ESTABLISHMENT OF TASK FORCE.—There is established in the legislative branch a task force to be known as the “National Task Force on the Response of the
(b) PURPOSES.—The purposes of the Task Force are to—

(1) examine, assess, and report upon the United States’ preparedness for, and response to, the COVID–19 pandemic, including—

(A) the initial Federal, State, local, and territorial responses in the United States;

(B) the ongoing Federal, State, local, and territorial responses in the United States, including the activities, policies, and decisions of the Trump Administration and the Biden Administration;

(C) the impact of the pandemic on public health and health care systems; and

(D) the initial outbreak in Wuhan, China, including efforts to determine the potential causes for the emergence of the SARS–CoV–2 virus, and Federal actions to mitigate its spread internationally;

(2) build upon existing or ongoing evaluations and avoid unnecessary duplication, by reviewing the findings, conclusions, and recommendations of other appropriate task forces, committees, commissions, or
entities established by other public or nonprofit private entities related to the United States’ preparedness for, and response to, the COVID–19 pandemic;

(3) identify gaps in public health preparedness and medical response policies, processes, and activities, including disparities in COVID–19 infection and mortality rates among people of color, older adults, people with disabilities, and other vulnerable or at-risk groups, and how such gaps impacted the ability of the United States to respond to the COVID–19 pandemic; and

(4) submit a report to the President and to Congress on its findings, conclusions, and recommendations to improve the United States’ preparedness for, and response to, future public health emergencies, including a public health emergency resulting from an emerging infectious disease.

(c) COMPOSITION OF TASK FORCE; MEETINGS.—

(1) MEMBERS.—The Task Force shall be composed of 12 members, of whom—

(A) 1 member shall be appointed by the majority leader of the Senate;

(B) 1 member shall be appointed by the minority leader of the Senate;
(C) 2 members shall be appointed by the chair of the Committee on Health, Education, Labor, and Pensions of the Senate;

(D) 2 members shall be appointed by the ranking member of the Committee on Health, Education, Labor, and Pensions of the Senate;

(E) 1 member shall be appointed by the Speaker of the House of Representatives;

(F) 1 member shall be appointed by the minority leader of the House of Representatives;

(G) 2 members shall be appointed by the chair of the Committee on Energy and Commerce of the House of Representatives; and

(H) 2 members shall be appointed by the ranking member of the Committee on Energy and Commerce of the House of Representatives.

(2) CHAIR AND VICE CHAIR.—Not later than 30 days after the date on which all members of the Task Force are appointed under paragraph (1), such members shall meet to elect a Chair and Vice Chair from among such members. The Chair and Vice Chair shall each be elected to serve upon an affirmative vote from 8 members of the Task Force. The
Chair and Vice Chair shall not be registered members of the same political party.

(3) QUALIFICATIONS.—

(A) Political party affiliation.—Not more than 6 members of the Task Force shall be registered members of the same political party.

(B) Nongovernmental appointees.—An individual appointed to the Task Force may not be an officer or employee of the Federal Government or any State, local, Tribal, or territorial government.

(C) Qualifications.—It is the sense of Congress that individuals appointed to the Task Force should be highly qualified citizens of the United States. Members appointed under paragraph (1) may include individuals with expertise in—

(i) public health, health disparities and at-risk populations, medicine, and related fields;

(ii) State, local, Tribal, or territorial government, including public health and medical preparedness and response and emergency management, workplace health
and safety, and other relevant public administration;

(iii) research regarding, or the development, manufacturing, distribution, and regulation of, medical products;

(iv) national security and foreign relations, including global health; and

(v) commerce, including transportation, supply chains, and small business.

(4) **DEADLINE FOR APPOINTMENT.**—All members of the Task Force shall be appointed not later than 90 days after the date of enactment of this Act.

(5) **MEETINGS.**—The Task Force shall meet and begin the operations of the Task Force as soon as practicable. After its initial meeting, the Task Force shall meet upon the call of the Chair and Vice Chair or 8 of its members.

(6) **QUORUM; VACANCIES.**—

(A) **QUORUM.**—Eight members of the Task Force shall constitute a quorum.

(B) **VACANCIES.**—Any vacancy in the Task Force shall not affect its powers, but may be filled in the same manner in which the original appointment was made, or, if the deadline
under paragraph (4) has expired, may be filled
by a member appointed by any person with ap-
pointing power under paragraph (1) who is of
the same political party and chamber of Con-
gress as the person with appointing power des-
ignated under paragraph (1) to make the ap-
pointment.

(d) Functions of Task Force.—The functions of
the Task Force are to—

(1) conduct a review that—

   (A) examines the initial outbreak of the
SARS–CoV–2 virus in Wuhan, China, includ-
ing—

   (i) engaging with willing partner gov-
ernments and global experts;

   (ii) seeking access to relevant records;

   and

   (iii) examining the potential causes of
the emergence and source of the virus;

   (B) examines the United States’ prepara-
tion for, and response to, the COVID–19 pan-
demic, including—

   (i) relevant laws, policies, regulations,
and processes that were in place prior to,
or put into place during, the public health
emergency declared by the Secretary of Health and Human Services under section 319 of the Public Health Service Act (42 U.S.C. 247d) with respect to COVID–19, including any that are put into place related to such public health emergency after the date of enactment of this Act and prior to the issuance of the final report pursuant to subsection (j)(2);

(ii) relevant actions taken by, and coordination between, Federal, State, local, Tribal, and territorial governments, non-governmental organizations, and international organizations on preparedness and response efforts, including coordination between governments and other public and private entities, during the—

(I) initial response in the United States;

(II) response during the Trump Administration; and

(III) ongoing response during the Biden Administration;

(iii) communication of public health and scientific information related to the
COVID–19 pandemic, including processes for the development, approval, and dissemination of Federal public health and other relevant public health or scientific guidance;

(iv) actions taken to support the development, manufacturing, and distribution of medical countermeasures and related medical supplies to prevent, detect, and treat COVID–19; and

(C) may include assessments relating to—

(i) the capacity and capabilities of Federal, State, local, Tribal, and territorial governments to respond to the COVID–19 pandemic;

(ii) the capacity and capabilities of health care facilities, including nursing homes and other long-term care facilities, and the health care workforce to respond to the COVID–19 pandemic;

(iii) medical countermeasure research and development and the supply chains of medical products necessary to respond to the COVID–19 pandemic;
(iv) international preparedness for
and response to COVID–19, and Federal
decision-making processes related to new
global health threats;

(v) containment and mitigation mea-
ures related to domestic and international
calls in response to COVID–19; and

(vi) the impact of the COVID–19 pan-
demic and related mitigation efforts on
hard-to-reach and at-risk or underserved
populations, including related health dis-
parities; and;

(2) identify, review, and evaluate the lessons
learned from the COVID–19 pandemic, including ac-
tivities to prepare for, and respond to, future poten-
tial pandemics and related public health emer-
gencies; and

(3) submit to the President and Congress such
reports as are required by this Act containing such
findings, conclusions, and recommendations as the
Task Force shall determine.

(e) POWERS OF TASK FORCE.—

(1) HEARINGS.—The Task Force may—

(A) hold such hearings and sit and act at
such times and places, take such testimony, re-
receive such evidence as determined by the Chair and Vice Chair, and administer such oaths as the Task Force or a designated member, as determined by the Chair or Vice Chair, may determine advisable to be necessary to carry out the functions of the Task Force; and

(B) subject to paragraph (2)(A), require, by subpoena or otherwise, the attendance and testimony of such witnesses and the production of such books, records, correspondence, memoranda, papers, and documents, as the persons described in paragraph (2)(A)(i) may determine advisable.

(2) SUBPOENAS.—

(A) ISSUANCE.—

(i) IN GENERAL.—A subpoena may be issued under this subsection only—

(I) by the agreement of the Chair and the Vice Chair; or

(II) by the affirmative vote of 9 members of the Task Force.

(ii) SIGNATURE.—Subpoenas issued under this subsection may be issued under the signature of the Chair or any member designated by a majority of the Task
(B) ENFORCEMENT.—In the case of continuance or failure to obey a subpoena issued under subsection, the United States district court for the judicial district in which the subpoenaed person resides, is served, or may be found, or where the subpoena is returnable, may issue an order requiring such person to appear at any designated place to testify or to produce documentary or other evidence. Any failure to obey the order of the court may be punished by the court as a contempt of that court.

(3) CONTRACTING.—The Task Force may, to such extent and in such amounts as are provided in appropriation Acts, enter into contracts to enable the Task Force to discharge its duties under this Act.

(4) INFORMATION FROM FEDERAL AGENCIES.—

(A) IN GENERAL.—The Task Force may access from any executive department, bureau, agency, board, commission, office, independent
establishment, or instrumentality of the Federal
Government, such information, documents, sug-
gestions, estimates, and statistics as the Task
Force considers necessary to carry out this sec-
tion.

(B) Provision of Information.—On
written request of the Chair, each department,
bureau, agency, board, commission, office, inde-
dependent establishment, or instrumentality shall,
to the extent authorized by law, provide such
information to the Task Force.

(C) Receipt, Handling, Storage, and
Dissemination.—Information shall only be re-
cieved, handled, stored, and disseminated by
members of the Task Force and its staff con-
sistent with all applicable statutes, regulations,
and executive orders.

(5) Assistance from Federal Agencies.—

(A) General Services Administra-
tion.—On request of the Chair and Vice Chair,
the Administrator of General Services Adminis-
tration shall provide to the Task Force, on a re-
imbursable basis, administrative support and
other assistance necessary for the Task Force
to carry out its duties.
(B) Other departments and agencies.—In addition to the assistance provided for in subparagraph (A), departments and agencies of the United States may provide to the Task Force such assistance as such departments and agencies may determine advisable and as authorized by law.

(6) Donations.—The Task Force may accept, use, and dispose of gifts or donations of services or property. Not later than 5 days after the acceptance of a donation under this subsection, the Task Force shall publicly disclose—

(A) the name of the entity that provided such donation;

(B) the service or property provided through such donation;

(C) the value of such donation; and

(D) how the Task Force plans to use such donation.

(7) Postal services.—The Task Force may use the United States mails in the same manner and under the same conditions as a department or agency of the United States.

(f) Non-applicability of Federal Advisory Committee Act.—
(1) In General.—The Federal Advisory Committee Act (5 U.S.C. App.) shall not apply to the Task Force.

(2) Public Meetings and Release of Public Versions of Reports.—The Task Force shall—

(A) hold public hearings and meetings to the extent appropriate; and

(B) release public versions of the reports required under paragraph (1) and (2) of subsection (j).

(3) Public Hearings.—Any public hearings of the Task Force shall be conducted in a manner consistent with the protection of information provided to or developed for or by the Task Force as required by any applicable statute, regulation, or Executive order.

(g) Staff of Task Force.—

(1) In General.—

(A) Appointment and Compensation.— The Chair of the Task Force, in agreement with the Vice Chair, in accordance with rules agreed upon by the Task Force, may appoint and fix the compensation of a staff director and such other personnel as may be necessary to en-
able the Task Force to carry out its functions, without regard to the provisions of title 5, United States Code, governing appointments in the competitive service, and without regard to the provisions of chapter 51 and subchapter III of chapter 53 of such title relating to classification and General Schedule pay rates, except that no rate of pay fixed under this subsection may exceed the equivalent of that payable for a position at level V of the Executive Schedule under section 5316 of title 5, United States Code.

(B) Personnel as Federal Employees.—

(i) In general.—The staff director and any personnel of the Task Force who are employees shall be employees under section 2105 of title 5, United States Code, for purposes of chapters 63, 81, 83, 84, 85, 87, 89, and 90 of that title.

(ii) Members of Task Force.—Clause (i) shall not be construed to apply to members of the Task Force.

(2) Detailees.—Upon request of the Chair and Vice Chair of the Task Force, the head of any
executive department, bureau, agency, board, commis-
mission, office, independent establishment, or instru-
mentality of the Federal Government employee may
detail, without reimbursement, any of its personnel
to the Task Force to assist in carrying out its duties
under this section. Any such detailee shall be with-
out interruption or loss of civil service status or
privilege.

(3) CONSULTANT SERVICES.—The Task Force
is authorized to procure the services of experts and
consultants in accordance with section 3109 of title
5, United States Code, but at rates not to exceed the
daily rate paid a person occupying a position at level
IV of the Executive Schedule under section 5315 of
title 5, United States Code.

(h) COMPENSATION AND TRAVEL EXPENSES.—Each
member of the Task Force shall serve without compensa-
tion, but shall receive travel expenses, including per diem
in lieu of subsistence, at rates authorized for an employee
of an agency under subchapter I of chapter 57 of title
5, United States Code.

(i) SECURITY CLEARANCES FOR TASK FORCE MEM-
BERS AND STAFF.—The appropriate Federal agencies or
departments shall cooperate with the Task Force in expe-
ditiously providing to the Task Force members and staff
appropriate security clearances, consistent with existing procedures and requirements. No person shall be provided with access to classified information under this section without the appropriate security clearances.

(j) Reports of Task Force; Termination.—

(1) Interim report.—Not later than 180 days after the date of enactment of this Act, the Task Force shall submit to the President, the Committee on Health, Education, Labor, and Pensions of the Senate, and the Committee on Energy and Commerce of the House of Representatives an interim report containing such findings, conclusions, and recommendations as have been agreed to by 8 members of the Task Force. Such interim report shall be made available online in a manner that does not compromise national security.

(2) Final report.—

(A) In general.—Not later than 18 months after the date on which the last member of the Task Force is appointed, the Task Force shall submit to the President, the Committee on Health, Education, Labor, and Pensions of the Senate, and the Committee on Energy and Commerce of the House of Representatives a final report containing such findings, conclu-
sions, and recommendations as have been agreed to by 8 members of the Task Force. The final report shall be made available online in a manner that does not compromise national security.

(B) EXTENSIONS.—

(i) IN GENERAL.—The submission and publication of the final report, as described in subparagraph (A), may be delayed by 6 months upon the agreement of 8 members of the Task Force.

(ii) NOTIFICATION.—The Task Force shall notify the President, the Committee on Health, Education, Labor, and Pensions of the Senate, the Committee on Energy and Commerce of the House of Representatives, and the public of any extension granted under clause (i).

(C) SPECIAL RULES AND CONSIDERATIONS.—

(i) RULE OF CONSTRUCTION.—Nothing in this subsection shall be construed as authorizing the Task Force to publicly disclose information otherwise prohibited from disclosure by law.
(ii) Special timing considerations.—Notwithstanding any other provision of this section, the Task Force shall not publish or make available any interim or final report during the 60-day periods ending November 8, 2022, and November 5, 2024.

(3) Termination.—

(A) In general.—The Task Force, and all the authorities of this section, shall terminate 60 days after the date on which the final report is submitted under paragraph (2).

(B) Administrative activities before termination.—The Task Force may use the 60-day period referred to in subparagraph (A) for the purpose of concluding its activities, including providing testimony to committees of Congress concerning its reports and disseminating the final report.

(k) Funding.—

(1) Authorization of appropriations.—There is authorized to be appropriated to carry out this section, a total of $3,000,000 for fiscal years 2023 and 2024.
(2) **Duration of availability.**—Amounts made available to the Task Force under paragraph (1) shall remain available until the termination of the Task Force.

**SEC. 102. APPOINTMENT AND AUTHORITY OF THE DIRECTOR OF THE CENTERS FOR DISEASE CONTROL AND PREVENTION.**

(a) **In general.**—Part A of title III of the Public Health Service Act (42 U.S.C. 241 et seq.) is amended by inserting after section 304 the following:

```
“SEC. 305. APPOINTMENT AND AUTHORITY OF THE DIRECTOR OF THE CENTERS FOR DISEASE CONTROL AND PREVENTION.

“(a) **In general.**—The Centers for Disease Control and Prevention (referred to in this section as the ‘CDC’) shall be headed by the Director of the Centers for Disease Control and Prevention (referred to in this section as the ‘Director’), who shall be appointed by the President, by and with the advice and consent of the Senate. Such individual shall also serve as the Administrator of the Agency for Toxic Substances and Disease Registry consistent with section 104(i) of the Comprehensive Environmental Response, Compensation, and Liability Act. The Director shall perform functions provided for in subsection (b) and such other functions as the Secretary may prescribe.
```
“(b) FUNCTIONS.—The Secretary, acting through the Director, shall—

“(1) implement and exercise applicable authorities and responsibilities provided for in this Act or other applicable law related to the investigation, detection, identification, prevention, or control of diseases or conditions to preserve and improve public health domestically and globally and address injuries and occupational and environmental hazards, as appropriate;

“(2) be responsible for the overall direction of the CDC and for the establishment and implementation of policies related to the management and operation of programs and activities within the CDC;

“(3) coordinate and oversee the operation of centers, institutes, and offices within the CDC;

“(4) support, in consultation with the heads of such centers, institutes, and offices, program coordination across such centers, institutes, and offices, including through priority setting reviews and the development of strategic plans, to reduce unnecessary duplication and encourage collaboration between programs;
“(5) oversee the development, implementation, and updating of the strategic plan established pursuant to subsection (c);

“(6) ensure that appropriate strategic planning, including the use of performance metrics, is conducted by such centers, institutes, and offices to facilitate and improve CDC programs and activities;

“(7) communicate, including through convening annual meetings, with public and private entities regarding relevant public health programs and activities, and, as applicable, the strategic plan established pursuant to subsection (c).

“(c) STRATEGIC PLAN.—

“(1) IN GENERAL.—Not later than 1 year after the date of enactment of the PREVENT Pandemics Act, and at least every 4 years thereafter, the Director shall develop and submit to the Committee on Health, Education, Labor, and Pensions and the Committee on Appropriations of the Senate and the Committee on Appropriations of the House of Represent-atives, and post on the website of the CDC, a coordinated strategy to provide strategic direction and fa-cilitate collaboration across the centers, institutes,
and offices within the CDC. Such strategy shall be known as the ‘CDC Strategic Plan’.

“(2) REQUIREMENTS.—The CDC Strategic Plan shall—

“(A) identify strategic priorities and objectives related to—

“(i) preventing, reducing, and eliminating the spread of communicable and noncommunicable diseases or conditions, and addressing injuries, and occupational and environmental hazards;

“(ii) supporting the efforts of State, local, and Tribal health departments to prevent and reduce the prevalence of the diseases or conditions under clause (i);

“(iii) containing, mitigating, and ending disease outbreaks;

“(iv) enhancing global and domestic public health capacity, capabilities, and preparedness, including public health data, surveillance, workforce, and laboratory capacity and safety; and

“(v) other priorities, as established by the Director;
“(B) describe the capacity and capabilities necessary to achieve the priorities and objectives under subparagraph (A), and progress towards achieving such capacity and capabilities, as appropriate; and

“(C) include a description of how the CDC Strategic Plan incorporates—

“(i) strategic communications;

“(ii) partnerships with private sector entities, and State, local, and Tribal health departments, and other public sector entities, as appropriate; and

“(iii) coordination with other agencies and offices of the Department of Health and Human Services and other Federal departments and agencies, as appropriate.

“(3) USE OF PLANS.—Strategic plans developed and updated by the centers, institutes, and offices of the CDC shall be prepared regularly and in such a manner that such plans will be informed by the CDC Strategic Plan developed and updated under this subsection.

“(d) APPEARANCES BEFORE CONGRESS.—

“(1) IN GENERAL.—Each fiscal year, the Director shall appear before the Committee on Health,
Education, Labor, and Pensions of the Senate and
the Committee on Energy and Commerce of the
House of Representatives at hearings on topics such
as—

“(A) support for State, local, and Tribal
public health preparedness and responses to any
recent or ongoing public health emergency, in-
cluding—

“(i) any objectives, activities, or initia-
tives that have been carried out, or are
planned, by the Director to prepare for, or
respond to, the public health emergency,
including relevant strategic communica-
tions or partnerships and any gaps or chal-
lenges identified in such objectives, activi-
ties, or initiatives;

“(ii) any objectives and planned ac-
tivities for the upcoming fiscal year to ad-
dress gaps in, or otherwise improve, State,
local, and Tribal public health prepared-
ness; and

“(iii) other potential all-hazard
threats that the Director is preparing to
address;
“(B) activities related to public health and functions of the Director described in subsection (b); and

“(C) updates on other relevant activities supported or conducted by the CDC, or in collaboration or coordination with the heads of other Federal departments, agencies, or stakeholders, as appropriate.

“(2) CLARIFICATIONS.—

“(A) WAIVER AUTHORITY.—The Chair of the Committee on Health, Education, Labor, and Pensions of the Senate or the Chair of the Committee on Energy and Commerce of the House of Representatives may waive the requirements of paragraph (1) for the applicable fiscal year with respect to the applicable Committee.

“(B) SCOPE OF REQUIREMENTS.—The requirements of this subsection shall not be construed to impact the appearance of other Federal officials or the Director at hearings of either Committee described in paragraph (1) at other times and for purposes other than the times and purposes described in paragraph (1).
“(3) CLOSED HEARINGS.—Information that is not appropriate for disclosure during an open hearing under paragraph (1) in order to protect national security may instead be discussed in a closed hearing that immediately follows the open hearing.”.

(b) APPLICATION.—The first sentence of section 305(a) of the Public Health Service Act, as added by subsection (a), shall not apply to the Director of the Centers for Disease Control and Prevention who is serving on the date of enactment of this Act.

SEC. 103. ADDITIONAL PROVISIONS RELATED TO THE CENTERS FOR DISEASE CONTROL AND PREVENTION.

Title III of the Public Health Service Act (42 U.S.C. 241 et seq.) is amended by inserting after section 305, as added by section 102, the following:

“SEC. 305A. ADDITIONAL PROVISIONS RELATED TO THE CENTERS FOR DISEASE CONTROL AND PREVENTION.

“(a) APPOINTMENTS.—

“(1) IN GENERAL.—Unless otherwise specified in statute, the heads of the centers or institutes of the Centers for Disease Control and Prevention shall be appointed by the Secretary, acting through the Director of the Centers for Disease Control and Pre-
vention (referred to in this section as the ‘Director’).

Each such individual shall be appointed for 5 years.

“(2) **REAPPOINTMENTS.**—An individual appointed under paragraph (1) may be reappointed in accordance with standards applicable to the relevant appointment mechanism and as determined by the Secretary. In a case in which a head is not reappointed and the successor does not take office at the end of a head’s term, such head shall continue to serve in such capacity until the appointment term of such a successor begins.

“(3) **NO LIMIT ON TERMS.**—There shall be no limit on the number of terms that any individual appointed under this subsection may serve.

“(4) **VACANCIES.**—If the position of a head of a center or institute described in paragraph (1) becomes vacant before the end of a term, the head of such center or institute appointed to fill the vacancy shall be appointed for a 5-year term starting on the date of such appointment.

“(5) **CURRENT POSITIONS AND EXEMPTIONS.**—

“(A) **IN GENERAL.**—Each such individual who is serving on the date of enactment of the PREVENT Pandemics Act shall be deemed to
be appointed for a 5-year term under this subsection beginning on such date of enactment.

“(B) EXEMPTIONS.—The Secretary may exempt the head of a center or institute from the 5-year term described in subparagraph (A) if such Secretary determines such exemption is necessary in order to hire or retain talented individuals.

“(6) RULE OF CONSTRUCTION.—Nothing in this subsection shall be construed to—

“(A) limit the authority of the Secretary or the Director to terminate the appointment of a head of a center or institute described in paragraph (1) before the expiration of such individual’s 5-year term; or

“(B) alter existing law regarding reassignment and transfer of career staff, as applicable, at the end of a 5-year term of a head of a center or institute.

“(7) NATURE OF APPOINTMENT.—Appointments and reappointments under this subsection shall be made on the basis of ability and experience as it relates to the mission of the Centers for Disease Control and Prevention and its components, including compliance with relevant legal requirements.
“(b) OTHER TRANSACTIONS.—

“(1) IN GENERAL.—In carrying out activities of the Centers for Disease Control and Prevention, the Director may enter into transactions other than a contract, grant, or cooperative agreement for purposes of infectious disease research, biosurveillance, infectious disease modeling, and public health preparedness and response.

“(2) WRITTEN DETERMINATION.—With respect to a project that is expected to cost the Centers for Disease Control and Prevention more than $40,000,000, the Director may exercise the authority under paragraph (1) only upon a written determination by the Assistant Secretary for Financial Resources of the Department of Health and Human Services, that the use of such authority is essential to promoting the success of the project. The authority of the Assistant Secretary for Financial Resources under this paragraph may not be delegated.

“(3) GUIDELINES.—The Director, in consultation with the Secretary, shall establish guidelines regarding the use of the authority under paragraph (1). Such guidelines shall include auditing requirements.”.
SEC. 104. ADVISORY COMMITTEE TO THE DIRECTOR OF
THE CENTERS FOR DISEASE CONTROL AND
PREVENTION.

Title III of the Public Health Service Act (42 U.S.C. 241 et seq.) is amended by inserting after section 305A, as added by section 103, the following:

“SEC. 305B. ADVISORY COMMITTEE TO THE DIRECTOR.

“(a) In General.—Not later than 60 days after the date of the enactment of the PREVENT Pandemics Act, the Secretary, acting through the Director of the Centers for Disease Control and Prevention (referred to in this section as the ‘Director’), shall maintain or establish an advisory committee within the Centers for Disease Control and Prevention to advise the Director on policy and strategies that enable the agency to fulfill its mission.

“(b) Functions and Activities.—The Advisory Committee may—

“(1) make recommendations to the Director regarding ways to prioritize the activities of the agency in alignment with the CDC Strategic Plan required under section 305(e);

“(2) advise on ways to achieve or improve performance metrics in relation to the CDC Strategic Plan, and other relevant metrics, as appropriate;
“(3) provide advice and recommendations on the development of the CDC Strategic Plan, and any subsequent updates, as appropriate;

“(4) advise on grants, cooperative agreements, contracts, or other transactions, as applicable;

“(5) provide other advice to the Director, as requested, to fulfill duties under sections 301 and 311; and

“(6) appoint subcommittees.

“(c) Membership.—

“(1) In general.—The Advisory Committee shall consist of not more than 15 non-Federal members, including the Chair, to be appointed by the Secretary under paragraph (3).

“(2) Ex officio members.—Any ex officio members of the Advisory Council may consist of—

“(A) the Secretary;

“(B) the Assistant Secretary for Health;

“(C) the Director; and

“(D) such additional officers or employees of the United States as the Secretary determines necessary for the advisory committee to effectively carry out its functions.
“(3) APPOINTED MEMBERS.—Individuals shall be appointed to the Advisory Committee under paragraph (1) as follows:

“(A) Twelve of the members shall be appointed by the Director from among the leading representatives of the health disciplines (including public health, global health, health disparities, biomedical research, public health preparedness, and other fields, as applicable) relevant to the activities of the agency or center, as applicable.

“(B) Three of the members may be appointed by the Secretary from the general public and may include leaders in fields of innovation, public policy, public relations, law, economics, or management.

“(4) COMPENSATION.—Ex officio members of the Advisory Council who are officers or employees of the United States shall not receive any compensation for service on the advisory committee. The remaining members of the advisory committee may receive, for each day (including travel time) they are engaged in the performance of the functions of the advisory committee, compensation at rates not to exceed the daily equivalent to the annual rate of basic
pay for level III of the Executive Schedule under
section 5314 of title 5, United States Code.

“(5) TERMS OF OFFICE.—

“(A) IN GENERAL.—The term of office of
a member of the advisory committee appointed
under paragraph (3) shall be 4 years, except
that any member appointed to fill a vacancy for
an unexpired term shall serve for the remainder
of such term. The Secretary shall make ap-
pointments to the advisory committee in such a
manner as to ensure that the terms of the
members not all expire in the same year. A
member of the advisory committee may serve
after the expiration of such member’s term
until a successor has been appointed and taken
office.

“(B) REAPPOINTMENTS.—A member who
has been appointed to the advisory committee
for a term of 4 years may not be reappointed
to the advisory committee during the 2-year pe-
riod beginning on the date on which such 4-
year term expired.

“(C) TIME FOR APPOINTMENT.—If a va-
cancy occurs in the advisory committee among
the members appointed under paragraph (3),
the Secretary shall make an appointment to fill such vacancy within 90 days from the date the vacancy occurs.

“(d) CHAIR.—The Secretary shall select a member of the advisory committee to serve as the Chair of the committee. The Secretary may so select an individual from among the appointed members. The term of office of the chair shall be 2 years.

“(e) MEETINGS.—The advisory committee shall meet at the call of the Chair or upon request of the Director, but in no event less than 2 times during each fiscal year.

“(f) EXECUTIVE SECRETARY AND STAFF.—The Director shall designate a member of the staff of the agency to serve as the executive secretary of the advisory committee. The Director shall make available to the advisory committee such staff, information, and other assistance as it may require to carry out its functions. The Director shall provide orientation and training for new members of the advisory committee to provide for their effective participation in the functions of the advisory committee.”.

SEC. 105. PUBLIC HEALTH AND MEDICAL PREPAREDNESS AND RESPONSE COORDINATION.

(a) PUBLIC HEALTH EMERGENCY FUND.—Section 319(b) of the Public Health Service Act (42 U.S.C. 247d(b)) is amended—
(1) in paragraph (2)—

(A) in subparagraph (E), by striking “and” at the end;

(B) by redesignating subparagraph (F) as subparagraph (G); and

(C) by inserting after subparagraph (E), the following:

“(F) support the initial deployment and distribution of contents of the Strategic National Stockpile, as appropriate; and”; and

(2) by amending paragraph (3)(A) to read as follows:

“(A) the expenditures made from the Public Health Emergency Fund in such fiscal year, including—

“(i) the amount obligated;

“(ii) the recipient or recipients of such obligated funds;

“(iii) the specific response activities such obligated funds will support; and

“(iv) the declared or potential public health emergency for which such funds were obligated; and”.

(b) IMPROVING PUBLIC HEALTH AND MEDICAL PREPAREDNESS AND RESPONSE COORDINATION.—
(1) COORDINATION WITH FEDERAL AGENCIES.—Section 2801 of the Public Health Service Act (42 U.S.C. 300hh) is amended by adding at the end the following:

“(c) COORDINATION WITH FEDERAL AGENCIES.—In leading the Federal public health and medical response to a declared or potential public health emergency, consistent with this section, the Secretary shall coordinate with, and may request support from, other Federal departments and agencies, as appropriate in order to carry out necessary activities and leverage the expertise of such departments and agencies, which may include the provision of assistance at the direction of the Secretary related to supporting the public health and medical response for States, localities, and Tribes.”.

(2) ASPR DUTIES.—Section 2811(b) of the Public Health Service Act (42 U.S.C. 300hh–10(b)) is amended—

(A) in paragraph (1), by inserting “and, consistent with the National Response Framework and other applicable provisions of law, assist the Secretary in carrying out the functions under section 2801” before the period; and

(B) in paragraph (4)—
(i) in subparagraph (E) by striking “the actions necessary to overcome these obstacles.” and inserting “recommend actions necessary to overcome these obstacles, such as—

“(i) improving coordination with relevant Federal officials;

“(ii) partnering with other public or private entities to leverage capabilities maintained by such entities, as appropriate and consistent with this subsection; and

“(iii) coordinating efforts to support or establish new capabilities, as appropriate.”;

(ii) in subparagraph (G)—

(I) by redesignating clauses (i) and (ii) as subclauses (I) and (II) and adjusting the margins accordingly;

(II) in the matter preceding subclause (I), as so redesignated—

(aa) by inserting “each year, including national-level and State-level full-scale exercises not less than once every 4 years” after “operational exercises”; and
(bb) by striking “exercises based on—” and inserting “exercises—“(i) based on”;

(III) by striking the period and inserting a semicolon; and

(IV) by adding at the end the following:

“(ii) that assess the ability of the Strategic National Stockpile, as appropriate, to provide medical countermeasures, medical products, and other supplies, including ancillary medical supplies, to support the response to a public health emergency or potential public health emergency, including a threat that requires the large-scale and simultaneous deployment of stockpiles and a long-term public health and medical response; and

“(iii) conducted in coordination with State and local health officials.”; and

(iii) by adding at the end the following:

“(J) MEDICAL PRODUCT AND SUPPLY CAPACITY PLANNING.—Coordinate efforts within
the Department of Health and Human Services to support—

“(i) preparedness for medical product and medical supply needs directly related to responding to chemical, biological, radiological, or nuclear threats, including emerging infectious diseases, and incidents covered by the National Response Framework, including—

“(I) sharing information, including with appropriate stakeholders, related to the anticipated need for, and availability of, such products and supplies during such responses;

“(II) supporting activities, which may include public-private partnerships, to maintain capacity of medical products and medical supplies, as applicable and appropriate; and

“(III) planning for potential surges in medical supply needs for purposes of a response to such a threat; and

“(ii) situational awareness with respect to anticipated need for, and avail-
ability of, such medical products and medi-
cal supplies within the United States dur-
ing a response to such a threat.”.

(c) APPEARANCES BEFORE AND REPORTS TO CON-
GRESS.—Section 2811 of the Public Health Service Act
(42 U.S.C. 300hh–10) is amended by adding at the end
the following:

“(g) APPEARANCES BEFORE CONGRESS.—

“(1) IN GENERAL.—Each fiscal year, the As-
sistant Secretary for Preparedness and Response
shall appear before the Committee on Health, Edu-
cation, Labor, and Pensions of the Senate and the
Committee on Energy and Commerce of the House
of Representatives at hearings, on topics such as—

“(A) coordination of Federal activities to
prepare for, and respond to, public health emer-
gencies;

“(B) activities and capabilities of the Stra-
tegic National Stockpile, including whether, and
the degree to which, recommendations made
pursuant to section 2811–1(c)(1)(A) have been
met;

“(C) support for State, local, and Tribal
public health and medical preparedness;
“(D) activities implementing the countermeasures budget plan described under subsection (b)(7), including—

“(i) any challenges in meeting the full range of identified medical countermeasure needs; and

“(ii) progress in supporting advanced research, development, and procurement of medical countermeasures, pursuant to subsection (b)(3);

“(E) the strategic direction of, and activities related to, the sustainment of manufacturing surge capacity and capabilities for medical countermeasures pursuant to section 319L and the distribution and deployment of such countermeasures;

“(F) any additional objectives, activities, or initiatives that have been carried out or are planned by the Assistant Secretary for Preparedness and Response and associated challenges, as appropriate;

“(G) the specific all-hazards threats that the Assistant Secretary for Preparedness and Response is preparing to address, or that are
being addressed, through the activities described in subparagraphs (A) through (F); and

“(H) objectives, activities, or initiatives related to the coordination and consultation required under subsections (b)(4)(H) and (b)(4)(I), in a manner consistent with paragraph (3), as appropriate.

“(2) CLARIFICATIONS.—

“(A) WAIVER AUTHORITY.—The Chair of the Committee on Health, Education, Labor, and Pensions of the Senate or the Chair of the Committee on Energy and Commerce of the House of Representatives may waive the requirements of paragraph (1) for the applicable fiscal year with respect to the applicable Committee.

“(B) SCOPE OF REQUIREMENTS.—The requirements of this subsection shall not be construed to impact the appearance of other Federal officials or the Assistant Secretary at hearings of either Committee described in paragraph (1) at other times and for purposes other than the times and purposes described in paragraph (1)
“(3) CLOSED HEARINGS.—Information that is not appropriate for disclosure during an open hearing under paragraph (1) in order to protect national security may instead be discussed in a closed hearing that immediately follows such open hearing.”.

(d) ANNUAL REPORT ON EMERGENCY RESPONSE AND PREPAREDNESS.—Section 2801 of the Public Health Service Act (42 U.S.C. 300hh), as amended by subsection (b), is further amended by adding at the end the following:

“(d) ANNUAL REPORT ON EMERGENCY RESPONSE AND PREPAREDNESS.—The Secretary shall submit a written report each fiscal year to the Committee on Health, Education, Labor, and Pensions and the Committee on Appropriations of the Senate and the Committee on Energy and Commerce and the Committee on Appropriations of the House of Representatives, containing—

“(1) updated information related to an assessment of the response to any public health emergency declared, or otherwise in effect, during the previous fiscal year;

“(2) findings related to drills and operational exercises completed in the previous fiscal year pursuant to section 2811(b)(4)(G);

“(3) the state of public health preparedness and response capabilities for chemical, biological, radio-
logical, and nuclear threats, including emerging infectious diseases; and

“(4) any challenges in preparing for or responding to such threats, as appropriate.”.

(e) GAO REPORT ON INTERAGENCY AGREEMENTS AND COORDINATION.—Not later than 3 years after the date of enactment of this Act, the Comptroller General of the United States shall—

(1) conduct a review of previous and current interagency agreements established between the Secretary of Health and Human Services and the heads of other relevant Federal departments or agencies pursuant to section 2801(b) of the Public Health Service Act (42 U.S.C. 300hh(b)), including—

(A) the specific roles and responsibilities of each Federal department or agency that is a party to any such interagency agreement;

(B) the manner in which specific capabilities of each such Federal department or agency may be utilized under such interagency agreements;

(C) the frequency with which such interagency agreements have been utilized;

(D) gaps, if any, in interagency agreements that prevent the Secretary from carrying
out the goals under section 2802 of the Public
Health Service Act (42 U.S.C. 300hh–1);

(E) barriers, if any, to establishing or uti-
lizing such interagency agreements; and

(F) recommendations, if any, on the ways
in which such interagency agreements can be
improved to address the gaps and barriers iden-
tified under subparagraphs (D) and (E);

(2) conduct a review of the implementation and
utilization of the authorities described under section
2801(c) of the Public Health Service Act (42 U.S.C.
300hh(c)); and

(3) submit to the Committee on Health, Edu-
cation, Labor, and Pensions of the Senate and the
Committee on Energy and Commerce of the House
of Representatives a report on the reviews under
paragraphs (1) and (2), including related rec-
ommendations, as applicable.

SEC. 106. STRENGTHENING PUBLIC HEALTH COMMUNICA-
TION.

Subsection (b) of section 319F of the Public Health
Service Act (42 U.S.C. 247d–6) is amended to read as
follows:

"(b) PUBLIC HEALTH INFORMATION AND COMMU-
NICATIONS ADVISORY COMMITTEE.—
“(1) IN GENERAL.—The Secretary shall establish an advisory committee to be known as the Public Health Information and Communications Advisory Committee (referred to in this subsection as the ‘Advisory Committee’).

“(2) DUTIES.—The Advisory Committee shall make recommendations to the Secretary and report on—

“(A) critical aspects of communication and dissemination of scientific and evidence-based public health information during public health emergencies, including—

“(i) the role and impact of misinformation on the response to such public health emergencies;

“(ii) the role of risk communication before and during such public health emergencies; and

“(iii) other relevant factors, as the Secretary determines appropriate;

“(B) information from academic institutions, community-based organizations, and other nongovernmental organizations related to evidence-based or evidence-informed strategies
and best practices to effectively communicate and disseminate such information;

“(C) strategies to improve communication and dissemination of scientific and evidence-based public health information to the public, including consideration of the delivery of such information in a manner that takes into account the range of communication needs of the intended recipients, including at-risk individuals, to improve such communication between Federal, State, local, and Tribal health officials, and, as appropriate, to address misinformation during public health emergencies, including strategies to—

“(i) identify the most effective methods for the dissemination of information during a public health emergency, with consideration of the needs of at-risk populations;

“(ii) determine best practices and communicate information to populations that may be impacted by such misinformation; and

“(iii) adapt approaches for the dissemination of information, as appropriate,
to address emerging trends related to misinformation.

“(3) COMPOSITION.—The Advisory Committee shall be composed of—

“(A) appropriate Federal officials, appointed by the Secretary, who shall serve as nonvoting members; and

“(B) individuals, appointed by the Secretary, with expertise in public health (including individuals with experience in State, local, and Tribal health departments), medicine, communications, related technology, psychology, mental health and substance use disorders, national security, and other areas, as the Secretary determines appropriate, who shall serve as voting members.

“(4) DISSEMINATION.—The Secretary shall review the recommendations of the Advisory Committee and, not later than 180 days after receipt of the report under paragraph (2), shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report describing any actions planned by the Secretary related to the communication and dissemination of
scientific and evidence-based public health information, including addressing misinformation, as appropriate.

“(5) TERMINATION.—The Advisory Committee shall terminate 4 years after the date of enactment of the PREVENT Pandemics Act.”

SEC. 107. OFFICE OF PANDEMIC PREPAREDNESS AND RESPONSE POLICY.

(a) IN GENERAL.—There is established in the Executive Office of the President an Office of Pandemic Preparedness and Response Policy (referred to in this section as the “Office”), which shall be headed by a Director (referred to in this section as the “Director”) appointed by the President and who shall be compensated at the rate provided for level II of the Executive Schedule in section 5313 of title 5, United States Code. The President is authorized to appoint not more than 2 Associate Directors, who shall be compensated at a rate not to exceed that provided for level III of the Executive Schedule in section 5314 of such title. Associate Directors shall perform such functions as the Director may prescribe.

(b) FUNCTIONS OF THE DIRECTOR.—The primary function of the Director is to provide advice, within the Executive Office of the President, on policy related to preparedness for, and response to, pandemic and other bio-
logical threats that may impact national security, and support strategic coordination and communication with respect to relevant activities across the Federal Government. In addition to such other functions and activities as the President may assign, the Director, consistent with applicable laws and the National Response Framework, shall—

(1) serve as the principal advisor to the President on all matters related to pandemic preparedness and response policy and make recommendations to the President regarding pandemic and other biological threats that may impact national security;

(2) coordinate Federal activities to prepare for, and respond to, pandemic and other biological threats, by—

(A) providing strategic direction to the heads of applicable Federal departments, agencies, and offices, including—

(i) the establishment, implementation, prioritization, and assessment of policy goals and objectives across the Executive Office of the President and such departments, agencies, and offices;

(ii) supporting the assessment and clarification of roles and responsibilities related to such Federal activities; and
(iii) supporting the development and implementation of metrics and performance measures to evaluate the extent to which applicable activities meet such goals and objectives;

(B) providing, in consultation with the Secretary of Health and Human Services and the heads of other relevant Federal departments, agencies, and offices, leadership with respect to the National Biodefense Strategy and related activities pursuant to section 1086 of the National Defense Authorization Act for Fiscal Year 2017 (6 U.S.C. 104) and section 363 of the William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 (6 U.S.C. 105);

(C) facilitating coordination and communication between such Federal departments, agencies, and offices to improve preparedness for, and response to, such threats;

(D) ensuring that the authorities, capabilities, and expertise of each such department, agency, and office are appropriately leveraged to facilitate the whole-of-Government response to such threats;
(E) overseeing coordination of Federal efforts to prepare for and support the production, supply, and distribution of relevant medical products and supplies during a response to a pandemic or other biological threat, as applicable and appropriate, including supporting Federal efforts to assess any relevant vulnerabilities in the supply chain of such products and supplies;

(F) overseeing coordination of Federal efforts for the basic and advanced research, development, manufacture, and procurement of medical countermeasures for such threats, including by—

(i) serving, with the Secretary of Health and Human Services, as co-Chair of the Public Health Emergency Medical Countermeasures Enterprise established pursuant to section 2811–1 of the Public Health Service Act (42 U.S.C. 300hh–10a);

(ii) promoting coordination between the medical countermeasure research, development, and procurement activities of respective Federal departments and agen-
cies, including to advance the discovery
and development of new medical products
and technologies;

(G) convening heads of Federal depart-
ments and agencies, as appropriate, on topics
related to capabilities to prepare for, and re-
spond to, such threats; and

(H) assessing and advising on inter-
national cooperation in preparing for, and re-
sponding to, such threats to advance the na-
tional security objectives of the United States;

(I) overseeing other Federal activities to
assess preparedness for, and responses to, such
threats, including—

(i) drills and operational exercises
conducted pursuant to applicable provi-
sions of law; and

(ii) Federal after-action reports devel-
oped following such drills and exercises or
a response to a pandemic or other biologi-
cal threat;

(3) promote and support the development of
relevant expertise and capabilities within the Federal
Government to ensure that the United States can
quickly detect, identify, and respond to such threats,
and provide recommendations, as appropriate, to the
President;

(4) consult with the Director of the Office of
Management and Budget and other relevant officials
within the Executive Office of the President, includ-
ing the Assistant to the President for National Secu-

(5) identify opportunities to leverage current

(6) ensure that findings of Federal after-action

(c) SUPPORT FROM OTHER AGENCIES.—Each de-

providing the Director such information as the Director
determines necessary to carry out the functions of the Di-
rector under this section.

(d) Preparedness Outlook Report.—

(1) In general.—Within its first year of oper-
ation, the Director, in consultation with the heads of
relevant Federal departments and agencies and
other officials within the Executive Office of the
President, shall through a report submitted to the
President and made available to the public, to the
extent practicable, identify and describe situations
and conditions which warrant special attention with-
in the next 5 years, involving current and emerging
problems of national significance related to pan-
demic or other biological threats, and opportunities
for, and the barriers to, the research, development,
and procurement of medical countermeasures to ade-
quately respond to such threats.

(2) Revisions.—The Office shall revise the re-
port under paragraph (1) not less than once every
5 years and work with relevant Federal officials to
address the problems, barriers, opportunities, and
actions identified under this report through the de-
velopment of the President’s Budgets and programs.
(c) INTERDEPARTMENTAL WORKING GROUP.—The Director shall lead an interdepartmental working group that will meet on a regular basis to evaluate national biosecurity and pandemic preparedness issues and make recommendations to the heads of applicable Federal departments, agencies and offices. The working group shall consist of representatives from—

(1) the Office of Pandemic Preparedness and Response Policy, to serve as the chair;

(2) the Department of Health and Human Services;

(3) the Department of Homeland Security;

(4) the Department of Defense;

(5) the Office of Management and Budget; and

(6) other Federal Departments and agencies.

(f) INDUSTRY LIAISON.—

(1) IN GENERAL.—Not later than 10 days after the initiation of a Federal response to a pandemic or other biological threat that may pose a risk to national security, the Director shall appoint an Industry Liaison within the Office of Pandemic Preparedness and Response Policy to serve until the termination of such response.

(2) ACTIVITIES.—The Industry Liaison shall—
(A) not later than 20 days after the initiation of such response, identify affected industries and develop a plan to regularly communicate with, and receive input from, affected industries; and

(B) work with relevant Federal departments and agencies to support information sharing and coordination with industry stakeholders.

(g) **Additional Functions of the Director.**—

The Director, in addition to the other duties and functions set forth in this section—

(1) shall—

(A) serve as a member of the Domestic Policy Council and the National Security Council;

(B) serve as a member of the Intergovernmental Science, Engineering, and Technology Advisory Panel under section 205(b) of the National Science and Technology Policy, Organization, and Priorities Act of 1976 (42 U.S.C. 6614(b)) and the Federal Coordinating Council for Science, Engineering and Technology under section 401 of such Act (42 U.S.C. 6651);
(C) consult with State, Tribal, local, and territorial governments, industry, academia, professional societies, and other stakeholders, as appropriate;

(D) use for administrative purposes, on a reimbursable basis, the available services, equipment, personnel, and facilities of Federal, State, and local agencies; and

(E) at the President’s request, perform such other duties and functions and enter into contracts and other arrangements for studies, analyses, and related services with public or private entities, as applicable and appropriate; and

(2) may hold such hearings in various parts of the United States as necessary to determine the views of the entities and individuals referred to in paragraph (1) and of the general public, concerning national needs and trends in pandemic preparedness and response.

(h) STAFFING AND DETAILEES.—In carrying out functions under this section, the Director may—

(1) appoint not more than 25 individuals to serve as employees of the Office as necessary to carry out this section;
(2) fix the compensation of such personnel at a rate to be determined by the Director, up to the amount of annual compensation (excluding expenses) specified in section 102 of title 3, United States Code;

(3) utilize the services of consultants, which may include by obtaining services described under section 3109(b) of title 5, United States Code, at rates not to exceed the rate of basic pay for level IV of the Executive Schedule; and

(4) direct, with the concurrence of the Secretary of a department or head of an agency, the temporary reassignment within the Federal Government of personnel employed by such department or agency, in order to carry out the functions of the Office.

(i) PREPAREDNESS REVIEW AND REPORT.—The Director, in consultation with the heads of applicable Federal departments, agencies, and offices, shall—

(1) not later than 1 year after the date of enactment of this Act, conduct a review of applicable Federal strategies, policies, procedures, and after-action reports to identify gaps and inefficiencies related to pandemic preparedness and response;
(2) not later than 18 months after the date of enactment of this Act, and every 2 years thereafter, submit to the President and the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report describing—

(A) current and emerging pandemic and other biological threats that pose a significant level of risk to national security;

(B) the roles and responsibilities of the Federal Government in preparing for, and responding to, such threats;

(C) the findings of the review conducted under paragraph (1);

(D) any barriers or limitations related to addressing such findings;

(E) current and planned activities to update Federal strategies, policies, and procedures to address such findings, consistent with applicable laws and the National Response Framework;

(F) current and planned activities to support the development of expertise within the Federal Government pursuant to subsection (b)(3); and
(G) opportunities to improve Federal preparedness and response capacities and capabilities through the use of current and emerging technologies.

(j) NONDUPICATION OF EFFORT.—The Director shall ensure that activities carried out under this section do not unnecessarily duplicate the efforts of other Federal departments, agencies, and offices.

(k) CONFORMING AMENDMENTS.—

(1) Section 2811–1 of the Public Health Service Act (42 U.S.C. 300hh–10a) is amended—

(A) in the second sentence of subsection (a), by striking “shall serve as chair” and inserting “and the Director of the Office of Pandemic Preparedness and Response Policy shall serve as co-chairs”; and

(B) in subsection (b)—

(i) by redesignating paragraph (10) as paragraph (11); and

(ii) by inserting after paragraph (9) the following:

“(10) The Director of the Office of Pandemic Preparedness and Response Policy.”.

(2) Section 101(c)(1) of the National Security Act of 1947 (50 U.S.C. 3021(e)(1)) is amended by
inserting “the Director of the Office of Pandemic Preparedness and Response Policy” after “Treasury.”.

(3) The National Science and Technology Policy, Organization, and Priorities Act of 1976 (42 U.S.C. 6601 et seq.) is amended—

(A) in section 205(b)(2) (42 U.S.C. 6614(b)(2))—

(i) by striking “and (C)” and inserting “(C)”;

(ii) by striking the period at the end and inserting “; and (D) the Director of the Office of Pandemic Preparedness and Response Policy.”;

(B) in section 401(b) (42 U.S.C. 6651(b)), by inserting “, the Director of the Office of Pandemic Preparedness and Response Policy,” after “Technology Policy”.

Subtitle B—State and Local Readiness

SEC. 111. IMPROVING STATE AND LOCAL PUBLIC HEALTH SECURITY.

(a) In General.—Section 319C–1(b)(2) of the Public Health Service Act (42 U.S.C. 247d–3a(b)(2)) is amended—
(1) in subparagraph (A)—

(A) in clause (vii), by inserting “during and” before “following a public health emergency”; 
(B) by amending clause (viii) to read as follows:

“(viii) a description of how the entity, as applicable and appropriate, will coordinate with State emergency preparedness and response plans in public health emergency preparedness, including State education agencies (as defined in section 8101 of the Elementary and Secondary Education Act of 1965), State child care lead agencies (designated under section 658D of the Child Care and Development Block Grant Act of 1990), and other relevant State agencies”;

(C) in clause (xi), by striking “; and” and inserting a semicolon;

(D) by redesignating clause (xii) as clause (xiii); and

(E) by inserting after clause (xi) the following:
“(xii) a description of how the entity will provide technical assistance to improve public health preparedness and response, as appropriate, to agencies or other entities that operate facilities within the entity’s jurisdiction in which there is an increased risk of infectious disease outbreaks in the event of a public health emergency declared under section 319, such as residential care facilities, group homes, and other similar settings; and”;

(2) by redesignating subparagraphs (D) through (H) as subparagraphs (E) through (I), respectively; and

(3) by inserting after subparagraph (C) the following:

“(D) an assurance that the entity will require relevant staff to complete relevant preparedness and response trainings, including trainings related to efficient and effective operation during an incident or event within an Incident Command System;”.

(b) APPLICABILITY.—The amendments made by subsection (a) shall not apply with respect to any cooperative
agreement entered into prior to the date of enactment of this Act.

SEC. 112. SUPPORTING ACCESS TO MENTAL HEALTH AND SUBSTANCE USE DISORDER SERVICES DURING PUBLIC HEALTH EMERGENCIES.

(a) AUTHORITIES.—Section 501(d) of the Public Health Service Act (42 U.S.C. 290aa(d)) is amended—

(1) by redesignating paragraphs (24) and (25) as paragraphs (25) and (26), respectively; and

(2) by inserting after paragraph (23) the following:

“(24) support the continued access to, or availability of, mental health and substance use disorder services during, or in response to, a public health emergency declared under section 319, including in consultation with, as appropriate, the Assistant Secretary for Preparedness and Response, the Director of the Centers for Disease Control and Prevention, and the heads of other relevant agencies, in preparing for, and responding to, a public health emergency;”.

(b) STRATEGIC PLAN.—Section 501(l)(4) of the Public Health Service Act (42 U.S.C. 290aa(l)(4)) is amended—
(1) in subparagraph (E), by striking “and” at the end;

(2) in subparagraph (F), by striking the period and inserting “; and”; and

(3) by adding at the end the following:

“(G) specify a strategy to support the continued access to, or availability of, mental health and substance use disorder services, including to at-risk individuals (as defined in section 2802(b)(4)), during, or in response to, public health emergencies declared pursuant to section 319.”.

(e) Biennial Report Concerning Activities and Progress.—Section 501(m) of the Public Health Service Act (42 U.S.C. 290aa(m)) is amended—

(1) by redesignating paragraphs (4) through (7) as paragraphs (5) through (8), respectively;

(2) by inserting after paragraph (3) the following:

“(4) a description of the Administration’s activities to support the continued provision of mental health and substance use disorder services, as applicable, in response to public health emergencies declared pursuant to section 319;”; and

(3) in paragraph (5), as so redesignated—
(A) by redesignating subparagraphs (D) and (E) as subparagraphs (E) and (F), respectively; and

(B) by inserting after subparagraph (C) the following:

“(D) relevant preparedness and response activities;”.

(d) ADVISORY COUNCILS.—Not later than 1 year after the date of enactment of this Act, the Assistant Secretary for Mental Health and Sub stance Use shall issue a report to the Committee on Health, Education, Labor, and Pensions and the Committee on Appropriations of the Senate and the Committee on Energy and Commerce and the Committee on Appropriations of the House of Representa tives, reflecting the feedback of the advisory councils for the Center for Substance Abuse Treatment, the Center for Substance Abuse Prevention, and the Center for Mental Health Services, pursuant to section 502 of the Public Health Service Act (42 U.S.C. 290aa–1), with recommendations to improve the continued provision of mental health and substance use disorder services during a public health emergency declared under section 319 of such Act (42 U.S.C. 247d), and the provision of such services as part of the public health and medical response to such an emergency, consistent with title XXVIII of such
Act (42 U.S.C. 300hh et seq.), including related to the 
capacity of the mental health and substance use disorder 
workforce and flexibilities provided to awardees of mental 
health and substance use disorder programs.

(e) GAO REPORT.—Not later than 3 years after the 
date of enactment of this Act, the Comptroller General 
of the United States shall submit to the Committee on 
Health, Education, Labor, and Pensions of the Senate and 
the Committee on Energy and Commerce of the House 
of Representatives a report on programs and activities of 
the Substance Abuse and Mental Health Services Admin-
istration to support the provision of mental health and 
substance use disorder services and related activities dur-
ing the COVID–19 pandemic, including the provision of 
such services as part of the medical and public health re-
response to such pandemic. Such report shall—

(1) examine the role played by the advisory 
councils described in section 502 of the Public 
Health Service Act (42 U.S.C. 290aa–1) and the 
National Mental Health and Substance Use Policy 
Laboratory established under section 501A of such 
Act (42 U.S.C. 290aa–0) in providing technical as-
stance and recommendations to the Substance 
Abuse and Mental Health Services Administration to 
support the response of such agency to the public
health emergency declared under section 319 of the Public Health Service Act (42 U.S.C. 247d) with respect to COVID–19;

(2) describe the manner in which existing awardees of mental health and substance use disorder programs provided and altered delivery of services during such public health emergency, including information on the populations served by such awardees and any barriers faced in delivering services; and

(3) describe activities of the Substance Abuse and Mental Health Services Administration to support the response to such public health emergency, including through technical assistance, provision of services, and any flexibilities provided to such existing awardees, and any barriers faced in implementing such activities.

SEC. 113. TRAUMA CARE REAUTHORIZATION.

(a) IN GENERAL.—Section 1201 of the Public Health Service Act (42 U.S.C. 300d) is amended—

(1) in subsection (a)—

(A) in paragraph (3)—

(i) by inserting “analyze,” after “compile,”; and
(ii) by inserting “and medically under-
served areas” before the semicolon;

(B) in paragraph (4), by adding “and”
after the semicolon;

(C) by striking paragraph (5); and

(D) by redesignating paragraph (6) as
paragraph (5);

(2) by redesignating subsection (b) as sub-
section (c); and

(3) by inserting after subsection (a) the fol-
lowing:

“(b) trauma care readiness and coordina-
tion.—the secretary, acting through the assistant sec-
retary for preparedness and response, shall support the
efforts of states and consortia of states to coordinate and
improve emergency medical services and trauma care dur-
ing a public health emergency declared by the secretary
pursuant to section 319 or a major disaster or emergency
declared by the president under section 401 or 501, re-
spectively, of the robert t. stafford disaster relief and
emergency assistance act. such support may include—

“(1) developing, issuing, and updating guid-
ance, as appropriate, to support the coordinated
medical triage and evacuation to appropriate medical
institutions based on patient medical need, taking into account regionalized systems of care;

“(2) disseminating, as appropriate, information on evidence-based or evidence-informed trauma care practices, taking into consideration emergency medical services and trauma care systems, including such practices identified through activities conducted under subsection (a) and which may include the identification and dissemination of performance metrics, as applicable and appropriate; and

“(3) other activities, as appropriate, to optimize a coordinated and flexible approach to the emergency response and medical surge capacity of hospitals, other health care facilities, critical care, and emergency medical systems.”.

(b) **GRANTS TO IMPROVE TRAUMA CARE IN RURAL AREAS.**—Section 1202 of the Public Health Service Act (42 U.S.C. 300d–3) is amended—

(1) by amending the section heading to read as follows: “**GRANTS TO IMPROVE TRAUMA CARE IN RURAL AREAS**”;

(2) by amending subsections (a) and (b) to read as follows:

“(a) **IN GENERAL.**—The Secretary shall award grants to eligible entities for the purpose of carrying out
research and demonstration projects to support the im-
provement of emergency medical services and trauma care
in rural areas through the development of innovative uses
of technology, training and education, transportation of
seriously injured patients for the purposes of receiving
such emergency medical services, access to prehospital
care, evaluation of protocols for the purposes of improve-
ment of outcomes and dissemination of any related best
practices, activities to facilitate clinical research, as appli-
cable and appropriate, and increasing communication and
coordination with applicable State or Tribal trauma sys-
tems.

“(b) ELIGIBLE ENTITIES.—

“(1) IN GENERAL.—To be eligible to receive a
grant under this section, an entity shall be a public
or private entity that provides trauma care in a
rural area.

“(2) PRIORITY.—In awarding grants under this
section, the Secretary shall give priority to eligible
entities that will provide services under the grant in
any rural area identified by a State under section
1214(d)(1).”; and

(3) by adding at the end the following:

“(d) REPORTS.—An entity that receives a grant
under this section shall submit to the Secretary such re-
ports as the Secretary may require to inform administration of the program under this section.”.

(c) PILOT GRANTS FOR TRAUMA CENTERS.—Section 1204 of the Public Health Service Act (42 U.S.C. 300d–6) is amended—

(1) by amending the section heading to read as follows: “PILOT GRANTS FOR TRAUMA CENTERS”;

(2) in subsection (a)—

(A) by striking “not fewer than 4” and inserting “10”;

(B) by striking “that design, implement, and evaluate” and inserting “to design, implement, and evaluate new or existing”;

(C) by striking “emergency care” and inserting “emergency medical”; and

(D) by inserting “, and improve access to trauma care within such systems” before the period;

(3) in subsection (b)(1), by striking subparagraphs (A) and (B) and inserting the following:

“(A) a State or consortia of States;

“(B) an Indian Tribe or Tribal organization (as defined in section 4 of the Indian Self-Determination and Education Assistance Act);
“(C) a consortium of level I, II, or III trauma centers designated by applicable State or local agencies within an applicable State or region, and, as applicable, other emergency services providers; or

“(D) a consortium or partnership of non-profit Indian Health Service, Indian Tribal, and urban Indian trauma centers.”;

(4) in subsection (c)—

(A) in the matter preceding paragraph (1)—

(i) by striking “that proposes a pilot project”; 

(ii) by striking “an emergency medical and trauma system that—” and inserting “a new or existing emergency medical and trauma system. Such eligible entity shall use amounts awarded under this subsection to carry out 2 or more of the following activities:”; 

(B) in paragraph (1) —

(i) by striking “coordinates” and inserting “Strengthening coordination and communication”; and
(ii) by striking “an approach to emergency medical and trauma system access throughout the region, including 9–1–1 Public Safety Answering Points and emergency medical dispatch;” and inserting “approaches to improve situational awareness and emergency medical and trauma system access, including distribution of patients during a mass casualty incident, throughout the region.”;

(C) in paragraph (2)—

(i) by striking “includes” and inserting “Providing”;

(ii) by inserting “support patient movement to” after “region to”; and

(iii) by striking the semicolon and inserting a period;

(D) in paragraph (3)—

(i) by striking “allows for” and inserting “Improving”; and

(ii) by striking “; and” and inserting a period;

(E) in paragraph (4), by striking “includes a consistent” and inserting “Supporting a consistent”; and
(F) by adding at the end the following:

“(5) Establishing, implementing, and disseminating, or utilizing existing, as applicable, evidence-based or evidence-informed practices across facilities within such emergency medical and trauma system to improve health outcomes, including such practices related to management of injuries, and the ability of such facilities to surge.

“(6) Conducting activities to facilitate clinical research, as applicable and appropriate.”;

(5) in subsection (d)(2)—

(A) in subparagraph (A)—

(i) in the matter preceding clause (i),

by striking “the proposed” and inserting “the applicable emergency medical and trauma system”; 

(ii) in clause (i), by inserting “or Tribal entity” after “equivalent State office”; and

(iii) in clause (vi), by striking “; and” and inserting a semicolon;

(B) by redesignating subparagraph (B) as subparagraph (C); and

(C) by inserting after subparagraph (A) the following:
“(B) for eligible entities described in sub-
paragraph (C) or (D) of subsection (b)(1), a de-
scription of, and evidence of, coordination with
the applicable State Office of Emergency Med-
ical Services (or equivalent State Office) or ap-
plicable such office for a Tribe or Tribal organi-
zation; and’’;

(6) in subsection (e)—

(A) in paragraph (1), by striking “$1 for
each $3” and inserting “$1 for each $5”; and

(B) by adding at the end the following:

“(3) WAIVER.—The Secretary may waive all or
part of the matching requirement described in para-
graph (1) for any fiscal year for a State, consortia
of States, Indian Tribe or Tribal organization, or
trauma center, if the Secretary determines that ap-
plying such matching requirement would result in
serious hardship or an inability to carry out the pur-
poses of the pilot program.”;

(7) in subsection (f), by striking “population in
a medically underserved area” and inserting “medi-
cally underserved population”; 

(8) in subsection (g)—

(A) in the matter preceding paragraph (1),
by striking “described in”;
(B) in paragraph (2), by striking “the system characteristics that contribute to” and inserting “opportunities for improvement, including recommendations for how to improve”;

(C) by striking paragraph (4);

(D) by redesigning paragraphs (5) and (6) as paragraphs (4) and (5), respectively;

(E) in paragraph (4), as so redesignated, by striking “; and” and inserting a semicolon;

(F) in paragraph (5), as so redesignated, by striking the period and inserting “; and”; and

(G) by adding at the end the following:

“(6) any evidence-based or evidence-informed strategies developed or utilized pursuant to subsection (e)(5).”; and

(9) by amending subsection (h) to read as follows:

“(h) DISSEMINATION OF FINDINGS.—Not later than 1 year after the completion of the final project under subsection (a), the Secretary shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report describing the information contained in each report submitted pursuant to sub-
section (g) and any additional actions planned by the Secretary related to regionalized emergency care and trauma systems.”.

(d) PROGRAM FUNDING.—Section 1232(a) of the Public Health Service Act (42 U.S.C. 300d–32(a)) is amended by striking “2010 through 2014” and inserting “2023 through 2027”.

SEC. 114. ASSESSMENT OF CONTAINMENT AND MITIGATION OF INFECTIOUS DISEASES.

(a) GAO STUDY.—The Comptroller General of the United States shall conduct a study that reviews a geographically diverse sample of States and territories that, in response to the COVID–19 pandemic, implemented preparedness and response plans that included isolation and quarantine recommendations or requirements. Such study shall include—

(1) a review of such State and territorial preparedness and response plans in place during the COVID–19 pandemic, an assessment of the extent to which such plans facilitated or presented challenges to State and territorial responses to such public health emergency, including response activities relating to isolation and quarantine to prevent the spread of COVID–19; and
(2) a description of the technical assistance provided by the Federal Government to help States and territories facilitate such response activities during responses to relevant public health emergencies declared by the Secretary of Health and Human Services pursuant to section 319 of the Public Health Service Act, including the public health emergency with respect to COVID–19, and a review of the degree to which such State and territorial plans were implemented and subsequently revised in response to the COVID–19 pandemic to address any challenges.

(b) Report.—Not later than 18 months after the date of enactment of this Act, the Comptroller General of the United States shall submit a report on the study under subsection (a) to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives.

SEC. 115. CONSIDERATION OF UNIQUE CHALLENGES IN NONCONTIGUOUS STATES AND TERRITORIES.

During any public health emergency declared under section 319 of the Public Health Service Act (42 U.S.C. 247d), the Secretary of Health and Human Services shall conduct quarterly meetings or consultations, as applicable or appropriate, with noncontiguous States and territories
with regard to addressing unique public health challenges
in such States and territories associated with such public
health emergency.

TITLE II—IMPROVING PUBLIC
HEALTH PREPAREDNESS AND
RESPONSE CAPACITY

Subtitle A—Addressing Disparities
and Improving Public Health
Emergency Responses

SEC. 201. ADDRESSING SOCIAL DETERMINANTS OF HEALTH
AND IMPROVING HEALTH OUTCOMES.

(a) In General.—Part B of title III of the Public
Health Service Act (42 U.S.C. 243 et seq.) is amended—
(1) by inserting after section 317U the fol-
lowing:

“SEC. 317V. ADDRESSING SOCIAL DETERMINANTS OF
HEALTH AND IMPROVING HEALTH OUT-
COMES.

“(a) In General.—The Secretary shall, as appro-
priate, award grants, contracts, or cooperative agreements
to eligible entities for the conduct of evidence-based or evi-
dence-informed projects, which may include the develop-
ment of networks to improve health outcomes and reduce
health disparities by improving the capacity of such enti-
ties to address social determinants of health in communities.

“(b) ELIGIBLE ENTITIES.—To be eligible to receive an award under this section, an entity shall—

“(1)(A) be a State, local, or Tribal health department, community-based organization, Indian Tribe or Tribal organization (as such terms are defined in section 4 of the Indian Self-Determination and Education Assistance Act), urban Indian organization (as defined in section 4 of the Indian Health Care Improvement Act), or other public or private entity, as the Secretary determines appropriate; or

“(B) be a consortia of entities described in subparagraph (A) or a public-private partnership, including a community partnership;

“(2) submit to the Secretary an application at such time, in such manner, and containing such information as the Secretary shall require;

“(3) in the case of an entity other than a community-based organization, demonstrate a history of successfully working with an established community-based organization to address health disparities;

“(4) submit a plan to conduct activities described in subsection (a) based on a community
needs assessment that takes into account community input; and

“(5) demonstrate the capacity to effectively implement evidence-based or evidence-informed strategies to address health disparities among underserved populations, which may include rural, racial, and ethnic minority populations and people with disabilities, in a timely manner.

“(c) USE OF FUNDS.—An entity described in subsection (b) shall use funds received under subsection (a), in consultation with State, local, and Tribal health departments, community-based organizations, entities serving medically underserved communities, and other entities, as applicable, with experience addressing social determinants of health or reducing health disparities, as applicable, for one or more of the following purposes:

“(1) Supporting the implementation, evaluation, and dissemination of strategies, including culturally-appropriate strategies, to address social determinants of health, based on the identified needs of the community that is the subject of the assessment submitted under subsection (b)(4), through evidence-informed or evidence-based programs and through the support and use of public health and health care
professionals to address such social determinants of health.

“(2) Establishing, maintaining, or improving, in consultation with State, local, or Tribal health departments, technology platforms or networks to support, in a manner that is consistent with applicable Federal and State privacy law—

“(A) coordination among appropriate entities;

“(B) information sharing on health and related social services;

“(C) technical assistance and related support for entities participating in the platforms or networks; and

“(D) as applicable and appropriate, activities to improve data collection for public health purposes and activities to improve coordination.

“(3) Implementing best practices for improving health outcomes and reducing disease among underserved populations, including rural or racial and ethnic minority populations.

“(4) Supporting consideration of social determinants of health in preparing for, and responding to, public health emergencies, through outreach, education, research, and other relevant activities.
“(d) **Best Practices and Technical Assistance.**—The Secretary, in consultation with the Director of the Office of Minority Health, the National Coordinator for Health Information Technology, and the Administrator of the Administration for Community Living, may award grants, contracts, and cooperative agreements to public or nonprofit private entities, including minority serving institutions (defined, for purposes of this subsection, as institutions and programs described in section 326(c)(1) of the Higher Education Act of 1965 and institutions described in section 371(a) of such Act of 1965), to—

“(1) identify or facilitate the development of best practices to support improved health outcomes and reduce health disparities by addressing social determinants of health;

“(2) provide technical assistance, training, and evaluation assistance to award recipients under subsection (a);

“(3) disseminate best practices, including to award recipients under subsection (a); and

“(4) leverage, establish, or operate regional centers to develop, evaluate, and disseminate effective strategies on the utilization of preventive health care services to address social determinants of health, in-
including supporting research and training related to such strategies.

“(e) AWARD PERIODS.—The Secretary shall issue awards under this section for periods of not more than 5 years and may issue extensions of such award periods for an additional period of up to 3 years.

“(f) REPORT.—Not later than September 30, 2026, the Secretary shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report that includes information on activities funded under this section. Such report shall include a description of—

“(1) changes in the capacity of public health entities to address social determinants of health in communities, including any applicable platforms or networks developed or utilized to coordinate health and related social services and any changes in workforce capacity or capabilities;

“(2) improvements in health outcomes and in reducing health disparities in medically underserved communities;

“(3) activities conducted to support consideration of social determinants of health in preparing for, and responding to, public health emergencies,
through outreach, education, and other relevant activities;

“(4) communities and populations served by recipients of awards under subsection (a);

“(5) activities supported under subsection (e); and

“(6) other relevant activities and outcomes, as determined by the Secretary.

“(g) Authorization of Appropriations.—To carry out this section, there are authorized to be appropriated $70,000,000 for each of fiscal years 2023 through 2027.”; and

(2) by striking section 330D (42 U.S.C. 254c–4).

(b) GAO Study and Report.—Not later than 4 years after the date of enactment of this Act, the Comptroller General of the United States shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Energy and Committee on Energy and Commerce of the House of Representatives a report on the program authorized under section 317V of the Public Health Service Act, as added by subsection (a), including a review of the outcomes and effectiveness of the program and coordination with other programs in the Department
of Health and Human Services with similar goals to ensure that there was no unnecessary duplication of efforts.

SEC. 202. NATIONAL ACADEMIES OF SCIENCES, ENGINEERING, AND MEDICINE REPORT.

(a) In General.—Not later than 45 days after the date of enactment of this Act, the Secretary of Health and Human Services shall seek to enter into a contract with the National Academies of Sciences, Engineering, and Medicine (referred to in this section as the “National Academies”) to conduct a study to examine health disparities and the effect of such disparities on health outcomes, which may include health outcomes related to pandemic and other public health emergencies.

(b) Report.—Pursuant to the contract under subsection (a), the National Academies shall, not later than 3 years after the date of enactment of this Act, issue a report informed by the study conducted under such subsection that includes—

(1) consideration of previous recommendations made by the National Academies related to health disparities, including in the report titled “Unequal Treatment: Confronting Racial and Ethnic Disparities in Healthcare”;
(2) recommendations for strategies to improve health outcomes by reducing health disparities, which may include education and training; and

(3) an assessment of ongoing research and strategies to reduce health disparities and improve health outcomes, including effective service delivery models.

(c) CLARIFICATION.—In completing the requirements of the contract under this section, the National Academies may leverage relevant ongoing work of the National Academies, including ongoing work related to the impact of Federal policies on health disparities.

(d) AUTHORIZATION OF APPROPRIATIONS.—There is authorized to be appropriated $2,000,000 for fiscal year 2023 to carry out this section.

Subtitle B—Improving Public Health Data

SEC. 211. MODERNIZING BIOSURVEILLANCE CAPABILITIES AND INFECTIOUS DISEASE DATA COLLECTION.

Section 319D of the Public Health Service Act (42 U.S.C. 247d–4) is amended—

(1) in subsection (b)(1)(A), by striking “, and local” and inserting “, local, and Tribal”; and

(2) in subsection (e)—
(A) in paragraph (1), by inserting “modernize,” after “establish,”;

(B) in paragraph (3)(B), by inserting “, and make recommendations to improve the quality of data collected pursuant to subparagraph (A) to ensure complete, accurate, and timely sharing of such data, as appropriate, across such elements as described in subparagraph (A)” after “under subparagraph (A)”;

(C) in paragraph (5)—

(i) in subparagraph (A)—

(I) in the matter preceding clause (i), by striking “and operating” and inserting “, operating, and updating, as appropriate,”;

(II) in clause (iv), by striking “and” at the end;

(III) in clause (v), by striking the period and inserting “; and”; and

(IV) by adding at the end the following:

“(vi) in collaboration with State, local, and Tribal public health officials, integrate and update applicable existing public health data systems and networks of the
Department of Health and Human Services to reflect technological advancements, consistent with section 2823, as applicable.”; and

(ii) in subparagraph (B)—

(I) in clause (i), by inserting “and 180 days after the date of enactment of the PREVENT Pandemics Act,” after “Innovation Act of 2019,”; 

(II) in clause (ii), by inserting “experts in privacy and data security;” after “forecasting);”; and

(III) in clause (iii)—

(aa) in subclause (V), by striking “and” at the end;

(bb) in subclause (VI), by striking the period and inserting a semicolon; and

(cc) by adding at the end the following: “(VII) strategies to integrate laboratory and public health data systems and capabilities to support rapid and accurate reporting of laboratory
test results and associated relevant data;

“(VIII) strategies to improve the collection and reporting of relevant, aggregated, deidentified demographic data to inform responses to public health emergencies, including identification of at-risk populations and to address potential health disparities; and

“(IX) strategies to improve the electronic exchange of health information between State and local health departments and health care providers and facilities to improve public health surveillance.”; and

(D) in paragraph (6)(A)—

(i) in the matter preceding clause (i), by inserting “and every 5 years thereafter,” after “Innovation Act of 2019,”

(ii) in clause (iii)—

(I) in subclause (III), by striking “and” at the end; and

(II) by adding at the end the following:
“(V) improve coordination and collaboration, as appropriate, with other Federal departments; and

“(VI) implement applicable lessons learned from recent public health emergencies to address gaps in situational awareness and biosurveillance capabilities;”;

(iii) in clause (iv), by striking “and” at the end;

(iv) in clause (v), by striking the period and inserting “, including a description of how such steps will further the goals of the network, consistent with paragraph (1); and”; and

(v) by adding at the end the following:

“(vi) identifies and demonstrates measurable steps the Secretary will take to further develop and integrate infectious disease detection, support rapid and accurate reporting of laboratory test results during a public health emergency, and improve coordination and collaboration with State, local, and Tribal public health officials, clinical laboratories, and other enti-
ties with expertise in public health surveil-

lance.”;

(3) in subsection (d)—

(A) in paragraph (1), by inserting “, act-

ing through the Director of the Centers for Dis-

case Control and Prevention and in coordina-

tion with the heads of other appropriate agen-

cies and offices within the Department of

Health and Human Services,” after “the Sec-

retary”; 

(B) in paragraph (2)(C), by inserting “, in-

cluding any public-private partnerships or

other partnerships entered into to improve such

capacity” before the semicolon; and

(C) by adding at the end the following:

“(6) NON-DUPLICATION OF EFFORT.—The Sec-

retary shall ensure that activities carried out under

an award under this subsection do not unnecessarily

duplicate efforts of other agencies and offices within

the Department of Health and Human Services.”;

(4) by amending subsection (i) to read as fol-

lows:

“(i) AUTHORIZATION OF APPROPRIATIONS.—There

are authorized to be appropriated—
“(1) to carry out subsection (a), $25,000,000
for each of fiscal years 2022 and 2023; and
“(2) to carry out subsections (b), (c), and (d),
$136,800,000 for each of fiscal years 2022 and
2023.”; and
(5) by striking “tribal” each place it appears
and inserting “Tribal”.
SEC. 212. GENOMIC SEQUENCING, ANALYTICS, AND PUBLIC
HEALTH SURVEILLANCE OF PATHOGENS.
(a) Guidance Supporting Genomic Sequencing
of Pathogens Collaboration.—The Secretary of
Health and Human Services (referred to in this section
as the “Secretary”), in consultation with the heads of
other Federal departments or agencies, as appropriate,
shall issue guidance to support collaboration relating to
genomic sequencing of pathogens, including the use of new
and innovative approaches and technology for the detec-
tion, characterization, and sequencing of pathogens, to im-
prove public health surveillance and preparedness and re-
response activities, consistent with section 2824 of the Pub-
lic Health Service Act, as added by subsection (b). Such
guidance shall address the secure sharing, for public
health surveillance purposes, of specimens of such patho-
gens, between appropriate entities and public health au-
thorities, consistent with the regulations promulgated
under section 264(c) of the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. 1320d–2 note), as applicable, and in a manner that protects personal privacy to the extent required by applicable privacy law, at a minimum, and the appropriate use of sequence data derived from such specimens.

(b) GENOMIC SEQUENCING PROGRAM.—Title XXVIII of the Public Health Service Act (42 U.S.C. 300hh et seq.) is amended by adding at the end the following

“SEC. 2824. GENOMIC SEQUENCING, ANALYTICS, AND PUBLIC HEALTH SURVEILLANCE OF PATHOGENS PROGRAM.

“(a) GENOMIC SEQUENCING, ANALYTICS, AND PUBLIC HEALTH SURVEILLANCE OF PATHOGENS PROGRAM.—The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in consultation with the Director of the National Institutes of Health and heads of other departments and agencies, as appropriate, shall strengthen and expand activities related to genomic sequencing of pathogens, including new and innovative approaches and technology for the detection, characterization, and sequencing of pathogens, analytics, and public health surveillance, including—
“(1) continuing and expanding activities, which may include existing genomic sequencing activities related to advanced molecular detection, to—

“(A) identify and respond to emerging infectious disease threats; and

“(B) identify the potential use of genomic sequencing technologies, advanced computing, and other advanced technology to inform surveillance activities and incorporate the use of such technologies, as appropriate, into related activities;

“(2) providing technical assistance and guidance to State, Tribal, local, and territorial public health departments to increase the capacity of such departments to perform genomic sequencing of pathogens, including recipients of funding under section 2821;

“(3) carrying out activities to enhance the capabilities of the public health workforce with respect to pathogen genomics, epidemiology, and bioinformatics, including through training; and

“(4) continuing and expanding activities, as applicable, with public and private entities, including relevant departments and agencies, laboratories, academic institutions, and industry.
“(b) PARTNERSHIPS.—For the purposes of carrying out the activities described in subsection (a), the Secretary, acting through the Director of the Centers for Disease Control and Prevention, may award grants, contracts, or cooperative agreements to entities, including academic and other laboratories, with expertise in genomic sequencing for public health purposes, including new and innovative approaches to, and related technology for, the detection, characterization, and sequencing of pathogens.

“(c) CENTERS OF EXCELLENCE.—

“(1) IN GENERAL.—The Secretary shall, as appropriate, award grants, contracts, or cooperative agreements to public health agencies for the establishment or operation of centers of excellence to promote innovation in pathogen genomics and molecular epidemiology to improve the control of and response to pathogens that may cause a public health emergency. Such centers shall, as appropriate—

“(A) identify and evaluate the use of genomics, or other related technologies that may advance public health preparedness and response;

“(B) improve the identification, development, and use of tools for integrating and analyzing genomic and epidemiologic data;
“(C) assist with genomic surveillance of, and response to, infectious diseases, including analysis of pathogen genomic data;

“(D) conduct applied research to improve public health surveillance of, and response to, infectious diseases through innovation in pathogen genomics and molecular epidemiology; and

“(E) develop and provide training materials for experts in the fields of genomics, microbiology, bioinformatics, epidemiology, and other fields, as appropriate.

“(2) REQUIREMENTS.—To be eligible for an award under paragraph (1), an entity shall submit to the Secretary an application containing such information as the Secretary may require, including a description of how the entity will partner, as applicable, with academic institutions or a consortium of academic partners that have relevant expertise, such as microbial genomics, molecular epidemiology, or the application of bioinformatics or statistics.

“(d) AUTHORIZATION.—For purposes of carrying out this section, there are authorized to be appropriated $175,000,000 for each of fiscal years 2023 through 2027.”.
SEC. 213. SUPPORTING PUBLIC HEALTH DATA AVAIL-
ABILITY AND ACCESS.

(a) DESIGNATION OF PUBLIC HEALTH DATA STAND-
ARDS.—Section 2823(a)(2) of the Public Health Service
Act (42 U.S.C. 300hh–33(a)(2)) is amended—

(1) by striking “In carrying out” and inserting
the following:

“(A) IN GENERAL.—In carrying out”; and

(2) by striking “shall, as appropriate and” and
inserting “shall, not later than 2 years after the date
of enactment of the PREVENT Pandemics Act,”;

and

(3) by adding at the end the following:

“(B) SELECTION OF DATA AND TECH-
NOLOGY STANDARDS.—The standards des-
ignated as described in subparagraph (A) may
include standards to improve—

“(i) the exchange of electronic health
information for—

“(I) electronic case reporting;

“(II) syndromic surveillance;

“(III) reporting of vital statistics;

and

“(IV) reporting test orders and
results electronically, including from
laboratories;
“(ii) automated electronic reporting to relevant public health data systems of the Centers for Disease Control and Prevention; and

“(iii) such other use cases as the Secretary determines appropriate.

“(C) NO DUPLICATIVE EFFORTS.—

“(i) IN GENERAL.—In carrying out the requirements of this paragraph, the Secretary, in consultation with the Office of the National Coordinator for Health Information Technology, may use input gathered (including input and recommendations gathered from the Health Information Technology Advisory Committee), and materials developed, prior to the date of enactment of the PREVENT Pandemics Act.

“(ii) DESIGNATION OF STANDARDS.— Consistent with sections 13111 and 13112 of the HITECH Act, the data and technology standards designated pursuant to this paragraph shall align with the standards and implementation specifications previously adopted by the Secretary pursuant to section 3004, as applicable.
“(D) Privacy and security.—Nothing in this paragraph shall be construed as modifying applicable Federal or State information privacy or security law.”

(b) Study on laboratory information standards.—

(1) In general.—Not later than 1 year after the date of enactment of this Act, the Office of the National Coordinator for Health Information Technology shall conduct a study to review the use of standards for electronic ordering and reporting of laboratory test results.

(2) Areas of concentration.—In conducting the study under paragraph (1), the Office of the National Coordinator for Health Information Technology shall—

(A) determine the extent to which clinical laboratories are using standards for electronic ordering and reporting of laboratory test results;

(B) assess trends in laboratory compliance with standards for ordering and reporting laboratory test results and the effect of such trends on the interoperability of laboratory data with public health data systems;
(C) identify challenges related to collection and reporting of demographic and other data elements with respect to laboratory test results;

(D) identify any challenges associated with using or complying with standards and reporting laboratory test results with data elements identified in standards for electronic ordering and reporting of such results; and

(E) review other relevant areas determined appropriate by the Office of the National Coordinator for Health Information Technology.

(3) REPORT.—Not later than 2 years after the date of enactment of this Act, the Office of the National Coordinator for Health Information Technology shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report concerning the findings of the study conducted under paragraph (1).

(c) SUPPORTING INFORMATION SHARING THROUGH DATA USE AGREEMENTS.—

(1) INTERAGENCY DATA USE AGREEMENTS WITHIN THE DEPARTMENT OF HEALTH AND HUMAN SERVICES FOR PUBLIC HEALTH EMERGENCIES.—
(A) IN GENERAL.—The Secretary of Health and Human Services (referred to in this subsection as the “Secretary”) shall, as appropriate, facilitate the development of, or updates to, memoranda of understanding, data use agreements, or other applicable interagency agreements regarding appropriate access, exchange, and use of public health data between the Centers for Disease Control and Prevention, the Office of the Assistant Secretary for Preparedness and Response, other relevant agencies or offices within the Department of Health and Human Services, and other relevant Federal agencies, in order to prepare for, identify, monitor, and respond to declared or potential public health emergencies.

(B) REQUIREMENTS.—In carrying out activities pursuant to subparagraph (A), the Secretary shall—

   (i) ensure that the agreements and memoranda of understanding described in such subparagraph—

   (I) address the methods of granting access to data held by one agency or office with another to support the
respective missions of such agencies or offices;

(II) consider minimum necessary principles of data sharing for appropriate use;

(III) include appropriate privacy and cybersecurity protections; and

(IV) are subject to regular updates, as appropriate;

(ii) collaborate with the Centers for Disease Control and Prevention, the Office of the Assistant Secretary for Preparedness and Response, the Office of the Chief Information Officer, and, as appropriate, the Office of the National Coordinator for Health Information Technology, and other entities within the Department of Health and Human Services; and

(iii) consider the terms and conditions of any existing data use agreements with other public or private entities and any need for updates to such existing agreements, consistent with paragraph (2).

(2) DATA USE AGREEMENTS WITH EXTERNAL ENTITIES.—The Secretary, acting through the Di-
rector of the Centers for Disease Control and Prevention and the Assistant Secretary for Preparedness and Response, may update memoranda of understanding, data use agreements, or other applicable agreements and contracts to improve appropriate access, exchange, and use of public health data between the Centers for Disease Control and Prevention and the Office of the Assistant Secretary for Preparedness and Response and external entities, including State, Tribal, and territorial health departments, laboratories, hospitals and other health care providers, electronic health records vendors, and other entities, as applicable and appropriate, in order to prepare for, identify, monitor, and respond to declared or potential public health emergencies.

(3) REPORT.—Not later than 90 days after the date of enactment of this Act, the Secretary shall report to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives on the status of the agreements under this subsection.

(d) IMPROVING INFORMATION SHARING AND AVAILABILITY OF PUBLIC HEALTH DATA.—Part A of title III
of the Public Health Service Act (42 U.S.C. 241 et seq.)
is amended by adding at the end the following:

“SEC. 310B. IMPROVING INFORMATION SHARING AND
AVAILABILITY OF PUBLIC HEALTH DATA.

“(a) IN GENERAL.—The Secretary may, in consulta-
tion with State, local, and Tribal public health officials,
carry out activities to improve the availability of appro-
priate and applicable public health data related to commu-
nicable diseases, and information sharing between, the Di-
rector of the Centers for Disease Control and Prevention,
the Assistant Secretary for Preparedness and Response,
and such State, local, and Tribal public health officials,
which may include such data from—

“(1) health care providers and facilities;
“(2) public health and clinical laboratories;
“(3) health information exchanges and health
information networks; and
“(4) State, local, and Tribal health depart-
ments.

“(b) CONTENT, FORM, AND MANNER.—The Sec-
retary shall, consistent with the requirements of this sec-
tion, work with such officials and relevant stakeholders to
provide information on the content, form, and manner in
which such data may most effectively support the ability
of State, local, and Tribal health departments to respond
to such communicable diseases, including related to the
collection and reporting of demographic and other relevant
data elements. Such form and manner requirements shall
align with the standards and implementation specifications adopted by the Secretary under section 3004, as applicable.

“(c) DECREASED BURDEN.—In facilitating the coord-
ination of efforts under subsection (a), the Secretary
shall make reasonable efforts to limit reported public
health data to the minimum necessary information needed
to accomplish the intended public health surveillance pur-
pose.

“(d) EXEMPTION OF CERTAIN PUBLIC HEALTH
DATA FROM DISCLOSURE.—The Secretary, acting
through the Director of the Centers for Disease Control
and Prevention, may exempt from disclosure under section
552(b)(3) of title 5, United States Code, public health
data that are gathered under this section if—

“(1) an individual is identified through such
data; or

“(2) there is at least a very small risk, as deter-
mined by current scientific practices or statistical
methods, that some combination of the information,
the request, and other available data sources or the
application of technology could be used to deduce the identity of an individual.”.

(c) Improving Public Health Data Collection.—

(1) In general.—The Secretary of Health and Human Services (referred to in this subsection as the “Secretary”) shall award grants, contracts, or cooperative agreements to eligible entities for purposes of identifying, developing, or disseminating best practices in the collection of electronic health information and the use of designated data standards and implementation specifications to improve the quality and completeness of data, including demographic data, collected, accessed, or used for public health purposes and to address health disparities and related health outcomes.

(2) Eligible entities.—To be eligible to receive an award under this subsection an entity shall—

(A) be a health care provider, academic medical center, community-based organization, State, local governmental entity, Indian Tribe or Tribal organization (as such terms are defined in section 4 of the Indian Self Determination and Education Assistance Act (25 U.S.C.
urban Indian organization (as defined in section 4 of the Indian Health Care Improvement Act (25 U.S.C. 1603)), or other appropriate public or private nonprofit entity, or a consortia of any such entities; and

(B) submit an application to the Secretary at such time, in such manner, and containing such information as the Secretary may require.

(3) ACTIVITIES.—Entities receiving awards under this subsection shall use such award to develop and test best practices for training health care providers to use standards and implementation specifications that assist in the capture, access, exchange, and use of electronic health information, including demographic information, disability status, veteran status, housing status, functional status, and other data elements. Such activities shall include, at a minimum—

(A) improving, understanding, and using data standards and implementation specifications;

(B) developing or identifying methods to improve communication with patients in a culturally- and linguistically-appropriate man-
ner, including to better capture information related to demographics of such individuals;

(C) developing methods for accurately categorizing and recording patient responses using available data standards;

(D) educating providers regarding the utility of such information for public health purposes and the importance of accurate collection and recording of such data; and

(E) other activities, as the Secretary determines appropriate.

(4) REPORTING.—

(A) REPORTING BY AWARD RECIPIENTS.—Each recipient of an award under this subsection shall submit to the Secretary a report on the results of best practices identified, developed, or disseminated through such award.

(B) REPORT TO CONGRESS.—Not later than 1 year after the completion of the program under this subsection, the Secretary shall submit a report to Congress on the success of best practices developed under such program, opportunities for further dissemination of such best practices, and recommendations for improving the capture, access, exchange, and use of infor-
117

1 mation to improve public health and reduce
2 health disparities.

(5) NON-DUPLICATION OF EFFORTS.—The Sec-
3 retary shall ensure that the activities and programs
4 carried out under this subsection are free of unnec-
5 essary duplication of effort.

(6) AUTHORIZATION OF APPROPRIATIONS.—
7 There are authorized to be appropriated
8 $10,000,000 for each of fiscal years 2023 through
9 2025 to carry out this subsection.

SEC. 214. EPIDEMIC FORECASTING AND OUTBREAK ANA-
LYTICS.

Title XXVIII of the Public Health Service Act (42
U.S.C. 300hh et seq.), as amended by section 212, is fur-
ther amended by adding at the end the following:

“SEC. 2825. EPIDEMIC FORECASTING AND OUTBREAK ANA-
LYTICS.

“(a) IN GENERAL.—The Secretary, acting through
the Director of the Centers for Disease Control and Pre-
vention, shall continue activities related to the develop-
ment of infectious disease outbreak analysis capabilities

to enhance the prediction, modeling, and forecasting of po-
tential public health emergencies and other infectious dis-
ease outbreaks, which may include activities to support
preparedness for, and response to, such emergencies and
outbreaks. In carrying out this subsection, the Secretary shall identify strategies to include and leverage, as appropriate, the capabilities to public and private entities, which may include conducting such activities through collaborative partnerships with public and private entities, including academic institutions, and other Federal agencies, consistent with section 319D, as applicable.

“(b) CONSIDERATIONS.—In carrying out subsection (a), the Secretary, acting through the Director of the Centers for Disease Control and Prevention, may consider public health data and, as appropriate, other data sources related to preparedness for, or response to, public health emergencies and infectious disease outbreaks.

“(c) ANNUAL REPORTS.—Not later than 1 year after the date of enactment of this section, and annually thereafter for each of the subsequent 4 years, the Secretary shall prepare and submit a report, to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives, regarding an update on progress on activities conducted under this section to develop infectious disease outbreak analysis capabilities and any additional information relevant to such efforts.”
SEC. 215. PUBLIC HEALTH DATA TRANSPARENCY.

(a) REPORT.—Not later than 1 year after the date of enactment of this Act, the Secretary of Health and Human Services shall issue a report assessing practices, objectives, and associated progress and challenges in achieving such objectives, of the Centers of Disease Control and Prevention with respect to the collection and dissemination of public health data related to a public health emergency declared under section 319 of the Public Health Service Act (42 U.S.C. 247d) or a potential public health emergency.

(b) PLAN.—Not later than 180 days following the issuance of the report pursuant to paragraph (1), the Director of the Centers for Disease Control and Prevention shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a plan that shall include—

(1) steps to improve the timely reporting and dissemination of public health data related to a public health emergency declared under section 319 of the Public Health Service Act (42 U.S.C. 247d) or a potential public health emergency that is collected by the Centers for Disease Control and Prevention, including any associated barriers;
(2) recommendations to Congress regarding
gaps in such practices and objectives described in
subsection (a); and

(3) considerations regarding the requirements
and limitations of data use agreements for such pur-
poses, as applicable.

SEC. 216. GAO REPORT ON PUBLIC HEALTH PREPARED-
NESS, RESPONSE, AND RECOVERY DATA CA-
PABILITIES.

(a) Study.—The Comptroller General of the United
States (referred to in this section as the “Comptroller
General”) shall conduct a study on the efforts of the De-
partment of Health and Human Services to ensure that
public health preparedness, response, and recovery data
capabilities related to pandemic and other biological
threats are not unnecessarily duplicative, overlapping, or
fragmented. Such study shall include—

(1) a comprehensive list of all public health pre-
paredness, response, and recovery data collection,
such as incidence and prevalence of disease tracking,
hospitalizations, critical care capacity, and testing
programs, at the Department of Health and Human
Services, as identified by the department and its
component agencies;
(2) an analysis of any duplication, overlap, or fragmentation of the programs identified in paragraph (1);

(3) identification of any efforts of the Department of Health and Human Services to reduce unnecessary duplication and improve coordination, efficiency, and effectiveness of such programs and any associated challenges; and

(4) a description of the funding and other resources dedicated to the operation of each such program identified in paragraph (1).

(b) REPORTING.—

(1) IN GENERAL.—Based on the study conducted under subsection (a), the Comptroller General shall—

(A) not later than 6 months after the date of enactment of this Act, provide a briefing to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives; and

(B) not later than 18 months after the date of enactment of this Act, submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on
Energy and Commerce of the House of Representa-
tives a complete report on such study.

(2) Recommendations.—The report under paragraph (1)(B) shall include recommendations, as appropriate, with respect to public health prepared-
ness, response, and recovery data programs at the Department of Health and Human Services, to—

(A) streamline data collection and reduce fragmentation and address any associated chal-
lenges;

(B) reduce duplication in such programs;

and

(C) improve information-sharing across programs.

Subtitle C—Revitalizing the Public Health Workforce

SEC. 221. IMPROVING RECRUITMENT AND RETENTION OF THE FRONTLINE PUBLIC HEALTH WORK-
FORCE.

(a) In General.—Section 776 of the Public Health Service Act (42 U.S.C. 295f–1) is amended—

(1) in subsection (a)—

(A) by striking “supply of” and inserting “supply of, and encourage recruitment and re-
tention of,”; and
(B) by striking “Federal,”; 

(2) in subsection (b)—

(A) by amending paragraph (1)(A) to read as follows:

“(1)(A)(i) be accepted for enrollment, or be enrolled, as a student in an accredited institution of higher education or school of public health in the final semester (or equivalent) of a program leading to a certificate or degree, including a master’s or doctoral degree, in public health, epidemiology, laboratory sciences, data systems, data science, data analytics, informatics, statistics, or another subject matter related to public health; and

“(ii) be employed by, or have accepted employment with, a State, local, or Tribal public health agency, or a related training fellowship at such State, local, or Tribal public health agency, as recognized by the Secretary, to commence upon graduation; or”; and

(B) in paragraph (1)(B)—

(i) in clause (i)—

(I) by striking “accredited educational institution in a State or territory” and inserting “accredited insti-
tuition of higher education or school of public health”; and

(II) by striking “a public health or health professions degree or certificate” and inserting “a certificate or degree, including a master’s or doctoral degree, in public health, epidemiology, laboratory sciences, data systems, data science, data analytics, informatics, statistics, or another subject matter related to public health”; and

(ii) in clause (ii)—

(I) by striking “Federal,”; and

(II) by striking “fellowship,” and inserting “fellowship at such State, local, or Tribal public health agency,”;

(3) in subsection (c)(2)—

(A) by striking “Federal,”; and

(B) by striking “equal to the greater of—” and all that follows through the end of sub
paragraph (B) and inserting “of at least 3 consecutive years;”; 

(4) in subsection (d)—
(A) by amending paragraph (1) to read as follows:

“(1) IN GENERAL.—A loan repayment provided for an individual under a written contract under the Program shall consist of payment, in accordance with paragraph (2), for the individual toward the outstanding principal and interest on education loans incurred by the individual in the pursuit of the relevant degree or certificate described in subsection (b)(1) in accordance with the terms of the contract.”; and

(B) in paragraph (2)—

(i) by striking “For each year” and inserting the following:

“(A) IN GENERAL.—For each year”;

(ii) by striking “$35,000” and inserting “$50,000”;

(iii) by striking “$105,000” and inserting “$150,000”; and

(iv) by adding at the end the following:

“(B) CONSIDERATIONS.—The Secretary may take action in making awards under this section to ensure that—
“(i) an appropriate proportion of contracts are awarded to individuals who are eligible to participate in the program pursuant to subsection (b)(1)(A); and

“(ii) contracts awarded under this section are equitably distributed among—

“(I) the geographical regions of the United States;

“(II) local, State, and Tribal public health departments; and

“(III) such public health departments under subclause (II) serving rural and urban areas.”;

(5) in subsection (e), by striking “receiving a degree or certificate from a health professions or other related school” and inserting “with a contract to serve under subsection (e)”;

(6) in subsection (f), by adding at the end the following: “In the event that a participant fails to either begin or complete the obligated service requirement of the loan repayment contract under this section, the Secretary may waive or suspend either the unfulfilled service or the assessed damages as provided for under section 338E(d), as appropriate.”;
(7) by redesignating subsection (g) as subsection (i);

(8) by inserting after subsection (f) the following:

“(g) ELIGIBLE LOANS.—The loans eligible for repayment under this section are each of the following:

“(1) Any loan for education or training for employment by a health department.

“(2) Any loan under part E of title VIII (relating to nursing student loans).

“(3) Any Federal Direct Stafford Loan, Federal Direct PLUS Loan, Federal Direct Unsubsidized Stafford Loan, or Federal Direct Consolidation Loan (as such terms are used in section 455 of the Higher Education Act of 1965).


“(5) Any other Federal loan, as the Secretary determines appropriate.

“(h) PILOT PROGRAM.—

“(1) IN GENERAL.—The Secretary shall, as appropriate, establish a pilot program, to be known as the Bio-Preparedness Workforce Pilot Program, to provide for loan repayment for health professionals with expertise in infectious diseases and emergency
preparedness and response activities to ensure an adequate supply of such professionals. Such program shall be administered consistent with the requirements of this section, except that, to be eligible to participate in the pilot program, an individual shall—

“(A)(i) be accepted for enrollment, or be enrolled, as a student in an accredited institution of higher education in the final semester (or equivalent) of a program leading to a health professions degree or certificate program relevant to such program; or

“(ii) have graduated, during the preceding 10-year period, from an accredited institution of higher education with a health professions degree or certificate program relevant to such program; and

“(B) be employed by, or have accepted employment with—

“(i) a Federal health care facility;

“(ii) a nonprofit health care facility that is located in a health professional shortage area (as defined in section 332), a frontier health professional shortage area (as defined in section 799B), or a medi-
cally underserved community (as defined in section 799B);

“(iii) an entity receiving assistance under title XXVI for the provision of clinical services;

“(iv) a health program, or a facility, operated by an Indian Tribe or Tribal organization (as those terms are defined in section 4 of the Indian Self-Determination and Education Assistance Act) or by an urban Indian organization (as defined in section 4 of the Indian Health Care Improvement Act); or

“(v) another relevant entity determined appropriate by the Secretary, as a health professional with expertise in infectious diseases or emergency preparedness and response.

“(2) NON-DUPLICATION OF EFFORT.—The Secretary shall ensure that the pilot program established under paragraph (1) does not unnecessarily duplicate the National Health Service Corps Loan Repayment Program, or any other loan repayment program operated by the Department of Health and Human Services.
“(3) Evaluation and report to Congress.—

“(A) in general.—The Secretary shall evaluate the pilot program at the conclusion of the first cycle of recipients funded by the pilot program.

“(B) report.—

“(i) in general.—The Secretary shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report on the evaluation under subparagraph (A). The report shall include, at a minimum, outcomes information from the pilot program, including any impact on recruitment and retention of health professionals with expertise in infectious diseases and emergency preparedness and response activities.

“(ii) recommendation.—The report under this subparagraph shall include a recommendation by the Secretary as to whether the pilot program under this subsection should be extended.”
(9) in subsection (i), as so redesignated, by striking “$195,000,000 for fiscal year 2010, and such sums as may be necessary for each of fiscal years 2011 through 2015” and inserting “such sums as may be necessary for each of fiscal years 2022 through 2025”; and

(10) by striking “tribal” each place such term appears and inserting “Tribal”.

(b) GAO STUDY ON PUBLIC HEALTH WORKFORCE.—Not later than 2 years after the date of enactment of this Act, the Comptroller General of the United States shall—

(1) conduct an evaluation of what is known about the public health workforce in the United States, which shall address—

(A) existing gaps in the Federal, State, local, Tribal, and territorial public health workforce, including positions that may be required to prepare for, and respond to, a public health emergency such as COVID–19;

(B) challenges associated with the hiring, recruitment, and retention of the Federal, State, local, Tribal, and territorial public health workforce; and
(C) Federal efforts to improve hiring, recruitment, and retention of the public health workforce; and

(2) submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report on such review.

SEC. 222. AWARDS TO SUPPORT COMMUNITY HEALTH WORKERS AND COMMUNITY HEALTH.

(a) IN GENERAL.—Section 399V of the Public Health Service Act (42 U.S.C. 280g–11) is amended—

(1) by amending the section heading to read as follows: “AWARDS TO SUPPORT COMMUNITY HEALTH WORKERS AND COMMUNITY HEALTH”;

(2) by amending subsection (a) to read as follows:

“(a) IN GENERAL.—The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in coordination with the Administrator of the Health Resources and Services Administration, shall award grants, contracts, or cooperative agreements to eligible entities to promote positive health behaviors and outcomes for populations in medically underserved communities by leveraging community health workers, including by addressing ongoing and longer-term community health
needs, and by building the capacity of the community health worker workforce. Such grants, contracts, and cooperative agreements shall be awarded in alignment and coordination with existing funding arrangements supporting community health workers.”;

(3) in subsection (b)—

(A) in the matter preceding paragraph (1)—

(i) by striking “Grants awarded” and inserting “Subject to any requirements for the scope of licensure, registration, or certification of a community health worker under applicable State law, grants, contracts, and cooperative agreements awarded”; and

(ii) by striking “support community health workers”;

(B) by redesignating paragraphs (3) through (5) as paragraphs (4) through (6), respectively;

(C) by striking paragraphs (1) and (2) and inserting the following:

“(1) recruit, hire, train, and retain community health workers that reflect the needs of the community;
“(2) support community health workers in providing education and outreach, in a community setting, regarding—

“(A) health conditions prevalent in—

“(i) medically underserved communities (as defined in section 799B), particularly racial and ethnic minority populations; and

“(ii) other such at-risk populations or geographic areas that may require additional support during public health emergencies, which may include counties identified by the Secretary using applicable measures developed by the Centers for Disease Control and Prevention or other Federal agencies; and

“(B) addressing social determinants of health and eliminating health disparities, including by—

“(i) promoting awareness of services and resources to increase access to health care, mental health and substance use disorder services, child services, technology, housing services, educational services, nu-
trition services, employment services, and
other services; and
“(ii) assisting in conducting individual
and community needs assessments;
“(3) educate community members, including re-
garding effective strategies to promote healthy be-
haviors;”;
(D) in paragraph (4), as so redesignated,
by striking “to educate” and inserting “edu-
cate”; (E) in paragraph (5), as so redesignated—
(i) by striking “to identify” and in-
serting “identify”; (i) by striking “healthcare agencies”
and inserting “health care agencies”; and
(ii) by striking “healthcare services
and to eliminate duplicative care; or” and
inserting “health care services and to
streamline care, including serving as a liai-
son between communities and health care
agencies; and”; and
(F) in paragraph (6), as so redesignated—
(i) by striking “to educate, guide, and
provide” and inserting “support commu-
nity health workers in educating, guiding, or providing”; and

(ii) by striking “maternal health and prenatal care” and inserting “chronic diseases, maternal health, prenatal, and postpartum care in order to improve maternal and infant health outcomes”; (4) in subsection (c), by striking “Each eligible entity” and all that follows through “accompanied by” and inserting “To be eligible to receive an award under subsection (a), an entity shall prepare and submit to the Secretary an application at such time, in such manner, and containing”; (5) in subsection (d)— (A) in the matter preceding paragraph (1), by striking “awarding grants” and inserting “making awards”; (B) by amending paragraph (1) to read as follows:

“(1) propose to serve— “(A) areas with populations that have a high rate of chronic disease, infant mortality, or maternal morbidity and mortality;
“(B) low-income populations, including medically underserved populations (as defined in section 330(b)(3));

“(C) populations residing in health professional shortage areas (as defined in section 332(a));

“(D) populations residing in maternity care health professional target areas identified under section 332(k); or

“(E) rural or traditionally underserved populations, including racial and ethnic minority populations or low-income populations;”;

(C) in paragraph (2), by striking “; and” and inserting “, including rural populations and racial and ethnic minority populations;”;

(D) in paragraph (3), by striking “with community health workers.” and inserting “and established relationships with community health workers in the communities expected to be served by the program;” and

(E) by adding at the end the following:

“(4) develop a plan for providing services to the extent practicable, in the language and cultural context most appropriate to individuals expected to be served by the program; and
“(5) propose to use evidence-informed or evidence-based practices, as applicable and appropriate.”;

(6) in subsection (e)—

(A) by striking “community health worker programs” and inserting “eligible entities”; and

(B) by striking “and one-stop delivery systems under section 121(e)” and inserting “, health professions schools, minority-serving institutions (defined, for purposes of this subsection, as institutions and programs described in section 326(e)(1) of the Higher Education Act of 1965 and institutions described in section 371(a) of such Act), area health education centers under section 751 of this Act, and one-stop delivery systems under section 121”;

(7) by striking subsections (f), (g), (h), (i), and (j) and inserting the following:

“(f) TECHNICAL ASSISTANCE.—The Secretary may provide to eligible entities that receive awards under subsection (a) technical assistance with respect to planning, development, and operation of community health worker programs authorized or supported under this section.

“(g) DISSEMINATION OF BEST PRACTICES.—Not later than 4 years after the date of enactment of the PRE-
VENT Pandemics Act, the Secretary shall, based on activities carried out under this section and in consultation with relevant stakeholders, identify and disseminate evidence-based or evidence-informed practices regarding recruitment and retention of community health workers and paraprofessionals to address ongoing public health and community health needs, and to prepare for, and respond to, future public health emergencies.

“(h) REPORT TO CONGRESS.—Not later than 4 years after the date of enactment of the PREVENT Pandemics Act, the Secretary shall submit to the Committee on Health, Education, Labor, and Pensions and the Committee on Appropriations of the Senate and the Committee on Energy and Commerce and the Committee on Appropriations of the House of Representatives a report concerning the effectiveness of the program under this section in addressing ongoing public health and community health needs. Such report shall include recommendations regarding any improvements to such program, including recommendations for how to improve recruitment, training, and retention of the community health workforce.

“(i) AUTHORIZATION OF APPROPRIATIONS.—For purposes of carrying out this section, there are authorized to be appropriated such sums as may be necessary for each of fiscal years 2023 through 2027.”;
(8) by redesignating subsection (k) as subsection (j); and

(9) in subsection (j), as so redesignated—

(A) by striking paragraphs (1), (2), and (4);

(B) by redesignating paragraph (3) as paragraph (1);

(C) in paragraph (1), as so redesignated—

(i) by striking “entity (including a State or public subdivision of a State)” and inserting “entity, including a State or political subdivision of a State, an Indian Tribe or Tribal organization, an urban Indian organization, a community-based organization”; and

(ii) by striking “as defined in section 1861(aa) of the Social Security Act)” and inserting “(as defined in section 1861(aa)(4) of the Social Security Act)”;

and

(D) by adding at the end the following:

“(2) INDIAN TRIBE; TRIBAL ORGANIZATION.—

The terms ‘Indian Tribe’ and ‘Tribal organization’ have the meanings given the terms ‘Indian tribe’ and ‘tribal organization’, respectively, in section 4 of the
141

Indian Self-Determination and Education Assistance

Act.

“(3) URBAN INDIAN ORGANIZATION.—The term ‘urban Indian organization’ has the meaning given such term in section 4 of the Indian Health Care Improvement Act.”.

(b) GAO STUDY AND REPORT.—Not later than 1 year after the date of submission of the report under subsection (h) of section 399V of the Public Health Service Act (42 U.S.C. 280g–11), as amended by subsection (a), the Comptroller General of the United States shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report on the program authorized under such section 399V, including a review of the efforts of the Secretary of Health and Human Services to coordinate such program with applicable programs of the Health Resources and Services Administration to ensure there is no unnecessary duplication of efforts among such programs, and identification of any areas of duplication.

SEC. 223. IMPROVING PUBLIC HEALTH EMERGENCY RESPONSE CAPACITY.

(a) CERTAIN APPOINTMENTS TO SUPPORT PUBLIC HEALTH EMERGENCY RESPONSES.—Section 319 of the
Public Health Service Act (42 U.S.C. 247d) is amended by adding at the end the following:

“(g) CERTAIN APPOINTMENTS TO SUPPORT PUBLIC HEALTH EMERGENCY RESPONSES.—

“(1) IN GENERAL.—In order to support the initial response to a public health emergency declared by the Secretary under this section, the Secretary may, subject to paragraph (2) and without regard to sections 3309 through 3318 of title 5, United States Code, appoint individuals directly to positions in the Department of Health and Human Services for which the Secretary has provided public notice in order to—

“(A) address a critical hiring need directly related to responding to a public health emergency declared by the Secretary under this section; or

“(B) address a severe shortage of candidates that impacts the operational capacity of the Department of Health and Human Services to respond in the event of a public health emergency declared by the Secretary under this section.

“(2) NUMBER OF APPOINTMENTS.—Each fiscal year in which the Secretary makes a determination
of a public health emergency under subsection (a) (not including a renewal), the Secretary may directly appoint not more than—

“(A) 400 individuals under paragraph (1)(A); and

“(B) 100 individuals under paragraph (1)(B).

“(3) COMPENSATION.—The annual rate of basic pay of an individual appointed under this subsection shall be determined in accordance with chapter 51 and subchapter III of chapter 53 of title 5, United States Code.

“(4) REPORTING.—The Secretary shall establish and maintain records regarding the use of the authority under this subsection, including—

“(A) the number of positions filled through such authority;

“(B) the types of appointments of such positions;

“(C) the titles, occupational series, and grades of such positions;

“(D) the number of positions publicly noticed to be filled under such authority;

“(E) the number of qualified applicants who apply for such positions;
“(F) the qualification criteria for such positions; and

“(G) the demographic information of individuals appointed to such positions.

“(5) Notification to Congress.—In the event the Secretary, within a single fiscal year, directly appoints more than 50 percent of the individuals allowable under either subparagraph (A) or (B) of paragraph (2), the Secretary shall, not later than 15 days after the date of such action, notify the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives. Such notification shall, in a manner that protects personal privacy, to the extent required by applicable Federal and State privacy law, at a minimum, include—

“(A) information on each such appointment within such fiscal year;

“(B) a description of how each such position relates to the requirements of subparagraph (A) or (B) of paragraph (1); and

“(C) the additional number of personnel, if any, the Secretary anticipates to be necessary to adequately support a response to a public
health emergency declared under this section using the authorities described in paragraph (1) within such fiscal year.

“(6) REPORTS TO CONGRESS.—Not later than September 30, 2023, and annually thereafter for each fiscal year in which the authority under this subsection is used, the Secretary shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report describing the total number of appointments filled under this subsection within the fiscal year and a description of how the positions relate to the requirements of subparagraph (A) or (B) of paragraph (1).

“(7) SUNSET.—The authority under this subsection shall expire on September 30, 2028.”.

(b) GAO REPORT.—Not later than 1 year after the issuance of the initial report under subsection (g)(6) of section 319 of the Public Health Service Act (42 U.S.C. 247d), as added by subsection (a), and again 180 days after the date on which the authority provided under section 319(g) of such Act expires pursuant to paragraph (7) of such section, the Comptroller General of the United States shall submit to the Committee on Health, Edu-
cation, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report on the use of the authority provided under such section. Such report shall, in a manner that protects personal privacy, at a minimum, include information on—

(1) the number of positions publicly noticed and filled under the authority of each of subparagraphs (A) and (B) of such section 319(g)(1);

(2) the occupational series, grades, and types of appointments of such positions;

(3) how such positions related to addressing a need or shortage described in subparagraph (A) or (B) of such section;

(4) how the Secretary of Health and Human Services made appointment decisions under each of subparagraphs (A) and (B) of such section;

(5) sources used to identify candidates for filling such positions;

(6) the number of individuals appointed under each such subparagraph;

(7) aggregated demographic information related to individuals appointed under each such subparagraph; and
(8) any challenges, limitations, or gaps related
to the use of the authority under each such subpara-
graph and any related recommendations to address
such challenges, limitations, or gaps.

SEC. 224. EXTENSION OF AUTHORITIES TO SUPPORT
HEALTH PROFESSIONAL VOLUNTEERS AT
COMMUNITY HEALTH CENTERS.

(a) IN GENERAL.—Section 224(q) of the Public
Health Service Act (42 U.S.C. 233(q)) is amended by
striking paragraph (6).

(b) TECHNICAL CORRECTIONS.—Section 224 of the
Public Health Service Act (42 U.S.C. 233) is amended—
(1) in subsection (g)(1)(H)(iv), by striking
“this section.” and inserting “this section.”;
(2) in subsection (k)(3), by inserting “gov-
erning board members,” after “officers,”; and
(3) in subsection (p)(7)(A)(i), by moving the
margin of subclause (II) 2 ems to the left.

SEC. 225. INCREASING EDUCATIONAL OPPORTUNITIES FOR
ALLIED HEALTH PROFESSIONS.

Section 755(b) of the Public Health Service Act (42
U.S.C. 294e(b)) is amended by adding at the end the fol-
lowing:
“(4) Increasing educational opportunities in
physical therapy, occupational therapy, respiratory
therapy, audiology, and speech-language pathology professions, which may include offering scholarships or stipends and carrying out other activities to improve retention, for individuals from disadvantaged backgrounds or individuals who are underrepresented in such professions.”.

SEC. 226. PUBLIC HEALTH SERVICE CORPS ANNUAL AND SICK LEAVE.

(a) In general.—Section 219 of the Public Health Service Act (42 U.S.C. 210–1) is amended—

(1) in subsection (a)—

(A) by striking “Reserve Corps” and inserting “Ready Reserve Corps”; and

(B) by striking “: Provided, That such regulations shall not authorize annual leave to be accumulated in excess of sixty days”;

(2) by inserting after subsection (a) the following:

“(b) The regulations described in subsection (a) may authorize accumulated annual leave of not more than 120 days for any commissioned officer of the Regular Corps or officer of the Ready Reserve Corps on active duty.”;

and

(3) by redesignating subsection (d) as subsection (e).
(b) APPLICATION.—The amendments made by subsection (a) shall apply with respect to accumulated annual leave (as defined in section 219 of the Public Health Service Act (42 U.S.C. 210–1)) that a commissioned officer of the Regular Corps or officer of the Ready Reserve Corps on active duty would, but for the regulations described in such section, lose at the end of fiscal year 2022 or a subsequent fiscal year.

SEC. 227. ASSESSING BARRIERS TO ADDITIONAL TRAINING.

(a) IN GENERAL.—The Secretary of Health and Human Services (referred to in this section as the “Secretary”) shall evaluate the need for, and identify service-related barriers to, participants of health professional loan repayment programs administered by the Health Resources and Services Administration receiving accredited postgraduate training (including internships, fellowships, and residency programs), in non-primary care specialties for which there are workforce shortages, including palliative care.

(b) ADDRESSING BARRIERS; REPORT.—The Secretary shall—

(1) as appropriate, take action to address barriers identified under subsection (a); and

(2) not later than 2 years after the date of enactment of this Act, issue a report to the Committee
on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives on the evaluation under subsection (a), including—

(A) any service-related barriers identified;

(B) steps taken to address such barriers under paragraph (1); and

(C) as applicable and appropriate, any limitations to implementation of actions to address such barriers.

(c) Rule of Construction.—Nothing in this section shall be construed as in any way affecting, modifying, repealing, or superseding the provisions authorizing health professional loan repayment programs administered by the Health Resources and Services Administration.

SEC. 228. LEADERSHIP EXCHANGE PILOT FOR PUBLIC HEALTH AND MEDICAL PREPAREDNESS AND RESPONSE POSITIONS AT THE DEPARTMENT OF HEALTH AND HUMAN SERVICES.

Title XXVIII of the Public Health Service Act (42 U.S.C. 300hh et seq.), as amended by section 214, is further amended by adding at the end the following:
"SEC. 2826. LEADERSHIP EXCHANGE PILOT FOR PUBLIC
HEALTH AND MEDICAL PREPAREDNESS AND
RESPONSE POSITIONS AT THE DEPARTMENT
OF HEALTH AND HUMAN SERVICES.

"(a) In General.—The Secretary may, not later
than 1 year after the date of enactment of the PREVENT
Pandemics Act, establish a voluntary program to provide
additional training to individuals in eligible positions, as
described in subsection (c), to support the continuous pro-
fessional development of such individuals.

"(b) Criteria.—

"(1) Duration.—The program under sub-
section (a) shall provide for fellowships, details, or
other relevant placements with Federal agencies or
departments, or State or local health departments,
pursuant to the guidance issued under paragraph
(2), for a maximum period of 2 years.

"(2) Guidance.—The Secretary shall issue
guidance establishing criteria for identifying place-
ments that demonstrate ongoing sufficient mastery
of knowledge, skills, and abilities to satisfy the field
experience criteria under the program established
under subsection (a), including assignments and ex-
periences that develop public health and medical pre-
paredness and response expertise.
“(c) ELIGIBLE POSITION.—For purposes of subsection (a), the term ‘eligible position’ means any position at the Department of Health and Human Services at or above grade GS–13 of the General Schedule, or the equivalent, for which not less than 50 percent of the time of such position is spent on activities related to public health preparedness or response.

“(d) PILOT PERIOD AND FINAL REPORT.—The pilot program authorized under this section shall not exceed 5 years. Not later than 90 days after the end of the program, the Secretary shall issue a report to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives that includes—

“(1) the number of individuals who participated in such pilot, as applicable;

“(2) a description of the professional growth experience in which individuals participated; and

“(3) an assessment of the outcomes of such program, including a recommendation on whether such program should be continued.”.
Subtitle D—Improving Public Health Responses

SEC. 231. CENTERS FOR PUBLIC HEALTH PREPAREDNESS AND RESPONSE.

(a) In General.—Section 319F of the Public Health Service Act (42 U.S.C. 247d–6) is amended—

(1) by striking subsection (d) and inserting the following:

“(d) CENTERS FOR PUBLIC HEALTH PREPAREDNESS AND RESPONSE.—

“(1) In General.—The Secretary, acting through the Director of the Centers for Disease Control and Prevention, may award grants, contracts, or cooperative agreements to institutions of higher education, including accredited schools of public health, or other nonprofit private entities to establish or maintain a network of Centers for Public Health Preparedness and Response (referred to in this subsection as ‘Centers’).

“(2) Eligibility.—To be eligible to receive an award under this subsection, an entity shall submit to the Secretary an application containing such information as the Secretary may require, including a description of how the entity will—
“(A) coordinate relevant activities with applicable State, local, and Tribal health departments and officials, health care facilities, and health care coalitions to improve public health preparedness and response, as informed by the public health preparedness and response needs of the community, or communities, involved;

“(B) prioritize efforts to implement evidence-informed or evidence-based practices to improve public health preparedness and response, including by helping to reduce the transmission of emerging infectious diseases; and

“(C) use funds awarded under this subsection, including by carrying out any activities described in paragraph (3).

“(3) USE OF FUNDS.—The Centers established or maintained under this subsection shall use funds awarded under this subsection to carry out activities to advance public health preparedness and response capabilities, which may include—

“(A) identifying, translating, and disseminating promising research findings or strategies into evidence-informed or evidence-based practices to inform preparedness for, and responses
to, chemical, biological, radiological, or nuclear
threats, including emerging infectious diseases,
and other public health emergencies, which may
include conducting research related to public
health preparedness and response systems;

“(B) improving awareness of such evi-
dence-informed or evidence-based practices and
other relevant scientific or public health infor-
mation among health care professionals, public
health professionals, other stakeholders, and the
public, including through the development, eval-
uation, and dissemination of trainings and
training materials, consistent with section
2802(b)(2), as applicable and appropriate, and
with consideration given to existing training
materials, to support preparedness for, and re-
sponses to, such threats;

“(C) utilizing and expanding relevant tech-
nological and analytical capabilities to inform
public health and medical preparedness and re-
sponse efforts;

“(D) expanding activities, including
through public-private partnerships, related to
public health preparedness and response, in-
cluding participation in drills and exercises and
training public health experts, as appropriate; and

“(E) providing technical assistance and expertise that relies on evidence-based practices, as applicable, related to responses to public health emergencies, as appropriate, to State, local, and Tribal health departments and other entities pursuant to paragraph (2)(A).

“(4) DISTRIBUTION OF AWARDS.—In awarding grants, contracts, or cooperative agreements under this subsection, the Secretary shall support not fewer than 10 Centers, subject to the availability of appropriations, and ensure that such awards are equitably distributed among the geographical regions of the United States.”; and

(2) in subsection (f)(1)(C), by striking “, of which $5,000,000 shall be used to carry out paragraphs (3) through (5) of such subsection”.

(b) REPEAL.—Section 319G of the Public Health Service Act (42 U.S.C. 247d–7) is repealed.

SEC. 232. VACCINE DISTRIBUTION PLANS.

Section 319A of the Public Health Service Act (42 U.S.C. 247d–1) is amended—

(1) in subsection (a)—
(A) by inserting "‘, or other federally pur-
chased vaccine to address another pandemic’"
before the period at the end of the first sen-
tence; and

(B) by inserting "‘or other pandemic’ be-
fore the period at the end of the second sen-
tence; and

(2) in subsection (d), by inserting "‘or other
pandemics’” after “‘influenza pandemics’”.

SEC. 233. COORDINATION AND COLLABORATION REGARD-
ING BLOOD SUPPLY.

(a) IN GENERAL.—The Secretary of Health and
Human Services, or the Secretary’s designee, shall—

(1) ensure coordination and collaboration be-
tween relevant Federal departments and agencies re-
lated to the safety and availability of the blood sup-
ply, including—

(A) the Department of Health and Human
Services, including the Office of the Assistant
Secretary for Health, the Centers for Disease
Control and Prevention, the Food and Drug
Administration, the Office of the Assistant Sec-
retary for Preparedness and Response, the Na-
tional Institutes of Health, the Centers for
Medicare & Medicaid Services, and the Health Resources and Services Administration;

(B) the Department of Defense; and

(C) the Department of Veterans Affairs;

and

(2) consult and communicate with private stakeholders, including blood collection establishments, health care providers, accreditation organizations, researchers, and patients, regarding issues related to the safety and availability of the blood supply.

(b) STREAMLINING BLOOD DONOR INPUT.—Chapter 35 of title 44, United States Code, shall not apply to the collection of information to which a response is voluntary and that is initiated by the Secretary of Health and Human Services to solicit information from blood donors or potential blood donors to support the development of recommendations by the Secretary concerning blood donation.

SEC. 234. SUPPORTING LABORATORY CAPACITY AND INTERNATIONAL COLLABORATION TO ADDRESS ANTIMICROBIAL RESISTANCE.

Section 319E of the Public Health Service Act (42 U.S.C. 247d–5) is amended—
(1) by redesignating subsections (k), (l), and (m) as subsections (m), (n), and (o), respectively; and

(2) by inserting after subsection (j), the following:

“(k) NETWORK OF ANTIBIOTIC RESISTANCE REGIONAL LABORATORIES.—

“(1) IN GENERAL.—The Secretary, acting through the Director of the Centers for Disease Control and Prevention, shall, as appropriate, maintain a network of antibiotic resistance laboratory sites to ensure the maintenance of appropriate capabilities, within existing laboratory capacity maintained or supported by the Centers for Disease Control and Prevention, to—

“(A) identify and monitor the emergence and changes in the patterns of antimicrobial-resistant pathogens;

“(B) detect, identify, confirm, and isolate such resistant pathogens, including, as appropriate, performing such activities upon the request of another laboratory and providing related technical assistance, and, as applicable, support efforts to respond to local or regional outbreaks of such resistant pathogens; and
“(C) perform activities to support the diagnosis of such resistant pathogens and determine the susceptibility of relevant pathogen samples to applicable treatments.

“(2) Geographic distribution.—The Secretary shall ensure that such capacity and capabilities are appropriately distributed among the geographical regions of the United States.

“(3) Partnerships and nonduplication of current domestic capacity.—Activities supported under this subsection may be based in an academic center, a State health department, or other facility operated by a public or private entity that carries out relevant laboratory or public health surveillance activities.

“(1) International collaboration.—

“(1) In general.—The Secretary, in coordination with heads of other relevant Federal departments and agencies, shall support activities related to addressing antimicrobial resistance internationally, including by—

“(A) supporting basic, translational, epidemiological, and clinical research related to antimicrobial-resistant pathogens, including such pathogens that have not yet been detected in
the United States, and improving related public health surveillance systems, and laboratory and other response capacity; and

“(B) providing technical assistance related to antimicrobial resistant infection and control activities.

“(2) AWARDS.—In carrying out paragraph (1), the Secretary may award grants, contracts, or cooperative agreements to public and private entities, including nongovernmental organizations, with applicable expertise, for purposes of supporting new and innovative approaches to the prevention, detection, and mitigation of antimicrobial-resistant pathogens.”.

SEC. 235. ONE HEALTH FRAMEWORK.

(a) ONE HEALTH FRAMEWORK.—The Secretary of Health and Human Services (referred to in this section as the “Secretary”), acting through the Director of the Centers for Disease Control and Prevention, shall develop, or update as appropriate, in coordination with other Federal departments and agencies, as appropriate, a One Health framework to address zoonotic diseases and advance public health preparedness.

(b) ONE HEALTH COORDINATION.—The Secretary, acting through the Director of the Centers for Disease
Control and Prevention, shall coordinate with the Secretary of Agriculture and the Secretary of the Interior to develop a One Health coordination mechanism at the Federal level to strengthen One Health collaboration related to prevention, detection, control, and response for zoonotic diseases and related One Health work across the Federal Government.

(c) Reporting.—Not later than 1 year after the date of enactment of this Act, the Secretary shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report providing an update on the activities under subsections (a) and (b).

SEC. 236. SUPPORTING CHILDREN DURING PUBLIC HEALTH EMERGENCIES.

Section 2811A of the Public Health Service Act (42 U.S.C. 300hh–10b) is amended—

(1) in subsection (b)—

(A) in paragraph (2)—

(i) by striking “and behavioral” and inserting “, behavioral, developmental”; and

(ii) by striking “; and” and inserting a semicolon;
163

(B) in paragraph (3), by striking the pe-

period and inserting ‘‘; and’’; and

(C) by adding at the end the following:

‘‘(4) provide advice and consultation with re-

spect to continuity of care and education for all chil-

dren and supporting parents and caregivers during

all-hazards emergencies.’’;

(2) in subsection (d)(2)—

(A) in subparagraph (C), by striking

‘‘care; and’’ and inserting ‘‘care;’’;

(B) by redesignating subparagraph (D) as

paragraph (E);

(C) by inserting after subparagraph (C)

the following:

‘‘(D) at least 4 non-Federal members rep-

resenting child care settings, State or local edu-

cational agencies, individuals with expertise in

children with disabilities, and parents; and’’;

and

(D) in subparagraph (E), as so redesign-

nated—

(i) by striking clause (ii); and

(ii) by redesignating clauses (iii) and

(iv) as clauses (ii) and (iii), respectively.
TITLE III—ACCELERATING RESEARCH AND COUNTER-MEASURE DISCOVERY

Subtitle A—Fostering Research and Development and Improving Coordination

SEC. 301. RESEARCH AND ACTIVITIES RELATED TO LONG-TERM HEALTH EFFECTS OF SARS-COV-2 INFECTION.

(a) In General.—The Secretary of Health and Human Services (referred to in this section as the “Secretary”) shall, as appropriate—

(1) coordinate activities among relevant Federal departments and agencies with respect to addressing the long-term health effects of SARS–CoV–2 infection, which may include conditions that arise as a result of such infection;

(2) continue to conduct or support basic, clinical, epidemiological, behavioral, and translational research and public health surveillance related to the pathogenesis, prevention, diagnosis, and treatment of the long-term health effects of SARS–CoV–2 infection, which may include conditions that arise as a result of such infection; and
(3) consistent with the findings of studies and research under paragraph (1), in consultation with health professional associations, scientific and medical researchers, and other relevant experts, develop and inform recommendations, guidance, and educational materials on the long-term effects of SARS–CoV–2 infection, which may include conditions that arise as a result of such infection, and provide such recommendations, guidance, and educational materials to health care providers and the general public. 

(b) CONSIDERATIONS.—In conducting or supporting research under this section, the Secretary shall consider the diversity of research participants or cohorts to ensure inclusion of a broad range of participants, as applicable and appropriate.

(e) ADDITIONAL ACTIVITIES.—The Secretary may—

(1) direct the Director of the Agency for Healthcare Research and Quality to—

(A) assist in the identification and development of evidence regarding the delivery of high-quality, high-value health care for individuals experiencing long-term health effects of SARS–CoV–2, which may include conditions that arise as a result of such infection;
(B) develop or identify tools and strategies to help healthcare entities and providers care for such populations; and

(C) disseminate such evidence, tools, and strategies; and

(2) establish a primary care technical assistance initiative to convene primary care providers and organizations in order to collect and disseminate best practices related to the care of individuals with long-term health effects of SARS-CoV-2 infection, which may include conditions that arise as a result of such infection.

(d) Annual Reports.—Not later than 1 year after the date of enactment of this Act, and annually thereafter for the next 4 years, the Secretary shall prepare and submit a report to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives regarding an overview of the research conducted or supported under this section and any relevant findings. Such reports may include information about how the research and relevant findings under this section relate to other research efforts supported by other public or private entities.

(e) Public Availability of Information.—In making information or reports publicly available under
this section, the Secretary shall take into consideration the
delivery of such information in a manner that takes into
account the range of communication needs of the intended
recipients, including at-risk individuals.

SEC. 302. RESEARCH CENTERS FOR PATHOGENS OF PAN-
DEMIC CONCERN.

Subpart 6 of part C of title IV of the Public Health
Service Act is amended by inserting after section 447C
(42 U.S.C. 285f–4) the following:

“SEC. 447D. RESEARCH CENTERS FOR PATHOGENS OF PAN-
DEMIC CONCERN.

“(a) IN GENERAL.—The Director of the Institute, in
collaboration, as appropriate, with the directors of applica-
ble institutes, centers, and divisions of the National Insti-
tutes of Health, the Assistant Secretary for Preparedness
and Response, and the Director of the Biomedical Ad-
vanced Research and Development Authority, shall estab-
lish or continue a multidisciplinary research program to
advance the discovery and preclinical development of med-
ical products for priority virus families and other viral
pathogens with a significant potential to cause a pan-
demic, through support for research centers.

“(b) USES OF FUNDS.—The Director of the Institute
shall award funding through grants, contracts, or coopera-
tive agreements to public or private entities to provide
support for research centers described in subsection (a) for the purpose of—

“(1) conducting basic research through pre-clinical development of new medical products or technologies, including platform technologies, to address pathogens of pandemic concern;

“(2) identifying potential targets for therapeutic candidates, including antivirals, to treat such pathogens;

“(3) identifying existing medical products with the potential to address such pathogens, including candidates that could be used in outpatient settings; and

“(4) carrying out or supporting other research related to medical products to address such pathogens, as determined appropriate by the Director.

“(c) COORDINATION.—The Director of the Institute shall, as appropriate, provide for the coordination of activities among the centers described in subsection (a), including through—

“(1) facilitating the exchange of information and regular communication among the centers, as appropriate; and
“(2) requiring the periodic preparation and submission to the Director of reports on the activities of each center.

“(d) PRIORITY.—In awarding funding through grants, contracts, or cooperative agreements under subsection (a), the Director of the Institute shall, as appropriate, give priority to applicants with existing frameworks and partnerships, as applicable, to support the advancement of such research.

“(e) COLLABORATION.—The Director of the Institute shall—

“(1) collaborate with the heads of other appropriate Federal departments, agencies, and offices with respect to the identification of additional priority virus families and other viral pathogens with a significant potential to cause a pandemic; and

“(2) collaborate with the Director of the Biomedical Advanced Research and Development Authority with respect to the research conducted by centers described in subsection (a), including, as appropriate, providing any updates on the research advancements made by such centers, identifying any advanced research and development needs for such countermeasures, consistent with section 319L(a)(6), and taking into consideration existing
manufacturing capacity and future capacity needs
for such medical products or technologies, including
platform technologies, supported by the centers de-
scribed in subsection (a).

“(f) SUPPLEMENT, NOT SUPPLANT.—Any support
received by a center described in subsection (a) under this
section shall be used to supplement, and not supplant,
other public or private support for activities authorized to
be supported.”.

SEC. 303. IMPROVING MEDICAL COUNTERMEASURE RE-
SEARCH COORDINATION.

Section 402(b) in the Public Health Service Act (42
U.S.C. 282(b)) is amended—

(1) in paragraph (24), by striking “and” at the
end;

(2) in paragraph (25), by striking the period
and inserting a semicolon; and

(3) by inserting after paragraph (25) the fol-
lowing:

“(26) shall consult with the Assistant Secretary
for Preparedness and Response, the Director of the
Biomedical Advanced Research and Development
Authority, the Director of the Centers for Disease
Control and Prevention, and the heads of other Fed-
eral agencies and offices, as appropriate, regarding
research needs to advance medical countermeasures to diagnose, mitigate, prevent, or treat harm from any biological agent or toxin, including emerging infectious diseases, chemical, radiological, or nuclear agent that may cause a public health emergency or other research needs related to emerging public health threats;”.

SEC. 304. ACCESSING SPECIMEN SAMPLES AND DIAGNOSTIC TESTS.

(a) IMPROVING RESEARCH AND DEVELOPMENT OF MEDICAL COUNTERMEASURES FOR NOVEL PATHOGENS.—

   (1) SAMPLE ACCESS.—Not later than 1 year after the date of enactment of this Act, the Secretary of Health and Human Services (referred to in this subsection as the “Secretary”) shall make publicly available policies and procedures related to public and private entities accessing specimens of, or specimens containing, pathogens or suitable surrogates for, or alternatives to, such pathogens as the Secretary determines appropriate to support public health preparedness and response activities or biomedical research for purposes of the development and validation, as applicable, of medical products to address emerging infectious diseases and for use to
otherwise respond to emerging infectious diseases. Such policies and procedures shall take into account, as appropriate, any applicable existing Federal resources.

(2) **GUIDANCE.**—The Secretary shall issue guidance regarding the procedures for carrying out paragraph (1), including—

(A) the method for requesting such samples;

(B) considerations for sample availability and use of suitable surrogates or alternatives to such pathogens, as appropriate, including applicable safeguard and security measures; and

(C) information required to be provided in order to receive such samples or suitable surrogates or alternatives.

(b) **EARLIER DEVELOPMENT OF DIAGNOSTIC TESTS.**—Title III of the Public Health Service Act is amended by inserting after section 319A (42 U.S.C. 247d–1) the following:

“SEC. 319B. EARLIER DEVELOPMENT OF DIAGNOSTIC TESTS.

“The Secretary may contract with public and private entities, as appropriate, to increase capacity in the rapid development, validation, manufacture, and dissemination
of diagnostic tests, as appropriate, to State, local, and Tribal health departments and other appropriate entities for immediate public health response activities to address an emerging infectious disease with respect to which a public health emergency is declared under section 319, or that has significant potential to cause such a public health emergency.”.

SEC. 305. NATIONAL ACADEMIES OF SCIENCES, ENGINEERING, AND MEDICINE STUDY ON NATURAL IMMUNITY IN RELATION TO THE COVID–19 PANDEMIC.

(a) In General.—Not later than 45 days after the date of enactment of this Act, the Secretary of Health and Human Services shall seek to enter into a contract with the National Academies of Sciences, Engineering, and Medicine (referred to in this section as the “National Academies”) to conduct a study related to the current scientific evidence on the durability of immunity to COVID–19.

(b) Inclusions.—The study pursuant to the contract under subsection (a) shall include—

(1) an assessment of scientific evidence related to the durability of immunity resulting from SARS–CoV–2 infection, COVID–19 vaccination, or both, including any differences between population groups;
(2) an assessment of the extent to which the Federal Government makes publicly available the scientific evidence used by relevant Federal departments and agencies to inform public health recommendations related to immunity resulting from SARS–CoV–2 infection and COVID–19 vaccination; and

(3) a summary of scientific studies and evidence related to SARS–CoV–2 infection-acquired immunity from a sample of other countries or multilateral organizations.

(c) REPORT.—Not later than 18 months after the date of enactment of this Act, the National Academies shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report on the study pursuant to subsection (a).

(d) AUTHORIZATION OF APPROPRIATION.—There is authorized to be appropriated such sums as may be necessary for fiscal year 2023 to carry out this section.
Subtitle B—Improving Biosafety and Biosecurity

SEC. 311. IMPROVING CONTROL AND OVERSIGHT OF SELECT BIOLOGICAL AGENTS AND TOXINS.

Section 351A of the Public Health Service Act (42 U.S.C. 262a) is amended—

(1) in subsection (b)(1), by amending subparagraph (A) to read as follows:

“(A) proper training, including with respect to notification requirements under this section, of—

“(i) individuals who are involved in the handling and use of such agents and toxins, including appropriate skills to handle such agents and toxins;

“(ii) individuals whose responsibilities routinely place them in close proximity to laboratory facilities in which such agents and toxins are being transferred, possessed, or used; and

“(iii) individuals who perform administrative or oversight functions of the facility related to the transfer, possession, or use of such agents and toxins on behalf of registered persons;”;}
(2) in subsection (e)(1), by striking “(including the risk of use in domestic or international terrorism)” and inserting “(including risks posed by the release, theft, or loss of such agent or toxin, or use in domestic or international terrorism)”;

(3) in subsection (k)—

(A) by redesignating paragraphs (1) and (2) as paragraphs (2) and (3), respectively;

(B) by inserting before paragraph (2), as so redesignated, the following:

“(1) Notification with respect to federal facilities.—In the event of the release, loss, or theft of an agent or toxin listed by the Secretary pursuant to subsection (a)(1), or by the Secretary of Agriculture pursuant to section 212(a)(1) of the Agricultural Bioterrorism Protection Act of 2002, from or within a laboratory facility owned or operated by the Department of Health and Human Services, or other Federal laboratory facility subject to the requirements of this section, the Secretary, in a manner that does not compromise national security, shall—

“(A) not later than 72 hours after such event is reported to the Secretary, notify the Committee on Health, Education, Labor, and
Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives of such event, including—

“(i) the Federal laboratory facility in which such release, loss, or theft occurred; and

“(ii) the circumstances of such release, loss, or theft; and

“(B) not later than 14 days after such notification, update such Committees on—

“(i) any actions taken or planned by the Secretary to mitigate any potential threat such release, loss, or theft may pose to public health and safety; and

“(ii) any actions taken or planned by the Secretary to review the circumstances of such release, loss, or theft, and prevent similar events.”; and

(C) by amending paragraph (2), as so redesignated, to read as follows:

“(2) ANNUAL REPORT.—The Secretary shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives on an annual basis a report—
“(A) summarizing the number and nature of notifications received under subsection (e)(8) (relating to theft or loss) and subsection (j) (relating to releases), during the preceding fiscal year;

“(B) describing actions taken by the Secretary to address such incidents, such as any corrective action plans required and steps taken to promote adherence to, and compliance with, safety and security best practices, standards, and regulations; and

“(C) describing any gaps, challenges, or limitations with respect to ensuring that such safety and security practices are consistently applied and adhered to, and actions taken to address such gaps, challenges, or limitations.”;

and

(4) in subsection (m), by striking “fiscal years 2002 through 2007” and inserting “fiscal years 2023 through 2027”.

SEC. 312. STRATEGY FOR FEDERAL HIGH-CONTAINMENT LABORATORIES.

(a) Strategy for Federal High-Containment Laboratories.—Not later than 1 year after the date of enactment of this Act, the Director of the Office of Science
and Technology Policy, in consultation with relevant Fed-
eral agencies and departments, shall establish a strategy
for the management, maintenance, and oversight of feder-
ally-owned laboratory facilities operating at Biosafety
Level 3 or 4, including equivalent classification levels and
facilities with Biosafety Level 4 capabilities. Such strategy
shall include—

(1) a description of the roles and responsibil-
ities of relevant Federal departments and agencies
with respect to the management, maintenance, and
oversight of Biosafety Level 3 or 4 laboratory facili-
ties;

(2) an assessment of the needs of the Federal
Government with respect to Biosafety Level 3 or 4
laboratory facilities;

(3) a summary of existing federally-owned Bio-
safety Level 3 or 4 laboratory facility capacity;

(4) a summary of other Biosafety Level 3 or 4
laboratory facility capacity established through Fed-
eral funds;

(5) a description of how the capacity described
in paragraphs (3) and (4) addresses the needs of the
Federal Government, including—

(A) how relevant Federal departments and
agencies coordinate to provide access to appro-
appropriate laboratory facilities to reduce unnecessary duplication; and

(B) any gaps in such capacity related to such needs;

(6) a summary of plans that are in place for the maintenance of such capacity, as applicable and appropriate, including processes for determining whether to maintain or expand such capacity, and a description of how the Federal Government will address rapid changes in the need for such capacity during a public health emergency; and

(7) a description of how the heads of relevant Federal departments and agencies will coordinate to ensure appropriate oversight of federally-owned laboratory facility capacity and leverage such capacity, as appropriate, to fulfill the needs of Federal departments and agencies in order to reduce unnecessary duplication and improve collaboration within the Federal Government.

SEC. 313. NATIONAL SCIENCE ADVISORY BOARD FOR BIOSECURITY.

(a) In General.—Part A of title IV of the Public Health Service Act (42 U.S.C. 281 et seq.) is amended by adding at the end the following:
SEC. 404O. NATIONAL SCIENCE ADVISORY BOARD FOR BIOSECURITY.

(a) Establishment.—The Secretary, acting through the Director of NIH, shall establish an advisory committee, to be known as the ‘National Science Advisory Board for Biosecurity’ (referred to in this section as the ‘Board’).

(b) Duties.—

(1) In general.—The National Science Advisory Board for Biosecurity referred to in section 205 of the Pandemic and All-Hazards Preparedness Act (Public Law 109–417) (referred to in this section as the ‘Board’) shall provide technical advice, guidance, or recommendations, to relevant Federal departments and agencies related to biosafety and biosecurity oversight of biomedical research, including—

(A) oversight of federally-conducted or federally-supported dual use biomedical research, such as the review of policies or frameworks used to assess and appropriately manage safety and security risks associated with such research, taking into consideration national security concerns, the potential benefits of such research, considerations related to the research community, transparency, and public avail-
“(B) continuing to carry out the activities required under section 205 of the Pandemic and All-Hazards Preparedness Act (Public Law 109–417).

“(c) CONSIDERATIONS.—In carrying out the duties under subsection (b), the Board may consider strategies to improve the safety and security of biomedical research, including through—

“(1) leveraging or using new technologies and scientific advancements to reduce safety and security risks associated with such research and improve containment of pathogens; and

“(2) outreach to, and education and training of, researchers, laboratory personnel, and other appropriate individuals with respect to safety and security risks associated with such research and mitigation of such risks.

“(d) MEMBERSHIP.—The Board shall be composed of the following:

“(1) Non-voting, ex officio members, including the following:

“(A) At least one representative of each of
“(i) The Department of Health and Human Services.

“(ii) The Department of Defense.

“(iii) The Department of Agriculture.


“(v) The Department of Energy.

“(vi) The Department of State.

“(vii) The Office of Science and Technology Policy.

“(viii) The Office of the Director of National Intelligence.

“(B) Representatives of such other Federal departments or agencies as the Secretary determines appropriate to carry out the requirements of this section.

“(2) Individuals, appointed by the Secretary, with expertise in biology, infectious diseases, public health, ethics, national security, and other fields, as the Secretary determines appropriate, who shall serve as voting members.”.

(b) ORDERLY TRANSITION.—The Secretary of Health and Human Services shall take such steps as are necessary to provide for the orderly transition to the authority of the National Science Advisory Board for Bio-
security established under section 404O of the Public Health Service Act, as added by subsection (a), from any authority of the Board described in section 205 of the Pandemic and All-Hazards Preparedness Act (Public Law 109–417), as in effect on the day before the date of enactment of this Act.

(c) Application.—The requirements under section 404O of the Public Health Service Act, as added by subsection (a), related to the mission, activities, or functions of the National Science Advisory Board for Biosecurity shall not apply until the completion of any work undertaken by such Board before the date of enactment of this Act.

SEC. 314. RESEARCH TO IMPROVE BIOSAFETY.

(a) In General.—The Secretary of Health and Human Services (referred to in this section as the “Secretary”) shall, as appropriate, conduct or support research to improve the safe conduct of biomedical research activities involving pathogens of pandemic potential or biological agents or toxins listed pursuant to section 351A(a)(1) of the Public Health Service Act (42 U.S.C. 262a(a)(1)).

(b) Report.—Not later than 5 years after the date of enactment of this Act, the Secretary shall prepare and submit a report to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on
Energy and Commerce of the House of Representatives regarding an overview of any research conducted or supported under this section, any relevant findings, and steps the Secretary is taking to disseminate any such findings to support the reduction of risks associated with biomedical research involving pathogens of pandemic potential or biological agents or toxins listed pursuant to section 351A(a)(1) of the Public Health Service Act (42 U.S.C. 262a(a)(1)).

SEC. 315. FEDERALLY-FUNDED RESEARCH WITH ENHANCED PATHOGENS OF PANDEMIC POTENTIAL.

(a) REVIEW AND OVERSIGHT OF ENHANCED PATHOGENS OF PANDEMIC POTENTIAL.—

(1) IN GENERAL.—The Director of the Office of Science and Technology Policy (referred to in this section as the “Director”), in consultation with the heads of relevant Federal departments and agencies, shall—

(A) not later than 1 year after the date of enactment of this Act—

(i) continue or conduct a review of existing Federal policies related to research proposed for Federal funding that may be reasonably anticipated to involve the cre-
(ii) establish or update a Federal policy for the consistent review and oversight of such proposed research that appropriately considers the risks associated with, and potential benefits of, such research; and

(B) not less than every 4 years thereafter, review and update such policy, as necessary and appropriate, to ensure that such policy fully accounts for relevant research that may be reasonably anticipated to involve the creation, transfer, or use of enhanced pathogens of pandemic potential, takes into consideration the benefits of such research, and supports the mitigation of related risks.

(2) REQUIREMENTS.—The policy established pursuant to paragraph (1) shall include—

(A) a clear scope to support the consistent identification of research proposals subject to such policy by relevant Federal departments and agencies;

(B) a framework for such reviews that accounts for safety, security, and ethical consider-
ations related to the creation, transfer, or use of enhanced pathogens of pandemic potential;

(C) measures to enhance the transparency and public availability of information related to such research activities in a manner that does not compromise national security, the safety and security of such research activities, or any identifiable, sensitive information of relevant individuals; and

(D) consistent procedures across relevant Federal department and agencies to ensure that—

(i) proposed research that has been determined to have scientific and technical merit and may be subject to such policy is identified and referred for review;

(ii) subjected research activities conducted under an award, including activities undertaken by any subrecipients of such award, are monitored regularly throughout the project period to ensure compliance with such policy and the terms and conditions of such award; and

(iii) in the event that federally-funded research activities not subject to such pol-
icy produce unanticipated results related to the creation, transfer, or use of enhanced pathogens of pandemic potential, such research activities are identified and appropriately reviewed under such policy.

(3) CLARIFICATION.—Reviews required pursuant to this section shall be in addition to any applicable requirements for research project applications required under the Public Health Service Act, including reviews required under section 492 of such Act (42 U.S.C. 289a), as applicable, or other applicable laws.

(b) IMPLEMENTATION.—

(1) IN GENERAL.—The Director shall direct all heads of relevant Federal departments and agencies to update, modernize, or promulgate applicable implementing guidance to implement the requirements of this section.

(2) UPDATES.—Consistent with the requirements under subsection (a)(1)(B), the Director shall require all heads of relevant Federal departments and agencies to update such policies consistent with any changes to the policy established pursuant to subsection (a)(1).
Subtitle C—Preventing Undue Foreign Influence in Biomedical Research

SEC. 321. FOREIGN TALENT PROGRAMS.

(a) Intramural Research.—

(1) In general.—Not later than 60 days after the date of enactment of this Act, the Secretary of Health and Human Services (referred to in this section as the “Secretary”) shall prohibit personnel of the National Institutes of Health engaged in intramural research from participation in foreign talent programs.

(2) Exemption.—Paragraph (1) shall not apply to participation in international conferences or other international exchanges, partnerships, or programs, for which such participation has been approved by the National Institutes of Health. In such circumstances, the National Institutes of Health shall ensure appropriate training is provided to the participant on how to respond to overtures from individuals associated with foreign talent programs.

(b) Extramural Research.—The Secretary shall require disclosure of participation in foreign talent programs, including the provision of copies of all grants, contracts, or other agreements related to such programs, and
'other supporting documentation related to such programs,
as a condition of receipt of Federal extramural biomedical
research funding awarded through the Department of
Health and Human Services.

SEC. 322. SECURING IDENTIFIABLE, SENSITIVE INFORMATION AND ADDRESSING OTHER NATIONAL SECURITY RISKS RELATED TO RESEARCH.

(a) In General.—The Secretary of Health and Human Services (referred to in this section as the “Secretary”), in consultation with the Director of National Intelligence, the Secretary of State, the Secretary of Defense, and other national security experts, as appropriate, shall ensure that biomedical research conducted or supported by the National Institutes of Health and other relevant agencies and offices within the Department of Health and Human Services is conducted or supported in a manner that appropriately considers national security risks, including national security implications related to research involving the sequencing of human genomic information, and collection, analysis, or storage of identifiable, sensitive information, as defined in section 301(d)(4) of the Public Health Service Act (42 U.S.C. 241(d)(4)), and the potential misuse of such data. Not later than 2 years after the date of enactment of this Act, the Secretary shall ensure that the National Institutes of Health and other
relevant agencies and offices within the Department of Health and Human Services, working with the heads of agencies and national security experts, including the Office of the National Security within the Department of Health and Human Services—

(1) develop a comprehensive framework for assessing and managing such national security risks that includes—

(A) criteria for how and when to conduct risk assessments for projects that may have national security implications;

(B) security controls and training for researchers or entities, including peer reviewers, that manage or have access to such data that may present national security risks; and

(C) methods to incorporate risk mitigation in the process for funding such projects that may have national security implications and monitor associated research activities following issuance of an award, including changes in the terms and conditions related to the use of such funds, as appropriate;

(2) not later than 1 year after the risk framework is developed under paragraph (1), develop and implement controls to ensure that—
(A) researchers or entities involved in projects reviewed under the risk framework, including such projects that manage or have access to sensitive, identifiable information, have complied with the requirements of paragraph (1) and ongoing requirements with such paragraph;

(B) consideration of funding for projects that may have national security implications takes into account the extent to which the country in which the proposed research will be conducted or supported poses a risk to the integrity of the United States biomedical research enterprise; and

(C) data access committees reviewing data access requests for projects that may have national security risks, as appropriate, include members with expertise in current and emerging national security threats, in order to make appropriate decisions, including related to access to such identifiable, sensitive information; and

(3) not later than 2 years after the risk framework is developed under paragraph (1), update data access and sharing policies related to human
genomic data, as appropriate, based on current and emerging national security threats.

(b) CONGRESSIONAL BRIEFING.—Not later than 1 year after the date of enactment of this Act, the Secretary shall provide a briefing to the Committee on Health, Education, Labor, and Pensions and the Select Committee on Intelligence of the Senate and the Committee on Energy and Commerce and the Permanent Select Committee on Intelligence of the House of Representatives on the activities required under subsection (a).

SEC. 323. DUTIES OF THE DIRECTOR.

Section 402(b) in the Public Health Service Act (42 U.S.C. 282(b)), as amended by section 303, is further amended by inserting after paragraph (26) (as added by section 303) the following:

“(27) shall consult with the Director of the Office of National Security within the Department of Health and Human Services, the Assistant Secretary for Preparedness and Response, the Director of National Intelligence, the Director of the Federal Bureau of Investigation, and the heads of other appropriate agencies on a regular basis, regarding biomedical research conducted or supported by the National Institutes of Health that may affect or be affected by matters of national security;
“(28) shall ensure that recipients of awards from the National Institutes of Health, and, as appropriate and practicable, entities collaborating with such recipients, have in place and are adhering to appropriate technology practices and policies for the security of identifiable, sensitive information, including information collected, stored, or analyzed by domestic and non-domestic entities; and

“(29) shall ensure that recipients of awards from the National Institutes of Health are in compliance with the terms and conditions of such award, which may include activities to support awareness of, and compliance with, such terms and conditions by any subrecipients of the award.”.

SEC. 324. PROTECTING AMERICA'S BIOMEDICAL RESEARCH ENTERPRISE.

(a) In General.—The Secretary of Health and Human Services (referred to in this section as the “Secretary”), in collaboration with Assistant to the President for National Security Affairs, the Director of National Intelligence, the Director of the Federal Bureau of Investigation, and the heads of other relevant departments and agencies, and in consultation with research institutions and research advocacy organizations or other relevant experts, as appropriate, shall—
(1) identify ways to improve the protection of intellectual property and other proprietary information, as well as identifiable, sensitive information of participants in biomedical research and development, from national security risks and other applicable threats, including the identification of gaps in policies and procedures in such areas related to biomedical research and development supported by the Department of Health and Human Services and biomedical research supported by other agencies as applicable, and make recommendations to institutions of higher education or other entities that have traditionally received Federal funding for biomedical research to protect such information;

(2) identify or develop strategies to prevent, mitigate, and address national security threats in biomedical research and development supported by the Federal Government, including such threats associated with foreign talent programs, by countries seeking to exploit United States technology and other proprietary information as it relates to such biomedical research and development;

(3) identify national security risks and potential misuse of proprietary information, and identifiable, sensitive information of biomedical research partici-
pants and other applicable risks, including with respect to peer review, and make recommendations for additional policies and procedures to protect such information;

(4) develop a framework to identify areas of biomedical research and development supported by the Federal Government that are emerging areas of interest for state actors and would compromise national security if they were to be subjected to undue foreign influence; and

(5) regularly review recommendations or policies developed under this section and make additional recommendations or updates, as appropriate.

(b) Report to President and to Congress.—Not later than 1 year after the date of enactment of this Act, the Secretary shall prepare and submit, in a manner that does not compromise national security, to the President and the Committee on Health, Education, Labor, and Pensions and the Select Committee on Intelligence of the Senate, the Committee on Energy and Commerce and the Permanent Select Committee on Intelligence of the House of Representatives, and other congressional committees as appropriate, a report on the findings and recommendations pursuant to subsection (a).
SEC. 325. GAO STUDY.

(a) IN GENERAL.—The Comptroller General of the United States (referred to in this section as the “Comptroller General”) shall conduct a study to assess the extent to which the Department of Health and Human Services (referred to in this section as the “Department”) utilizes or provides funding to entities that utilize such funds for human genomic sequencing services or genetic services (as such term is defined in section 201(6) of the Genetic Information Nondiscrimination Act of 2008 (42 U.S.C. 2000ff(6))) provided by entities, or subsidiaries of such entities, organized under the laws of a country or countries of concern, in the estimation of the Director of National Intelligence or the head of another Federal department or agency, as appropriate.

(b) CONSIDERATIONS.—In carrying out the study under this section, the Comptroller General shall—

(1) consider—

(A) the extent to which the country or countries of concern could obtain human genomic information of citizens and residents of the United States from such entities that sequence, analyze, collect, or store human genomic information and which the Director of National Intelligence or the head of another Federal department or agency reasonably an-
participants may use such information in a manner inconsistent with the national security interests of the United States;

(B) whether the Department or recipient of such funds from the Department sought to provide funding to, or to use, domestic entities with no such ties to the country or countries of concern for such purposes and any barriers to the use of domestic entities; and

(C) whether data use agreements, data security measures, and other such measures taken by the Department or recipient of such funds from the Department are sufficient to protect the identifiable, sensitive information of the people of the United States and the national security interests of the United States; and

(2) make recommendations to address any vulnerabilities to the United States national security identified, as appropriate.

(c) ESTIMATION.—In conducting the study under this section, the Comptroller General may, as appropriate and necessary to complete such study, investigate specific instances of such utilization of genetic sequencing services or genetic services, as described in subsection (a), to
produce estimates of the potential prevalence of such utilization among entities in receipt of Departmental funds.

(d) **REPORT.**—Not later than 2 years after the date of enactment of this Act, the Comptroller General shall submit a report on the study under this section, in a manner that does not compromise national security, to the Committee on Health, Education, Labor, and Pensions and the Select Committee on Intelligence of the Senate, and the Committee on Energy and Commerce and the Permanent Select Committee on Intelligence of the House of Representatives. The report shall be submitted in unclassified form, to the extent practicable, but may include a classified annex.

**SEC. 326. REPORT ON PROGRESS TO ADDRESS UNDUE FOREIGN INFLUENCE.**

Not later than 1 year after the date of enactment of this Act and annually thereafter, the Secretary of Health and Human Services shall prepare and submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce in the House of Representatives, in a manner that does not compromise national security, a report on actions taken by such Secretary—
(1) to address cases of noncompliance with disclosure requirements or research misconduct related to foreign influence, including—

(A) the number of potential noncompliance cases investigated by the National Institutes of Health or reported to the National Institutes of Health by a research institution, including relating to undisclosed research support, undisclosed conflicts of interest or other conflicts of commitment, and peer review violations;

(B) the number of cases referred to the Office of Inspector General of the Department of Health and Human Services, the Office of National Security of the Department of Health and Human Services, the Federal Bureau of Investigation, or other law enforcement agencies;

(C) a description of enforcement actions taken for noncompliance related to undue foreign influence; and

(D) any other relevant information; and

(2) to prevent, address, and mitigate instances of noncompliance with disclosure requirements or research misconduct related to foreign influence.
Subtitle D—Advanced Research Projects Authority for Health

SEC. 331. ADVANCED RESEARCH PROJECTS AUTHORITY FOR HEALTH.

Part E of title IV of the Public Health Service Act (42 U.S.C. 287 et seq.) is amended by inserting after subpart 2 of such part the following:

“Subpart 3—Advanced Research Projects Authority for Health

“SEC. 483. ADVANCED RESEARCH PROJECTS AUTHORITY FOR HEALTH.

“(a) DEFINITIONS.—In this section:

“(1) ARPA–H.—The term ‘ARPA–H’ means the Advanced Research Projects Authority for Health established under subsection (b).

“(2) DIRECTOR.—The term ‘Director’ means the Director of ARPA–H appointed under subsection (c).

“(3) OTHER TRANSACTIONS.—The term ‘other transactions’ has the meaning given such term in section 319L(a)(3).

“(b) ESTABLISHMENT OF THE ADVANCED RESEARCH PROJECTS AUTHORITY FOR HEALTH.—There is established within the National Institutes of Health the
Advanced Research Projects Authority for Health, for purposes of—

“(1) supporting high-impact, cutting-edge research in biomedicine and broadly applicable breakthrough technologies that have the potential to significantly transform and advance areas of biomedical science and medicine in a manner that cannot readily be accomplished through traditional biomedical research or commercial activity; and

“(2) overcoming long-term and significant technological and scientific barriers to advancing such technologies in order to improve the prevention, diagnosis, mitigation, treatment, and cure of health conditions.

“(c) DIRECTOR.—

“(1) IN GENERAL.—ARPA–H shall be headed by a Director, who shall be appointed by the President. The Director shall report to the Director of NIH.

“(2) QUALIFICATIONS.—The Director shall be an individual who, by reason of professional background and experience, is especially qualified to advise the Secretary on, and manage, research programs that advance the purposes of ARPA–H in promoting biomedical and novel technology innova-
tion pursuant to this section, and who has a demonstrated ability to identify and develop partnerships to address strategic needs in meeting such purposes.

“(3) APPOINTMENT.—Notwithstanding section 405(a)(2), the Director shall be appointed for a period of 4 years. The President may extend the term of a Director for a period of up to 4 additional years.

“(4) DUTIES.—The Director shall—

“(A) establish strategic goals, objectives, and priorities for ARPA–H, pursuant to the purposes of ARPA–H described in subsection (b);

“(B) approve all new programs within ARPA–H and terminate any program within ARPA–H that is not achieving its goals;

“(C) establish criteria for funding and assessing the success of programs through the establishment of technical milestones;

“(D) ensure that applications for funding disclose current and previous research and development efforts, and identify any challenges associated with such efforts, including any scientific or technical barriers encountered in the course of such efforts or challenges in securing
sources of funding, as applicable and appropriate, in pursuit of the technology area for which funding is requested;

“(E) facilitate coordination between the Department of Health and Human Services, relevant agencies within such Department, and other relevant Federal departments and agencies, with respect to research supported by ARPA–H;

“(F) support transformative, translational, applied, and advanced research in areas of biomedical science to address specific technical or scientific questions by —

“(i) prioritizing investments based on scientific potential and impact on the field of biomedicine, as described in subsection (b), especially in areas that require public-private partnerships in order to effectively advance research and development activities;

“(ii) translating scientific discoveries and cutting-edge innovation into technological advancements;
“(iii) encouraging opportunities to develop broadly applicable technologies, using a multi-disciplinary approach; and

“(iv) making investments in high-risk, high-reward research related to broadly applicable technologies, capabilities, and platforms that may have an application for medicine and health;

“(G) encourage strategic collaboration and partnerships with a broad range of entities, including institutions of higher education, industry, nonprofit organizations, or consortia of such entities, which may include federally-funded research and development centers; and

“(H) ensure that the United States maintains global leadership in researching and developing health technologies.

“(d) Personnel.—

“(1) In general.—The Director shall establish and maintain within ARPA–H a staff with appropriate qualifications and expertise to enable ARPA–H to carry out the responsibilities under this section.

“(2) Program managers.—

“(A) In general.—The Director shall designate employees to serve as program man-
agers for the programs established or supported pursuant to subsection (e)(4).

“(B) Responsibilities.—A program manager shall—

“(i) establish, in consultation with the Director, research and development goals for the program, including timelines and milestones, and make such goals available to the public;

“(ii) provide project oversight and management of strategic initiatives to advance the purpose of the program;

“(iii) encourage research collaborations, including by identifying and supporting applicable public-private partnerships;

“(iv) select the projects to be supported under the program after considering—

“(I) the novelty, scientific, and technical merit of the proposed projects;

“(II) the demonstrated capabilities of the applicants to successfully carry out the proposed project and
achieve designated milestones within
the applicable timeline;

“(III) the potential future com-
mercial applications of the project
proposed by the applicant;

“(IV) the degree to which the
project addresses a scientific or tech-
nical question pursuant to subsection
(e)(4)(F) and has the potential to
transform biomedicine, as described in
subsection (b); and

“(V) other criteria as established
by the Director;

“(v) recommend program restructure,
expansion, or termination of research
projects or whole projects, as necessary
and appropriate; and

“(vi) communicate with leaders in the
health care and biomedical research and
development fields, including from both the
public and private sectors, representatives
of patient organizations, institutions of
higher education, and nonprofit organiza-
tions, to identify areas of need and sci-
entific opportunity with the potential to
transform biomedicine as described in subsection (b).

“(C) TERM.—The term of a program manager shall be not more than 3 years, and, at the discretion of the Director, may be renewed for one additional period of up to 3 years.

“(3) CONSIDERATIONS.—The Director—

“(A) in designating employees to serve as program managers under paragraph (1), shall consider, as appropriate, individuals with demonstrated scientific expertise and management skills required to advance the purposes of ARPA–H, and who represent a diverse set of professional experiences or backgrounds, including individuals with experience in academia, industry, government, nonprofit organizations, or other sectors; and

“(B) in making appointments of personnel to staff or support ARPA–H, may consider other factors, as appropriate, such as populations that are traditionally underrepresented in the biomedical research enterprise.

“(4) HIRING.—

“(A) IN GENERAL.—The Director may—
“(i) make or rescind appointments of scientific, medical, and professional personnel, without regard to any provision of title 5, United States Code governing appointments under the civil service laws and notwithstanding section 202 of the Department of Health and Human Services Appropriations Act, 1993 (Public Law 102–394); and

“(ii) fix the compensation of such personnel at a rate to be determined by the Director, up to the amount of annual compensation (excluding expenses) specified in section 102 of title 3, United States Code.

“(B) REPORTING.—The Director shall establish and maintain records regarding the use of the authority under subparagraph (A)(i), including—

“(i) the number of positions filled through such authority;

“(ii) the types of appointments of such positions;

“(iii) the titles, occupational series, and grades of such positions;
“(iv) the number of positions publicly
noticed to be filled under such authority;
“(v) the number of qualified appli-
cants who apply for such positions;
“(vi) the qualification criteria for such
positions; and
“(vii) the demographic information of
individuals appointed to such positions.

“(C) REPORTS TO CONGRESS.—Not later
than one year after the date of enactment of
the PREVENT Pandemics Act, and annually
thereafter for each fiscal year in which such au-
thority is used, the Director shall submit to the
Committee on Health, Education, Labor, and
Pensions of the Senate and the Committee on
Energy and Commerce of the House of Rep-
resentatives a report describing the total num-
ber of appointments filled under this subsection
within the fiscal year and how the positions re-
late to the purposes of ARPA–H.

“(D) PRIVATE RECRUITING FIRMS.—The
Director may contract with private recruiting
firms for the hiring of qualified technical staff
to carry out this section.

“(E) CLARIFICATIONS.—
“(i) Previous positions.—The Director shall ensure that the personnel who are appointed to staff or support ARPA-H are individuals who, at the time of appointment and for 3 years prior to such appointment, were not employed by the National Institutes of Health.

“(ii) Number of personnel.—The Director may appoint not more than 120 personnel under this section. The Director shall submit a notification to Congress if the Director determines that additional personnel are required to carry out this section.

“(F) GAO report.—Not later than 2 years after the date of enactment of the PREVENT Pandemics Act, the Comptroller General of the United States shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report on the use of the authority provided under subparagraph (A)(i). Such report shall, in a manner that protects personal privacy, to the extent required by applicable Fed-
eral and State privacy law, at a minimum, include information on—

“(i) the number of positions publicly noticed and filled under the authority under this subsection;

“(ii) the occupational series, grades, and types of appointments of such positions;

“(iii) how such positions related to advancing the purposes of ARPA–H;

“(iv) how the Director made appointment decisions under this subsection;

“(v) sources used to identify candidates for filling such positions;

“(vi) the number of individuals appointed;

“(vii) aggregated demographic information related to individuals appointed; and

“(viii) any challenges, limitations, or gaps related to the use of the authority under this subsection and any related recommendations to address such challenges, limitations, or gaps.

“(e) FUNDING AWARDS.—
“(1) IN GENERAL.—In carrying out this section, the Director may award grants, contracts, cooperative agreements, cash prizes, and enter into other transactions, as described in paragraph (2).

“(2) OTHER TRANSACTIONS.—

“(A) LIMITATIONS ON ENTERING INTO OTHER TRANSACTIONS.—

“(i) IN GENERAL.—To the maximum extent practicable, competitive procedures shall be used when entering into other transactions to carry out projects under this section.

“(B) WRITTEN DETERMINATIONS REQUIRED.—The authority of this paragraph may be exercised for a project if the project manager—

“(i) submits a proposal to the Director for each individual use of such authority before conducting or supporting a project, including why the use of such authority is essential to promoting the success of the project;

“(ii) receives approval for the use of such authority from the Director; and
“(iii) for each year in which the program manager has used such authority in accordance with this paragraph, submits a report to the Director on the activities of the program relating to such project.

“(3) PRIZE COMPETITIONS.—The Director may utilize the authorities and processes established under section 24 of the Stevenson-Wydler Technology Innovation Act of 1980 (15 U.S.C. 3719) to support prize competitions, in accordance with this section.

“(4) FEDERAL DEMONSTRATION OF TECHNOLOGIES.—The Director may seek opportunities to partner with procurement programs of Federal agencies to demonstrate technologies resulting from activities funded through ARPA–H.

“(5) CLARIFICATIONS.—Research supported by this section shall not be subject to the requirements of section 406(a)(3)(A)(ii) or 492.

“(f) COORDINATION, COLLABORATION, NONDUPPLICATION, AND CONSULTATION.—

“(1) COORDINATION.—To the maximum extent practicable, the Director shall ensure that the activities of ARPA–H are coordinated with, and do not duplicate the efforts of—
“(A) other programs within, or research conducted or supported by, the Department of Health and Human Services, including the National Institutes of Health and the Biomedical Advanced Research and Development Authority; and

“(B) other relevant efforts or research and development programs operated or overseen by other departments, agencies, or offices of the Federal Government.

“(2) FUNDING DETERMINATIONS.—The Director shall ensure that ARPA–H does not provide funding for a research program or project unless the applicant for such funding demonstrates that—

“(A)(i) such applicant has made sufficient unsuccessful attempts to secure private financing, and that there is a lack of significant private support for the program or project; or

“(ii) such program or project is in the best interests of the United States; and

“(B) such program or project has the potential to significantly transform and advance the field of biomedicine, as described in subsection (b).
“(3) CONSULTATION.—In carrying out this section, the Director may seek input from—

“(A) the President’s Council of Advisors on Science and Technology;

“(B) representatives of professional or scientific organizations with expertise in specific technologies under consideration or development by ARPA–H; and

“(C) representatives of patient organizations, public health, innovators, and other public and private entities.

“(4) ENHANCED COLLABORATION AND COMMUNICATION.—

“(A) IN GENERAL.—In order to facilitate enhanced collaboration and communication with respect to the most current priorities of ARPA–H, the Food and Drug Administration may meet with ARPA–H and any other appropriate Federal partners, such as the Biomedical Advanced Research and Development Authority, at appropriate intervals, to discuss the development status, and actions that may be taken to facilitate the development, of medical products and projects that are the highest priorities to ARPA–H.
“(B) Relation to otherwise authorized activities of the Food and Drug Administration.—Utilizing interagency agreements or other appropriate resource allocation mechanisms available, the Director shall reimburse the Food and Drug Administration, as appropriate, for activities identified by the Commissioner of Food and Drugs and the Director as being conducted by the Food and Drug Administration under the authority of this section, using funds made available to ARPA–H.

“(g) Advisory Committee.—

“(1) In general.—There is established an ARPA–H Interagency Advisory Committee (referred to in this subsection as the ‘Advisory Committee’) to coordinate efforts and provide advice and assistance on specific program or project tasks and the overall direction of ARPA–H.

“(2) Members.—The Advisory Committee established under paragraph (1) shall consist of the heads of the following agencies or their designees:

“(A) The National Institutes of Health.

“(B) The Centers for Disease Control and Prevention.
“(C) The Food and Drug Administration.

“(D) The Office of the Assistant Secretary for Preparedness and Response.

“(E) The Office of the Assistant Secretary of Health.


“(H) The National Science Foundation.

“(I) Any other agency with subject matter expertise that the Director of ARPA–H determines appropriate to advance programs or projects under this section.

“(3) NONAPPLICABILITY OF FACA.—The Federal Advisory Committee Act (5 U.S.C. App.) shall not apply to the Advisory Committee.

“(4) ADVISORY NATURE.—The functions of the Advisory Committee shall be advisory in nature, and nothing in this subsection shall be construed as granting such Committee authority over the activities authorized under this section.

“(5) PERFORMANCE MEASURES FRAMEWORK.—The Director, in consultation with the Advisory Committee, shall develop a performance measures
framework for programs or projects supported by ARPA–H in order to inform and facilitate the evaluation required under subsection (m), including identification of any data needed to perform such evaluation, consistent with subsection (l).

“(h) FACILITIES.—

“(1) AUTHORITIES.—The Director is authorized to—

“(A) acquire (by purchase, lease, condemnation or otherwise), construct, improve, repair, operate, and maintain such real and personal property as are necessary to carry out this section; and

“(B) lease an interest in property for not more than 20 years, notwithstanding section 1341(a)(1) of title 31, United States Code.

“(2) LOCATIONS.—

“(A) IN GENERAL.—ARPA–H, including its headquarters, shall not be located, including headquartered, inside of, or in close proximity to, the National Capital region, and shall not be located on any part of the National Institutes of Health campuses.

“(B) CONSIDERATIONS.—In determining the location of facilities, the Director shall con-
consider the characteristics of the intended location and the extent to which such location will facilitate advancement of the ARPA–H purposes pursuant to subsection (b).

“(i) Rule of Construction.—The authorities granted by this section—

“(1) are in addition to existing authorities granted to the Secretary; and

“(2) shall not be construed to modify or supersede any existing authorities.

“(j) Protection of Information.—

“(1) In General.—Nothing in this section shall be construed as authorizing the Secretary to disclose any information that is a trade secret, or other privileged or confidential information subject to section 552(b)(4) of title 5, United States Code, or section 1905 of title 18, United States Code.

“(2) Reporting.—One year after the date of enactment of the PREVENT Pandemics Act, and annually thereafter, the Director shall report to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives on—

“(A) the number of instances in which the Secretary has used the authority under this
subsection to withhold information from disclosure; and

“(B) the nature of any request under section 552 of title 5, United States Code, or section 1905 of title 18, United States Code, that was denied using such authority.

“(k) REPORTS AND STRATEGIC PLANS.—

“(1) ANNUAL REPORT.—As part of the annual budget request submitted for each fiscal year, the Director shall provide to the Committee on Health, Education, Labor, and Pensions and the Committee on Appropriations of the Senate and the Committee on Energy and Commerce and the Committee on Appropriations of the House of Representatives a report that describes—

“(A) projects supported by ARPA–H during the previous fiscal year, and, with respect to each such project, the stage of development and details as to whether the project is meeting project milestones;

“(B) projects supported by ARPA–H in the previous fiscal year that were terminated, and the reasons for termination;

“(C) projects supported by ARPA–H during the previous fiscal year that examine topics
and technologies closely related to other activities funded by the Department of Health and Human Services, including an analysis of whether in supporting such projects, the Director is in compliance with the requirements of this section; and

“(D) current, proposed, and planned projects to be carried out.

“(2) STRATEGIC PLAN.—Not later than 180 days after the appointment of the first Director pursuant to subsection (c), and every 4 years thereafter, the Director shall provide to the Committee on Health, Education, Labor, and Pensions and the Committee on Appropriations of the Senate and the Committee on Energy and Commerce and the Committee on Appropriations of the House of Representatives a plan describing the strategic plan that ARPA–H will use to guide future investments over the following 4 fiscal years. Every 2 years after the date of submission of the initial plan, the Director shall submit a supplemental strategic plan that details any changes to such strategic vision, as appropriate. The requirements regarding individual institute and center strategic plans under section
402(m), including paragraph (3) of such subsection, shall not apply to ARPA–H.

“(l) NATIONAL ACADEMIES OF SCIENCES, ENGINEERING, AND MEDICINE EVALUATION.—

“(1) IN GENERAL.—Not later than 3 years after the date of enactment of the PREVENT Pandemics Act, the Director shall seek to enter into a contract with the National Academies of Sciences, Engineering, and Medicine under which the National Academies conducts an evaluation of ARPA–H regarding the goals and purposes of ARPA–H and the degree to which the activities of ARPA–H support, and align with, such goals and purposes.

“(2) INCLUSIONS.—The evaluation under paragraph (1) may include—

“(A) recommendations on how to improve upon the operation of, and projects carried out by, ARPA–H, which may include lessons learned from other advanced research and development agencies or authorities within the Department of Health and Human Services and in other departments, agencies, or offices of the Federal Government;

“(B) a description of lessons learned from the establishment and operation of ARPA–H,
and the manner in which those lessons may
apply to the operation of other programs of the
Department of Health and Human Services;
and
“(C) an analysis of whether any projects
supported by ARPA–H were duplicative of
other research programs supported by the De-
partment of Health and Human Services or
other another relevant Federal department or
agency.
“(3) Availability.—Upon completion of the
evaluation, the evaluation shall be submitted by the
Director to the Committee on Health, Education,
Labor, and Pensions and the Committee on Approp-
riations of the Senate and the Committee on En-
ergy and Commerce and the Committee on Approp-
riations of the House of Representatives and made
publicly available.
“(m) Authorization of Appropriations.—To
carry out this section, there are authorized to be appro-
priated such sums as may be necessary for each of fiscal
years 2023 through 2027.
“(n) Additional Budget Clarification.—Any
budget request for ARPA–H shall be separate from the
other budget requests of the National Institutes of Health.”.

**TITLE IV—MODERNIZING AND STRENGTHENING THE SUPPLY CHAIN FOR VITAL MEDICAL PRODUCTS**

**SEC. 401. WARM BASE MANUFACTURING CAPACITY FOR MEDICAL COUNTERMEASURES.**

(a) **IN GENERAL.**—Section 319L of the Public Health Service Act (42 U.S.C. 247d–7e) is amended—

(1) in subsection (a)(6)(B)—

(A) by redesignating clauses (iv) and (v) as clauses (v) and (vi), respectively;

(B) by inserting after clause (iii), the following:

“(iv) activities to support, maintain, and improve domestic manufacturing surge capacity and capabilities, as appropriate, including through the utilization of advanced manufacturing and platform technologies, to increase the availability of products that are or may become qualified countermeasures or qualified pandemic or epidemic products;”; and
(C) in clause (vi) (as so redesignated), by inserting “manufacturing,” after “improve-
ment,”;

(2) in subsection (b)—

(A) in the first sentence of paragraph (1), by inserting “support for domestic manufac-
turing surge capacity and capabilities,” after “initiatives for innovation,”; and

(B) in paragraph (2)—

(i) in subparagraph (B), by striking “and” at the end;

(ii) by redesignating subparagraph (C) as subparagraph (D); and

(iii) by inserting after subparagraph (B), the following:

“(C) activities to support, maintain, and improve domestic manufacturing surge capacity and capabilities, as appropriate, including through the utilization of advanced manufac-
turing and platform technologies, to increase the availability of products that are or may be-
come qualified countermeasures or qualified pandemic or epidemic products; and”;

(3) in subsection (c)—
(A) in paragraph (2)(B), by inserting before the semicolon “, including through the establishment and maintenance of domestic manufacturing surge capacity and capabilities, consistent with subsection (a)(6)(B)(iv)”;

(B) in paragraph (4)—

(i) in subparagraph (A)—

(I) in clause (i)—

(aa) in subclause (I), by striking “and” at the end; and

(bb) by adding at the end the following:

“(III) facilitating such communication, as appropriate, regarding manufacturing surge capacity and capabilities with respect to qualified countermeasures and qualified pandemic or epidemic products to prepare for, or respond to, a public health emergency or potential public health emergency; and

“(IV) facilitating such communication, as appropriate and in a manner that does not compromise national security, with respect to potential eli-
gibility for the material threat medical
countermeasure priority review voucher-
program under section 565A of the
Federal Food, Drug, and Cosmetic
Act;’’;

(II) in clause (ii)(III), by striking
“and” at the end;

(III) by redesignating clause (iii)
as clause (iv); and

(IV) by inserting after clause (ii),
the following:

“(iii) communicate regularly with enti-
ties in receipt of an award pursuant to
subparagraph (B)(v), and facilitate com-
munication between such entities and other
entities in receipt of an award pursuant to
subparagraph (B)(iv), as appropriate, for
purposes of planning and response regarding
the availability of countermeasures and
the maintenance of domestic manufac-
turing surge capacity and capabilities, in-
cluding any planned uses of such capacity
and capabilities in the near- and mid-term,
and identification of any significant chal-
lenges related to the long-term mainte-
and the

(ii) in subparagraph (B)—

(I) in clause (iii), by striking “and” at the end;

(II) in clause (iv), by striking the period and inserting “; and”;

(III) by adding at the end the following:

“(v) award contracts, grants, and cooperative agreements and enter into other transactions to support, maintain, and improve domestic manufacturing surge capacity and capabilities, including through supporting flexible or advanced manufacturing, to ensure that additional capacity is available to rapidly manufacture products that are or may become qualified countermeasures or qualified pandemic or epidemic products in the event of a public health emergency declaration or significant potential for a public health emergency.”;

(iii) in subparagraph (C)—

(I) in clause (i), by striking “and” at the end;
(II) in clause (ii), by striking the period at the end and inserting "; and"

(III) by adding at the end the following:

"(iii) consult with the Commissioner of Food and Drugs, pursuant to section 565(b)(2) of the Federal Food, Drug, and Cosmetic Act, to ensure that facilities performing manufacturing, pursuant to an award under subparagraph (B)(v), are in compliance with applicable requirements under such Act and this Act, as appropriate, including current good manufacturing practice pursuant to section 501(a)(2)(B) of the Food, Drug, and Cosmetic Act; and"

(iv) in subparagraph (D)(i), by inserting "including to improve manufacturing capacities and capabilities for medical countermeasures" before the semicolon;

(v) in subparagraph (E)(ix), by striking "2023" and inserting "2028"; and

(vi) by adding at the end the following:
“(G) Annual reports by award recipients.—As a condition of receiving an award under subparagraph (B)(v), a recipient shall develop and submit to the Secretary annual reports related to the maintenance of such capacity and capabilities, including ensuring that such capacity and capabilities are able to support the rapid manufacture of countermeasures as required by the Secretary.”; and

(C) in paragraph (5), by adding at the end the following:

“(H) Supporting warm-base and surge capacity and capabilities.—Pursuant to an award under subparagraph (B)(v), the Secretary may make payments for activities necessary to maintain domestic manufacturing surge capacity and capabilities supported under such award to ensure that such capacity and capabilities are able to support the rapid manufacture of countermeasures as required by the Secretary to prepare for, or respond to, an existing or potential public health emergency or otherwise address threats that pose a significant level of risk to national security. The Secretary may support the utilization of such ca-
capacity and capabilities under awards for countermeasure and product advanced research and development, as appropriate, to provide for the maintenance of such capacity and capabilities.”; and

(4) in subsection (f)—

(A) in paragraph (1), by striking “Not later than 180 days after the date of enactment of this subsection” and inserting “Not later than 180 days after the date of enactment of the PREVENT Pandemics Act”;

(B) in paragraph (2)—

(i) in the matter preceding subparagraph (A), by striking “this subsection” and inserting “the PREVENT Pandemics Act”;

(ii) in subparagraph (B), by striking “and” at the end; and

(iii) in subparagraph (C), by striking the period and inserting “; and”; and

(C) by adding at the end the following: “(D) plans for the near-, mid-, and long-term sustainment of manufacturing activities carried out under this section, including such activities pursuant to subsection (e)(5)(H), spe-
specific actions to regularly assess the ability of recipients of an award under subsection (c)(4)(B)(v) to rapidly manufacture countermeasures as required by the Secretary, and recommendations to address challenges, if any, related to such activities.”.

SEC. 402. SUPPLY CHAIN CONSIDERATIONS FOR THE STRATEGIC NATIONAL STOCKPILE.

Subclause (II) of section 319F–2(a)(2)(B)(i) of the Public Health Service Act (42 U.S.C. 247d–6b(a)(2)(B)(i)) is amended to read as follows:

“(II) planning considerations for appropriate manufacturing capacity and capability to meet the goals of such additions or modifications (without disclosing proprietary information), including—

“(aa) consideration of the effect such additions or modifications may have on the availability of such products and ancillary medical supplies on the health care system; and

“(bb) an assessment of the current supply chain for such
products, including information on supply chain redundancies, any known domestic manufacturing capacity for such products, and any related vulnerabilities;”.

SEC. 403. STRATEGIC NATIONAL STOCKPILE EQUIPMENT MAINTENANCE.

Section 319F–2(a)(3) of the Public Health Service Act (42 U.S.C. 247d–6b(a)(3)) is amended—

(1) in subparagraph (B), by inserting “, regularly reviewed, and updated” after “followed”; and

(2) by amending subparagraph (D) to read as follows:

“(D) review and revise, as appropriate, the contents of the stockpile on a regular basis to ensure that—

“(i) emerging threats, advanced technologies, and new countermeasures are adequately considered;

“(ii) the potential depletion of countermeasures currently in the stockpile is identified and appropriately addressed, including through necessary replenishment; and
“(iii) such contents are in working condition or usable, as applicable, and are ready for deployment, which may include conducting maintenance services on such contents of the stockpile and disposing of such contents that are no longer in working condition, or usable, as applicable;”.

SEC. 404. IMPROVING TRANSPARENCY AND PREDICTABILITY OF PROCESSES OF THE STRATEGIC NATIONAL STOCKPILE.

(a) GUIDANCE.—Not later than 60 days after the date of enactment of this Act, the Secretary of Health and Human Services (referred to in this section as the “Secretary”) shall issue guidance describing the processes by which the Secretary deploys the contents of the Strategic National Stockpile under section 319F–2(a) of the Public Health Service Act (42 U.S.C. 247d–6b(a)), or otherwise distributes medical countermeasures, as applicable, to States, territories, Indian Tribes and Tribal organizations (as such terms are defined under section 4 of the Indian Self-Determination and Education Assistance Act), and other applicable entities. Such guidance shall include information related to processes by which to request access to the contents of the Strategic National Stockpile, factors considered by the Secretary when making deployment or
distribution decisions, and processes and points of contact through which entities may contact the Secretary to address any issues related to products requested or received by such entity from the stockpile, and on other relevant topics.

(b) **ANNUAL MEETINGS.**—Section 319F–2(a)(3) of the Public Health Service Act (42 U.S.C. 247d–6b(a)(3)) is amended—

1. in subparagraph (I), by striking “and” at the end;
2. in subparagraph (J), by striking the period at the end and inserting “; and”; and
3. by adding at the end the following:

   “(K) convene meetings, not less than once per year, with representatives from State, local, and Tribal health departments or officials, relevant industries, other Federal agencies, and other appropriate stakeholders, in a manner that does not compromise national security, to coordinate and share information related to maintenance and use of the stockpile, including a description of future countermeasure needs and additions, modifications, and replenishments of the contents of the stockpile, and considerations related to the manufacturing and
procurement of products consistent with the re-
quirements of the Buy American Act of 1933,
as appropriate.”.

SEC. 405. IMPROVING SUPPLY CHAIN FLEXIBILITY FOR THE
STRATEGIC NATIONAL STOCKPILE.

(a) In General.—Section 319F–2 of the Public
Health Service Act (42 U.S.C. 247d–6b) is amended—

(1) in subsection (a)—

(A) in paragraph (3)(F), by striking “as
required by the Secretary of Homeland Secu-
rity” and inserting “at the discretion of the
Secretary, in consultation with, or at the re-
quest of, the Secretary of Homeland Security,”;

(B) by redesignating paragraphs (5) and
(6) as paragraphs (6) and (7), respectively;

(C) by inserting after paragraph (4) the
following:

“(5) VENDOR-MANAGED INVENTORY AND
WARM-BASE SURGE CAPACITY.—

“(A) In general.—For the purposes of
maintaining the stockpile under paragraph (1)
and carrying out procedures under paragraph
(3), the Secretary may enter into contracts or
cooperative agreements with vendors, which
may include manufacturers or distributors of
medical products, with respect to medical products intended to be delivered to the ownership of the Federal Government. Each such contract or cooperative agreement shall be subject to such terms and conditions as the Secretary may specify, including terms and conditions with respect to—

“(i) procurement, maintenance, storage, and delivery of products, in alignment with inventory management and other applicable best practices, under such contract or cooperative agreement, which may consider, as appropriate, costs of transporting and handling such products; or

“(ii) maintenance of domestic manufacturing capacity and capabilities of such products to ensure additional reserved production capacity and capabilities are available, and that such capacity and capabilities are able to support the rapid manufacture, purchase, storage, and delivery of such products, as required by the Secretary to prepare for, or respond to, an existing or potential public health emergency.
“(B) REPORT.—Not later than 2 years after the date of enactment of the PREVENT Pandemics Act, and annually thereafter, the Secretary shall submit to the Committee on Health, Education, Labor, and Pensions and the Committee on Appropriations of the Senate and the Committee on Energy and Commerce and the Committee on Appropriations of the House of Representatives a report on any contracts or cooperative agreements entered into under subparagraph (A) for purposes of establishing and maintaining vendor-managed inventory or reserve manufacturing capacity and capabilities for products intended for the stockpile, including a description of—

“(i) the amount of each award;

“(ii) the recipient of each award;

“(iii) the product or products covered through each award; and

“(iv) how the Secretary works with each recipient to ensure situational awareness related to the manufacturing capacity for, or inventory of, such products and coordinates the distribution and deployment
of such products, as appropriate and appl-
cable.”; and

(D) in subparagraph (A) of paragraph (6),
as so redesignated—

(i) in clause (viii), by striking “; and”
and inserting a semicolon;

(ii) in clause (ix), by striking the pe-
period and inserting “; and”; and

(iii) by adding at the end the fol-
lowing:

“(x) with respect to reports issued in
2027 or any subsequent year, an assess-
ment of selected contracts or cooperative
agreements entered into pursuant to para-
graph (5).”; and

(2) in subsection (c)(2)(C), by striking “on an
annual basis” and inserting “not later than March
15 of each year”.

(b) AUTHORIZATION OF APPROPRIATIONS.—Section
319F–2(f)(1) of the Public Health Service Act (42 U.S.C.
247d–6b(f)(1)) is amended by striking “$610,000,000 for
each of fiscal years 2019 through 2023” and inserting
“$610,000,000 for each of fiscal year 2019 through 2021,
and $750,000,000 for each of fiscal years 2022 and
2023”.
Paragraph (7) of section 319F–2(a) of the Public Health Service Act (42 U.S.C. 247d–6b(a)), as so redesignated by section 405(a)(1)(B), is amended to read as follows:

“(7) REIMBURSEMENT FOR CERTAIN SUPPLIES.—

“(A) IN GENERAL.—The Secretary may, at appropriate intervals, make available for purchase excess contents procured for, and maintained within, the stockpile under paragraph (1) to any Federal agency or State, local, or Tribal government. The Secretary shall make such contents available for purchase only if—

“(i) such contents are in excess of what is required for appropriate maintenance of such stockpile;

“(ii) the Secretary determines that the costs for maintaining such excess contents are not appropriate to expend to meet the needs of the stockpile; and

“(iii) the Secretary determines that such action does not compromise national security and is in the national interest.

“(B) REIMBURSEMENT AND COLLECTION.—The Secretary may require reimburse-
ment for contents that are made available under subparagraph (A), in an amount that reflects the cost of acquiring and maintaining such contents and the costs incurred to make available such contents in the time and manner specified by the Secretary. Amounts collected under this subsection shall be credited to the appropriations account or fund that incurred the costs to procure such contents, and shall remain available, without further appropriation, until expended, for the purposes of the appropriation account or fund so credited.

“(C) Rule of Construction.—This paragraph shall not be construed to preclude transfers of contents in the stockpile under other authorities.

“(D) Report.—Not later than 2 years after the date of enactment of the PREVENT Pandemics Act, and annually thereafter, the Secretary shall submit to the Committee on Health, Education, Labor, and Pensions and the Committee on Appropriations of the Senate and the Committee on Energy and Commerce and the Committee on Appropriations of the House of Representatives a report on the use of
the authority provided under this paragraph, in-
cluding details of each action taken pursuant to
this paragraph, the account or fund to which
any collected amounts have been credited, and
how the Secretary has used such amounts.

“(E) SUNSET.—The authority under this
paragraph shall terminate on September 30,
2028.”.

SEC. 407. ACTION REPORTING ON STOCKPILE DEPLETION.

Section 319 of the Public Health Service Act (42
U.S.C. 247d), as amended by section 223, is further
amended by adding at the end the following:

“(h) STOCKPILE DEPLETION REPORTING.—The Sec-
retary shall, not later than 30 days after the deployment
of contents of the Strategic National Stockpile under sec-
tion 319F–2(a) to respond to a public health emergency
declared by the Secretary under this section or an emer-
gency or major disaster declared by the President under
the Robert T. Stafford Disaster Relief and Emergency As-
sistance Act, and every 30 days thereafter until the expira-
tion or termination of such public health emergency, emer-
gency, or major disaster, submit a report to the Com-
mittee on Health, Education, Labor, and Pensions and the
Committee on Appropriations of the Senate and the Com-
mittee on Energy and Commerce and the Committee on Appropriations of the House of Representatives on—

“(1) the deployment of the contents of the stockpile in response to State, local, and Tribal re-
quests;

“(2) the amount of such products that remain within the stockpile following such deployment; and

“(3) plans to replenish such products, as appro-
priate, including related timeframes and any barriers or limitations to replenishment.”.

SEC. 408. PROVISION OF MEDICAL COUNTERMEASURES TO INDIAN PROGRAMS AND FACILITIES.

(a) CLARIFICATION.—Section 319F–2(a)(3) of the Public Health Service Act (42 U.S.C. 247d–6b(a)(3)) is amended—

(1) in subparagraph (C), by striking “and local” and inserting “local, and Tribal”; and

(2) in subparagraph (J), by striking “and local” and inserting “local, and Tribal”.

(b) DISTRIBUTION OF MEDICAL COUNTERMEASURES TO INDIAN TRIBES.—Title III of the Public Health Serv-

ice Act (42 U.S.C. 241 et seq.) is amended by inserting after section 319F–4 the following:
“SEC. 319F–5. PROVISION OF MEDICAL COUNTERMEASURES TO INDIAN PROGRAMS AND FACILITIES.

“In the event that the Secretary deploys the contents of the Strategic National Stockpile under section 319F–2(a), or otherwise distributes medical countermeasures to States to respond to a public health emergency declared by the Secretary under section 319, the Secretary shall, in consultation with the applicable States, make such contents or countermeasures directly available to Indian Tribes and Tribal organizations (as such terms are defined in section 4 of the Indian Self-Determination and Education Assistance Act (25 U.S.C. 5304), which may include through health programs or facilities operated by the Indian Health Service, that are affected by such public health emergency.”

SEC. 409. GRANTS FOR STATE STRATEGIC STOCKPILES.

(a) Section 319F–2 of the Public Health Service Act (42 U.S.C. 247d–6b) is amended by adding at the end the following:

“(i) Pilot Program to Support State Medical Stockpiles.—

“(1) In general.—The Secretary, in consultation with the Assistant Secretary for Preparedness and Response and the Director of the Centers for Disease Control and Prevention, shall award grants or cooperative agreements to not fewer than 5
States, or consortia of States, with consideration
given to distribution among the geographical regions
of the United States, to establish, expand, or main-
tain a stockpile of appropriate drugs, vaccines and
other biological products, medical devices, and other
medical supplies determined by the State to be nec-
essary to respond to a public health emergency de-
clared by the Governor of a State or by the Sec-
retary under section 319, or a major disaster or
emergency declared by the President under section
401 or 501, respectively, of the Robert T. Stafford
Disaster Relief and Emergency Assistance Act, in
order to support the preparedness goals described in
paragraphs (2) through (6) and (8) of section
2802(b).

“(2) Requirements.—

“(A) Application.—To be eligible to re-
ceive an award under paragraph (1), an entity
shall prepare, in consultation with appropriate
health care entities and health officials within
the jurisdiction of such State or States, and
submit to the Secretary an application that con-
tains such information as the Secretary may re-
quire, including—
“(i) a plan for such stockpile, consistent with paragraph (4), including—

“(I) a description of the activities such entity will carry out under the agreement;

“(II) an assurance that such entity will use funds under such award in alignment with the requirements of chapter 83 of title 41, United States Code (commonly referred to as the ‘Buy American Act’); and

“(III) an outline of proposed expenses; and

“(ii) a description of how such entity will coordinate with relevant entities in receipt of an award under section 319C–1 or 319C–2 pursuant to paragraph (4), including through promoting alignment between the stockpile plan established pursuant to clause (i) and applicable plans that are established by such entity pursuant to section 319C–1 or 319C–2.

“(B) MATCHING FUNDS.—

“(i) Subject to clause (ii), the Secretary may not make an award under this
subsection unless the applicant agrees, with respect to the costs to be incurred by the applicant in carrying out the purpose described in this subsection, to make available non-Federal contributions toward such costs in an amount equal to—

“(I) for each of fiscal years 2023 and 2024, not less than $1 for each $20 of Federal funds provided in the award; and

“(II) for fiscal year 2025 and each fiscal year thereafter, not less than $1 for each $10 of Federal funds provided in the award.

“(ii) WAIVER.—The Secretary may, upon the request of a State, waive the requirement under clause (i), in whole or in part, if the Secretary determines that extraordinary economic conditions in the State in the fiscal year involved or in the previous fiscal year justify the waiver. A waiver provided by the Secretary under this subparagraph shall apply only to the fiscal year involved.
“(C) Administrative Expenses.—Not more than 10 percent of amounts received by an entity pursuant to an award under this subsection may be used for administrative expenses.

“(3) Lead Entity.—An entity in receipt of an award under paragraph (1) may designate a lead entity, which may be a public or private entity, as appropriate, to manage the stockpile at the direction of the State or consortium of States.

“(4) Use of Funds.—An entity in receipt of an award under paragraph (1) shall use such funds to—

“(A) purchase, store, and maintain a stockpile of appropriate drugs, vaccines and other biological products, medical devices, and other medical supplies to be used during a public health emergency, major disaster, or emergency described in paragraph (1), in such numbers, types, and amounts as the entity determines necessary, consistent with such entity’s stockpile plan established pursuant to paragraph (2)(A)(i);

“(B) deploy the stockpile as required by the entity to respond to an actual or potential
public health emergency, major disaster, or
other emergency described in paragraph (1);

“(C) replenish and make necessary addi-
tions or modifications to the contents of such
stockpile, including to address potential deple-
tion;

“(D) in consultation with Federal, State,
and local officials, take into consideration the
availability, deployment, dispensing, and admin-
istration requirements of medical products with-
in the stockpile;

“(E) ensure that procedures are followed
for inventory management and accounting, and
for the physical security of the stockpile, as ap-
propriate;

“(F) review and revise, as appropriate, the
contents of the stockpile on a regular basis to
ensure that, to the extent practicable, new tech-
nologies and medical products are considered;

“(G) carry out exercises, drills, and other
training for purposes of stockpile deployment,
dispensing, and administration of medical prod-
ucts, and for purposes of assessing the capa-
bility of such stockpile to address the medical
supply needs of public health emergencies,
major disasters, or other emergencies described in paragraph (1) of varying types and scales, which may be conducted in accordance with requirements related to exercises, drills, and other training for recipients of awards under section 319C–1 or 319C–2, as applicable; and

“(H) carry out other activities related to the State strategic stockpile as the entity determines appropriate, to support State efforts to prepare for, and respond to, public health threats.

“(5) SUPPLEMENT NOT SUPPLANT.—Awards under paragraph (1) shall supplement, not supplant, the maintenance and use of the Strategic National Stockpile by the Secretary under subsection (a).

“(6) GUIDANCE FOR STATES.—Not later than 180 days after the date of enactment of this subsection, the Secretary, in consultation with States, health officials, and other relevant stakeholders, as appropriate, shall issue guidance, and update such guidance as appropriate, for States related to maintaining and replenishing a stockpile of medical products, which may include strategies and best practices related to—
“(A) types of medical products and medical supplies that are critical to respond to public health emergencies, and may be appropriate for inclusion in a stockpile by States, with consideration of threats that require the large-scale and simultaneous deployment of stockpiles, including the stockpile maintained by the Secretary pursuant to subsection (a), and long-term public health and medical response needs;

“(B) appropriate management of the contents of a stockpile, including management by vendors of reserve amounts of medical products and supplies intended to be delivered to the ownership of the State and appropriate disposition of excess products, as applicable; and

“(C) the procurement of medical products and medical supplies consistent with the requirements of chapter 83 of title 41, United States Code (commonly referred to as the ‘Buy American Act’).

“(7) TECHNICAL ASSISTANCE.—The Secretary shall provide assistance to States, including technical assistance, as appropriate, in establishing, maintaining, improving, and utilizing a medical stockpile, in-
including appropriate inventory management and disposition of products.

“(8) Reporting.—

“(A) State reports.—Each entity receiving an award under paragraph (1) shall update, as appropriate, the plan established pursuant to paragraph (2)(A)(i) and submit to the Secretary an annual report on implementation of such plan, including any changes to the contents of the stockpile supported under such award. The Secretary shall use information obtained from such reports to inform the maintenance and management of the Strategic National Stockpile pursuant to subsection (a).

“(B) Reports to Congress.—Not later than 1 year after the initial issuance of awards pursuant to paragraph (1), and annually thereafter for the duration of the program established under this subsection, the Secretary shall submit to the Committee on Health, Education, Labor, and Pensions and the Committee on Appropriations of the Senate and the Committee on Energy and Commerce and the Committee on Appropriations of the House of Representatives a report on such program, including—
“(i) Federal and State expenditures to support stockpiles under such program;

“(ii) activities conducted pursuant to paragraph (4); and

“(iii) any additional information from the States that the Secretary determines relevant.

“(9) Authorization of Appropriations.—

To carry out this subsection, there is authorized to be appropriated such sums as may be necessary for each of fiscal years 2023 through 2028.”.

(b) GAO Report.—Not later than 3 years after the date on which awards are first issued pursuant to subsection (i)(1) of section 319F–2 of the Public Health Service Act (42 U.S.C. 247d–6b), as added by subsection (a), the Comptroller General of the United States shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report on the State stockpiles established or maintained pursuant to this section. Such report shall include an assessment of—

(1) coordination and communication between the Secretary of Health and Human Services and entities in receipt of an award under this section, or a lead entity designated by such entity;
(2) technical assistance provided by the Secretary of Health and Human Services to such entities; and

(3) the impact of such stockpiles on the ability of the State to prepare for and respond to a public health emergency, major disaster, or other emergency described in subsection (i)(1) of section 319F–2 of the Public Health Service Act (42 U.S.C. 247d–6b), as added by subsection (a), including the availability and distribution of items from such State stockpile to health care entities and other applicable entities.

SECTION 410. STUDY ON INCENTIVES FOR DOMESTIC PRODUCTION OF GENERIC MEDICINES.

(a) IN GENERAL.—The Secretary of Health and Human Services (referred to in this section as the “Secretary”), acting through the Assistant Secretary for Planning and Evaluation of the Department of Health and Human Services shall—

(1) conduct a study on the feasibility, including related to sustainment, and potential effectiveness, and utility of providing incentives for increased domestic production and capacity of specified generic medicines and their active pharmaceutical ingredients; and
(2) not later than 1 year after the date of enactment of this Act, submit a report on such study to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives.

(b) Specified Generic Medicine.—In this section, the term “specified generic medicine” means a generic drug approved under section 505(j) of the Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)) that is—

(1) used to prevent, mitigate, or treat a serious or life-threatening disease or condition, or used in a common procedure that could be life-threatening without such medicine;

(2) an antibiotic or antifungal used to treat a serious or life-threatening infectious disease;

(3) critical to the public health during a public health emergency; or

(4) life-supporting, life-sustaining, or intended for use in the prevention or treatment of a debilitating disease or condition.
TITLE V—ENHANCING DEVELOPMENT AND COMBATING SHORTAGES OF MEDICAL PRODUCTS

Subtitle A—Development and Review

SEC. 501. ADVANCING QUALIFIED INFECTIONIOUS DISEASE PRODUCT INNOVATION.

(a) In General.—Section 505E of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355f) is amended—

(1) in subsection (c)—

(A) in paragraph (2), by striking “; or” and inserting “;”;  

(B) in paragraph (3), by striking the period and inserting “; or”; and

(C) by adding at the end the following:

“(4) an application pursuant to section 351(a) of the Public Health Service Act.”;

(2) in subsection (d)(1), by inserting “of this Act or section 351(a) of the Public Health Service Act” after “section 505(b)”;

(3) by amending subsection (g) to read as follows:
“(g) Qualified Infectious Disease Product.— The term ’qualified infectious disease product’ means a drug (including a biological product), including an antibacterial or antifungal drug, for human use that—

“(1) acts directly on bacteria or fungi or on substances produced by such bacteria or fungi; and

“(2) is intended to treat a serious or life-threatening infection, including such an infection caused by—

“(A) an antibacterial or antifungal resistant pathogen, including novel or emerging infectious pathogens; or

“(B) qualifying pathogens listed by the Secretary under subsection (f).”.

(b) Priority Review.—Section 524A(a) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360n–1(a)) is amended by inserting “of this Act, or section 351(a) of the Public Health Service Act, that requires clinical data (other than bioavailability studies) to demonstrate safety or effectiveness” before the period.

SEC. 502. MODERNIZING CLINICAL TRIALS.

(a) Clarifying the Use of Digital Health Technologies in Clinical Trials.—

(1) In general.—Not later than 1 year after the date of enactment of this Act, the Secretary of
Health and Human Services (referred to in this section as the “Secretary”) shall issue or revise draft guidance regarding the appropriate use of validated digital health technologies in clinical trials to help improve recruitment for, retention in, participation in, and data collection during, clinical trials, and provide for novel clinical trial designs utilizing such technology for purposes of supporting the development of, and review of applications for, drugs and devices. Not later than 18 months after the public comment period on such draft guidance ends, the Secretary shall issue a revised draft guidance or final guidance.

(2) CONTENT.—The guidance described in paragraph (1) shall include—

(A) recommendations for data collection methodologies by which sponsors may incorporate the use of digital health technologies in clinical trials to collect data remotely from trial participants;

(B) considerations for privacy and security protections for data collected during a clinical trial, including—

(i) recommendations for the protection of trial participant data that is col-
lected or used in research, using digital health technologies;

(ii) compliance with the regulations promulgated under section 264(c) of the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. 1320d–2 note), subpart B of part 50 of title 21, Code of Federal Regulations, subpart C of part 56 of title 21, Code of Federal Regulations, the Federal policy for the protection of human subjects under subpart A of part 46 of title 45, Code of Federal Regulations (commonly known as the “Common Rule”), and part 2 of title 42, Code of Federal Regulations (or any successor regulations); and

(iii) recommendations for protection of clinical trial participant data against cybersecurity threats, as applicable;

(C) considerations on data collection methods to help increase recruitment of clinical trial participants and the level of participation of such participants, reduce burden on clinical trial participants, and optimize data quality;
(D) recommendations for the use of electronic methods to obtain informed consent from clinical trial participants, taking into consideration applicable Federal law, including subpart B of part 50 of title 21, Code of Federal Regulations (or successor regulations), and, as appropriate, State law;

(E) best practices for communication and early engagement between sponsors and the Secretary on the development of data collection methods;

(F) the appropriate format to submit such data to the Secretary;

(G) a description of the manner in which the Secretary may assess or evaluate data collected through digital health technologies to support the development of the drug or device;

(H) recommendations regarding the data and information needed to demonstrate that a digital health technology is fit-for-purpose for a clinical trial, and a description of how the Secretary will evaluate such data and information; and

(I) recommendations for increasing access to, and the use of, digital health technologies in
clinical trials to facilitate the inclusion of diverse and underrepresented populations, as appropriate, including considerations for access to, and the use of, digital health technologies in clinical trials by people with disabilities and pediatric populations.

(b) ADVANCING DECENTRALIZED CLINICAL TRIALS.—

(1) IN GENERAL.—Not later than 1 year after the date of enactment of this Act, the Secretary shall issue or revise draft guidance to provide recommendations to clarify and advance the use of decentralized clinical trials to support the development of drugs and devices and help improve trial participant engagement and advance the use of flexible and novel clinical trial designs. Not later than 18 months after the public comment period on such draft guidance ends, the Secretary shall issue a revised draft guidance or final guidance.

(2) CONTENT.—The guidance described in paragraph (1) shall include—

(A) recommendations for methods of remote data collection, including trial participant experience data, though the use of digital health technologies, telemedicine, local laboratories,
local health care providers, or other options for data collection;

(B) considerations for sponsors to minimize or reduce burdens for clinical trial participants associated with participating in a clinical trial, such as the use of digital technologies, telemedicine, local laboratories, local health care providers, or other data collection or assessment options, health care provider home visits, direct-to-participant shipping of investigational drugs and devices, and electronic informed consent, as appropriate;

(C) recommendations regarding conducting decentralized clinical trials to facilitate and encourage diversity among the clinical trial participants, as appropriate;

(D) recommendations for strategies and methods for recruiting, retaining, and engaging with clinical trial participants, including communication regarding the role of trial participants and community partners to facilitate clinical trial recruitment and engagement, including with respect to diverse and underrepresented populations, as appropriate;
(E) considerations for review and oversight by sponsors and institutional review boards, including remote trial oversight;

(F) recommendations for decentralized clinical trial protocol designs and processes for evaluating such proposed trial designs;

(G) recommendations for digital health technology and other remote assessment tools that may support decentralized clinical trials, including guidance on appropriate technological platforms and tools, data collection and use, data integrity, and communication to clinical trial participants through such technology;

(H) a description of the manner in which the Secretary will assess or evaluate data collected within a decentralized clinical trial to support the development of the drug or device, if the manner is different from that used for a non-decentralized trial;

(I) considerations for sponsors to validate digital technologies and establish appropriate clinical endpoints for use in decentralized trials;

(J) considerations for privacy and security of personally identifiable information of trial participants; and
(K) considerations for conducting clinical trials using centralized approaches in conjunction with decentralized approaches.

(c) SEAMLESS AND CONCURRENT CLINICAL TRIALS.—

(1) IN GENERAL.—Not later than 1 year after the date of enactment of this Act, the Secretary shall issue or revise draft guidance on the use of seamless, concurrent, and other innovative clinical trial designs to support the expedited development and review of applications for drugs, as appropriate. Not later than 18 months after the public comment period on such draft guidance ends, the Secretary shall issue a revised draft guidance or final guidance.

(2) CONTENT.—The guidance described in paragraph (1) shall include—

(A) recommendations on the use of expansion cohorts and other seamless clinical trial designs to assess different aspects of product candidates in one continuous trial, including how such clinical trial designs can be used as part of meeting the substantial evidence standard under section 505(d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(d));
(B) recommendations on the use of clinical trial designs that involve the concurrent conduct of different or multiple clinical trial phases, and the concurrent conduct of pre-clinical testing, to expedite the development of new drugs and facilitate the timely collection of data;

(C) recommendations for how to streamline trial logistics and facilitate the efficient collection and analysis of clinical trial data, including any planned interim analyses and how such analyses could be used to streamline the product development and review processes;

(D) considerations to assist sponsors in ensuring the rights, safety, and welfare of clinical trial participants, maintaining compliance with good clinical practice regulations, minimizing risks to clinical trial data integrity, and ensuring the reliability of clinical trial results;

(E) recommendations for communication and early engagement between sponsors and the Food and Drug Administration on the development of seamless, concurrent, or other adaptive trial designs, including review of, and feedback on, clinical trial protocols; and
(F) a description of the manner in which
the Secretary will assess or evaluate data col-
lected through seamless, concurrent, or other
adaptive trial designs to support the develop-
ment of the drug.

(d) INTERNATIONAL HARMONIZATION.—The Sec-
retary shall work with foreign regulators pursuant to
memoranda of understanding or other arrangements gov-
erning the exchange of information to facilitate inter-
national harmonization of the regulation and use of decen-
tralized clinical trials, digital technology in clinical trials,
and seamless, concurrent, and other adaptive or innovative
clinical trial designs.

SEC. 503. ACCELERATING COUNTERMEASURE DEVELO-
MENT AND REVIEW.

Section 565 of the Federal Food, Drug, and Cosmetic
Act (21 U.S.C. 360bbb–4) is amended by adding at the
end the following:

“(h) ACCELERATING COUNTERMEASURE DEVELO-
PMENT AND REVIEW DURING AN EMERGENCY.—

“(1) ACCELERATION OF COUNTERMEASURE DE-
VELOPMENT AND REVIEW.—The Secretary may, at
the request of the sponsor of a countermeasure, dur-
ing a domestic, military, or public health emergency
or material threat described in section
564A(a)(1)(C), expedite the development and review of countermeasures that are intended to address such domestic, military, or public health emergency or material threat for approval, licensure, clearance, or authorization under this title or section 351 of the Public Health Service Act.

“(2) ACTIONS.—The actions to expedite the development and review of a countermeasure under paragraph (1) may include the following:

“(A) Expedited review of submissions made by sponsors of countermeasures to the Food and Drug Administration, including rolling submissions of countermeasure applications and other submissions.

“(B) Expedited and increased engagement with sponsors regarding countermeasure development and manufacturing, including—

“(i) holding meetings with the sponsor and the review team and providing timely advice to, and interactive communication with, the sponsor regarding the development of the countermeasure to ensure that the development program to gather the nonclinical and clinical data necessary for
approval, licensure, clearance, or authorization is as efficient as practicable;

“(ii) involving senior managers and experienced review staff, as appropriate, in a collaborative, cross-disciplinary review;

“(iii) assigning a cross-disciplinary project lead for the review team to facilitate;

“(iv) taking steps to ensure that the design of the clinical trials is as efficient as practicable, when scientifically appropriate, such as by minimizing the number of patients exposed to a potentially less efficacious treatment; and

“(v) streamlining the review of approved, licensed, cleared, or authorized countermeasures to treat or prevent new or emerging threats, including the review of any changes to such countermeasures.

“(C) Expedited issuance of guidance documents and publication of other regulatory information regarding countermeasure development and manufacturing.

“(D) Other steps to expedite the development and review of a countermeasure applica-
tion submitted for approval, licensure, clearance, or authorization, as the Secretary determines appropriate.

“(3) LIMITATION OF EFFECT.—Nothing in this subsection shall be construed to require the Secretary to grant, or take any other action related to, a request of a sponsor to expedite the development and review of a countermeasure for approval, licensure, clearance, or authorization under paragraph (1).”.

SEC. 504. THIRD PARTY TEST EVALUATION DURING EMERGENCIES.

(a) IN GENERAL.—Section 565 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb–4), as amended by section 503, is further amended by adding at the end the following:

“(i) THIRD PARTY EVALUATION OF TESTS USED DURING AN EMERGENCY.—

“(1) IN GENERAL.—For purposes of conducting evaluations regarding whether an in vitro diagnostic product (as defined in section 809.3 of title 21, Code of Federal Regulations (or any successor regulations)) for which a request for emergency use authorization is submitted under section 564 meets the criteria for issuance of such authorization, the Sec-
retary may, as appropriate, consult with persons
with appropriate expertise with respect to such eval-
uations or enter into cooperative agreements or con-
tracts with such persons under which such persons
conduct such evaluations and make such rec-
ommendations, including, as appropriate, evaluations
and recommendations regarding the scope of author-
ization and conditions of authorization.

“(2) REQUIREMENTS REGARDING EVALUATIONS
AND RECOMMENDATIONS.—

“(A) IN GENERAL.—In evaluating and
making recommendations to the Secretary re-
grading the validity, accuracy, and reliability of
in vitro diagnostic products, as described in
paragraph (1), a person shall consider and doc-
ument whether the relevant criteria under sub-
section (c)(2) of section 564 for issuance of au-
thorization under such section are met with re-
spect to the in vitro diagnostic product.

“(B) WRITTEN RECOMMENDATIONS.—Re-
ommendations made by a person under this
subsection shall be submitted to the Secretary
in writing, and shall include the reasons for
such recommendation and other information
that may be requested by the Secretary.
“(3) RULE OF CONSTRUCTION.— Nothing in this subsection shall be construed to require the Secretary to consult with, or enter into cooperative agreements or contracts with, persons as described in paragraph (1) for purposes of authorizing an in vitro diagnostic product or otherwise affecting the emergency use authorization authorities under this section or section 564.”.

(b) GUIDANCE.—Not later than 1 year after the date of enactment of this Act, the Secretary of Health and Human Services (referred to in this subsection as the “Secretary”) shall issue draft guidance on consultations with persons under subsection (i) of section 565 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb–4), as added by subsection (a), including considerations concerning conflicts of interest, compensation arrangements, and information sharing. Not later than 1 year after the public comment period on such draft guidance ends, the Secretary shall issue a revised draft guidance or final guidance.

SEC. 505. FACILITATING THE USE OF REAL WORLD EVIDENCE.

Not later than 1 year after the date of enactment of this Act, the Secretary of Health and Human Services shall issue or revise existing guidance on considerations
for the use of real world data and real world evidence to support regulatory decision-making, as follows:

(1) With respect to drugs, such guidance shall address the use of such data and evidence to support the approval of a drug application under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) or a biological product application under section 351 of the Public Health Service Act (42 U.S.C. 262), or to support an investigational use exemption under section 505(i) of the Federal Food, Drug, and Cosmetic Act or section 351(a)(3) of the Public Health Service Act. Such guidance shall include considerations for the inclusion, in such applications, of real world data and real world evidence obtained as a result of the use of drugs authorized for emergency use under section 564 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb–3), and considerations for standards and methodologies for collection and analysis of real world evidence included in such applications, submissions, or requests, as appropriate.

(2) With respect to devices, such guidance shall address the use of such data and evidence to support the approval, clearance, or classification of a device pursuant to an application or submission submitted
under section 510(k), 513(f)(2), or 515 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360(k), 360c(f)(2), 360e), to support an investigational use exemption under section 520(g) of such Act (21 U.S.C. 360j(g)), or to support a determination by the Secretary for purposes of section 353 of the Public Health Service Act (42 U.S.C. 263a) (including the category described under subsection (d)(3) of such section). Such guidance shall include considerations for the inclusion, in such applications, submissions, or requests, of real world data and real world evidence obtained as a result of the use of devices authorized for emergency use under section 564 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb–3), including considerations related to a determination under section 353(d)(3) of the Public Health Service Act (42 U.S.C. 263a(d)(3)), and considerations for standards and methodologies for collection and analysis of real world evidence included in such applications, submissions, or requests, as appropriate.

SEC. 506. PLATFORM TECHNOLOGIES.

(a) In General.—Chapter V of the Federal Food, Drug, and Cosmetic Act is amended by inserting after section 506J of such Act (21 U.S.C. 356j) the following:
"SEC. 506K. PLATFORM TECHNOLOGIES.

(a) In General.—The Secretary shall establish a process for the designation of platform technologies that meet the criteria described in subsection (b).

(b) Criteria.—A platform technology incorporated within or utilized by a drug or biological product is eligible for designation as a designated platform technology under this section if—

(1) the platform technology is incorporated in, or utilized by, a drug approved under section 505 of this Act or a biological product licensed under section 351 of the Public Health Service Act;

(2) preliminary evidence submitted by the sponsor of the approved or licensed drug described in paragraph (1), or a sponsor that has been granted a right of reference to data submitted in the application for such drug, demonstrates that the platform technology has the potential to be incorporated in, or utilized by, more than one drug without an adverse effect on quality, manufacturing, or safety; and

(3) data or information submitted by the applicable person under paragraph (2) indicates that incorporation or utilization of the platform technology has a reasonable likelihood to bring signifi-
cant efficiencies to the drug development or manufacturing process and to the review process.

“(c) Request for Designation.—A person may request the Secretary designate a platform technology as a designated platform technology concurrently with, or at any time after, submission under section 505(i) of this Act or section 351(a)(3) of the Public Health Service Act for the investigation of a drug that incorporates or utilizes the platform technology that is the subject of the request.

“(d) Designation.—

“(1) In general.—Not later than 90 calendar days after the receipt of a request under subsection (c), the Secretary shall determine whether the platform technology that is the subject of the request meets the criteria described in subsection (b).

“(2) Designation.—If the Secretary determines that the platform technology meets the criteria described in subsection (b), the Secretary shall designate the platform technology as a designated platform technology and may expedite the development and review of any subsequent application submitted under section 505(b) of this Act or section 351(a) of the Public Health Service Act for a drug that uses or incorporates the platform technology pursuant to subsection (e), as appropriate.
“(3) Determination Not to Designate.—If the Secretary determines that the platform technology does not meet the criteria under subsection (b), the Secretary shall include with the determination not to designate the technology a written description of the rationale for such determination.

“(4) Revocation of Designation.—The Secretary may revoke a designation made under paragraph (2), if the Secretary determines that the designated platform technology no longer meets the criteria described in subsection (b). The Secretary shall communicate the determination to revoke a designation to the requesting sponsor in writing, including a description of the rationale for such determination.

“(5) Applicability.—Nothing in this section shall prevent a product that uses or incorporates a designated platform technology from being eligible for expedited approval pathways if it is otherwise eligible under this Act or the Public Health Service Act.

“(e) Actions.—The Secretary may take actions to expedite the development and review of an application for a drug that incorporates or utilizes a designated platform technology, including—
“(1) engaging in early interactions with the sponsor to discuss the use of the designated platform technology and what is known about such technology, including data previously submitted that is relevant to establishing, as applicable, safety or efficacy under section 505(b) of this Act or safety, purity, or potency under section 351(a) of the Public Health Service Act;

“(2) providing timely advice to, and interactive communication with, the sponsor regarding the development of the drug that proposes to use the designated platform technology to ensure that the development program designed to gather data necessary for approval or licensure is as efficient as practicable, which may include holding meetings with the sponsor and the review team throughout the development of the drug; and

“(3) considering inspectional findings, including prior findings, related to the manufacture of a drug that incorporates or utilizes the designated platform technology.

“(f) **Leveraging Data From Designated Platform Technologies.**—The Secretary shall, consistent with applicable standards for approval, authorization, or licensure under this Act and section 351(a) of the Public
Health Service Act, allow the sponsor of an application under section 505(b) of this Act or section 351(a) of the Public Health Service Act or a request for emergency use authorization under section 564, in order to support approval, licensure, or authorization, to reference or rely upon data and information within such application or request that incorporates or utilizes the same or substantially similar platform technology designated under subsection (d), provided that—

“(1) such data and information was submitted by the same sponsor, pursuant to the application for the drug with respect to which designation of the designated platform technology under subsection (d) was granted; or

“(2) the sponsor relying on such data and information received a right of reference to such data and information from the sponsor described in paragraph (1).

“(g) CHANGES TO A DESIGNATED PLATFORM TECHNOLOGY.—A sponsor of more than one application approved under section 505(b) of this Act or section 351(a) of the Public Health Service Act for drugs that incorporate or utilize the same designated platform technology may submit a single supplemental application for the same proposed changes to the designated platform technology
that is applicable to more than one drug that incorporates
or utilizes such designated platform technology. Such sup-
plemental application may be cross referenced in other ap-
plications incorporating such change and may include one
or more comparability protocols regarding how such
changes to the platform technology would be made for
each applicable application.

“(h) GUIDANCE.—Not later than 1 year after the
date of enactment of this section, the Secretary shall issue
draft guidance on the implementation of this section. Such
guidance shall include examples of drugs that can be man-
ufactured using platform technologies, including drugs
that contain or consist of vectors and nucleic acids, inform-
mation about the Secretary’s review of platform tech-
nologies, information regarding submitting for designa-
tion, consideration for persons submitting a request for
designation who has been granted a right of reference, the
implementation of the designated platform technology des-
ignation program, efficiencies that may be achieved in the
development and review of products that incorporate or
utilize designated platform technologies, and recommenda-
tions and requirements for making and reporting manu-
facturing changes to a designated platform technology in
accordance with section 506A.

“(i) DEFINITIONS.—For purposes of this section:
“(1) The term ‘platform technology’ means—

“(A) a technology incorporated into a drug
or biological product, such as a nucleic acid se-
quence, molecular structure, mechanism of ac-
tion, delivery method, vector, or other tech-
nology the Secretary determines to be appro-
priate, or combination of any such technologies,
that—

“(i) is essential to the characterization
of the drug or biological product; and

“(ii) can be adapted for, or incor-
porated or utilized in, more than one drug
or biological product sharing common
structural elements; or

“(B) a standardized production or manu-
facturing process that is used to create or de-
velop more than one drug sharing common
structural elements that can be incorporated
into multiple different drugs.

“(2) The term ‘designated platform technology’
means a platform technology that is designated as a
platform technology under subsection (d).

“(j) RULE OF CONSTRUCTION.—Nothing in this sec-
tion shall be construed to—
“(1) alter the authority of the Secretary to approve drugs pursuant to section 505 of this Act or license biological products pursuant to section 351 of the Public Health Service Act, including standards of evidence and applicable conditions for approval or licensure under the applicable Act; or

“(2) confer any new rights with respect to the permissibility of a sponsor of an application for a drug product or biological product referencing information contained in another application submitted by the holder of an approved application under section 505(c) of this Act or of a license under section 351(a) of the Public Health Service Act.”.

(b) REPORT.—Not later than 2 years after the date of enactment of this Act, the Secretary of Health and Human Services shall issue a report to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives, on the platform technology designation program under section 506K of the Federal Food, Drug, and Cosmetic Act, as added by subsection (a). Such report shall include—

(1) the number of requests for designation under such program;
(2) the number of designations under such program issued, active, and revoked;

(3) the resources required to carry out such program (including the review time used for full-time equivalent employees);

(4) any efficiencies gained in the development, manufacturing, and review processes associated with such designations; and

(5) recommendations, if any, to strengthen the program to better leverage platform technologies that can be used in more than one drug and meet patient needs in a manner as timely as possible, taking into consideration the resources available to the Secretary of Health and Human Services for carrying out such program.

SEC. 507. INCREASING EUA DECISION TRANSPARENCY.

Section 564(h)(1) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb–3(h)(1)) is amended—

(1) by inserting “on the internet website of the Food and Drug Administration and” after “promptly publish”; and

(2) by striking “application under section 505(i), 512(j), or 520(g), even if such summary may indirectly reveal the existence of such application” and inserting “application, request, or submission
under this section or section 505(b), 505(i), 505(j),
512(b), 512(j), 512(n), 515, 510(k), 513(f)(2),
520(g), 520(m), 571, or 572 of this Act, or section
351(a) or 351(k) of the Public Health Service Act,
even if such summary may reveal the existence of
such an application, request, or submission, or data
contained in such application, request, or submis-
sion”.

SEC. 508. IMPROVING FDA GUIDANCE AND COMMUNICA-
TION.

(a) FDA REPORT AND IMPLEMENTATION OF GOOD
GUIDANCE PRACTICES.—The Secretary of Health and
Human Services (referred to in this section as the “Sec-
retary”) shall develop, and publish on the website of the
Food and Drug Administration—

(1) a report identifying best practices for the
efficient prioritization, development, issuance, and
use of guidance documents, within centers, across
the Food and Drug Administration, and across other
applicable agencies; and

(2) a plan for implementation of such best
practices, including across other applicable agencies,
which shall address—
(A) streamlining development and review of guidance documents within centers and across the Food and Drug Administration;

(B) streamlining processes for regulatory submissions to the Food and Drug Administration, including through the revision or issuance of guidance documents; and

(C) implementing innovative guidance development processes and practices and transitioning or updating guidance issued during the COVID–19 public health emergency, as appropriate.

(b) Report and Implementation of FDA Best Practices for Communicating with External Stakeholders.—The Secretary, acting through the Commissioner of Food and Drugs, shall develop and publish on the website of the Food and Drug Administration a report on the practices of the Food and Drug Administration to broadly communicate with external stakeholders, other than through guidance documents, which shall include—

(1) a review of the types and methods of public communication that the Food and Drug Administration uses to communicate and interact with medical product sponsors and other external stakeholders;
(2) the identification of best practices for the efficient development, issuance, and use of such communications; and

(3) a plan for implementation of best practices for communication with external stakeholders, which shall address—

(A) advancing the use of innovative forms of communication, including novel document types and formats, to provide increased regulatory clarity to product sponsors and other stakeholders, and advancing methods of communicating and interacting with medical product sponsors and other external stakeholders, including the use of tools such as product submission templates, webinars, and frequently asked questions communications;

(B) streamlining processes for regulatory submissions; and

(C) implementing innovative communication development processes and transitioning or updating communication practices used during the COVID–19 public health emergency, as appropriate.

(c) CONSULTATION.—In developing and publishing the report and implementation plan under this section, the
Secretary shall consult with stakeholders, including researchers, academic organizations, pharmaceutical, biotechnology, and medical device developers, clinical research organizations, clinical laboratories, health care providers, patient groups, and other appropriate stakeholders.

(d) MANNER OF ISSUANCE.—For purposes of carrying out this section, the Secretary may update an existing report or plan, and may combine the reports and implementation plans described in subsections (a) and (b) into one or more documents.

(e) TIMING.—The Secretary shall—

(1) not later than 1 year after the date of enactment of this Act, publish a draft of the reports and plans required under this section; and

(2) not later than 180 days after publication of the draft reports and plans under paragraph (1)—

(A) publish a final report and plan; and

(B) begin implementation of the best practices pursuant to such final plan.

SEC. 509. GAO STUDY AND REPORT ON HIRING CHALLENGES AT FDA.

(a) IN GENERAL.—Not later than 18 months after the date of enactment of this Act, the Comptroller General of the United States shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and
the Committee on Energy and Commerce of the House of Representatives a report assessing the policies, practices, processes, and programs of the Food and Drug Administration with respect to hiring, recruiting, and retention, and the impact of such policies, practices, processes, and programs on the agency’s ability to carry out its public health mission, including the agency’s ability to respond to the COVID–19 public health emergency. Such report may involve policies, practices, processes, and programs of the Department of Health and Human Services and other agencies, as applicable.

(b) CONTENT OF REPORT.—The report required under subsection (a) shall include an assessment of—

(1) challenges related to the efficient hiring, recruiting, professional development, and retention of the Food and Drug Administration workforce, including, as applicable, the end-to-end hiring process, time to hire, multiple hiring authorities, salary levels, vacancy rates, and identification and availability of candidates with necessary expertise;

(2) causes of the challenges identified under paragraph (1), including an analysis of relevant policies, practices, processes, programs, organizational structure, resources, training, remote work capabilities, and data systems;
(3) challenges facing the Food and Drug Administration workforce, including with respect to workload, diversity, employee engagement, and morale;

(4) the impact of challenges identified under paragraphs (1) and (3) on operations of the Food and Drug Administration, including on meeting user fee agreement performance goals and inspection activities;

(5) any hiring or retention plans of the Food and Drug Administration, and progress towards implementation and the metrics to measure success of such plans;

(6) successful or efficient hiring policies or authorities, including any relevant hiring authorities that resulted in efficient hiring for vacant positions, such as temporary direct hiring authorities during the COVID–19 public health emergency response;

(7) whether policies, practices, processes, and programs related to hiring, recruiting, professional development, and retention are implemented consistently across the Food and Drug Administration;

(8) recommendations to address challenges identified, including recommendations regarding improvements to policies, practices, processes, and pro-
grams of the Food and Drug Administration with respect to hiring, recruiting, professional development, and retention; and

(9) challenges related to hiring, recruiting, and retaining a qualified workforce to meet public health emergency response needs, including any such challenges identified during the COVID–19 public health emergency.

Subtitle B—Mitigating Shortages

SEC. 511. ENSURING REGISTRATION OF FOREIGN DRUG AND DEVICE MANUFACTURERS.

(a) Registration of Certain Foreign Establishments.—Section 510(i) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360(i)) is amended by adding at the end the following:

“(5) The requirements of paragraphs (1) and (2) shall apply regardless of whether the drug or device undergoes further manufacture, preparation, propagation, compounding, or processing at a separate establishment outside the United States prior to being imported or offered for import into the United States.”.

(b) Updating Regulations.—Not later than 2 years after the date of enactment of this Act, the Secretary of Health and Human Services shall update regula-
ections, as appropriate, to implement the amendment made
by subsection (a).

SEC. 512. EXTENDING EXPIRATION DATES FOR CERTAIN
DRUGS.

(a) IN GENERAL.—Not later than 1 year after the
date of enactment of this Act, the Secretary of Health and
Human Services (referred to in this section as the “Sec-
retary”) shall issue draft guidance, or revise existing guid-
ance, to address recommendations for sponsors of applica-
tions submitted under section 505 of the Federal Food,
Drug, and Cosmetic Act (21 U.S.C. 355) or section 351
of the Public Health Service Act (42 U.S.C. 262) regard-
ing—

(1) the submission of stability testing data in
such applications, including considerations for data
requirements that could be streamlined or reduced
to facilitate faster review of longer proposed expira-
tion dates;

(2) establishing in the labeling of drugs the
longest feasible expiration date scientifically sup-
ported by such data, taking into consideration how
extended expiration dates may—

(A) help prevent or mitigate drug short-
ages; and

(B) affect product quality; and
(3) the use of innovative approaches for drug and combination product stability modeling to support initial product expiration dates and expiration date extensions.

(b) REPORT.—Not later than 2 years after the date of enactment of this Act, and again 2 years thereafter, the Secretary shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report that includes—

(1) the number of drugs for which the Secretary has requested the manufacturer make a labeling change regarding the expiration date; and

(2) for each drug for which the Secretary has requested a labeling change with respect to the expiration date, information regarding the circumstances of such request, including—

(A) the name and dose of such drug;

(B) the rationale for the request;

(C) whether the drug, at the time of the request, was listed on the drug shortage list under section 506E of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 356e), or was at risk of shortage;
(D) whether the request was made in connection with a public health emergency declared under section 319 of the Public Health Service Act (42 U.S.C. 247d); and

(E) whether the manufacturer made the requested change by the requested date, and for instances where the manufacturer does not make the requested change, the manufacturer’s justification for not making the change, if the manufacturer agrees to provide such justification for inclusion in the report.

SEC. 513. UNANNOUNCED FOREIGN FACILITY INSPECTIONS PILOT PROGRAM.

(a) In General.—The Secretary of Health and Human Services (referred to in this section as the “Secretary”) shall conduct a pilot program under which the Secretary increases the conduct of unannounced inspections of foreign human drug facilities and evaluates the differences between inspections of domestic and foreign human drug facilities, including the impact of announcing inspections to persons who own or operate foreign human drug facilities in advance of an inspection. Such pilot program shall evaluate—

(1) differences in the number and type of violations of section 501(a)(2)(B) of the Federal Food,
identified during unannounced and announced ins-
spections of foreign human drug facilities and any
other significant differences between each type of in-
spection;

(2) costs and benefits associated with con-
ducting announced and unannounced inspections of
foreign human drug facilities;

(3) barriers to conducting unannounced inspec-
tions of foreign human drug facilities and any chal-
lenges to achieving parity between domestic and for-
eign human drug facility inspections; and

(4) approaches for mitigating any negative ef-
teffects of conducting announced inspections of foreign
human drug facilities.

(b) PILOT PROGRAM INITIATION.—The Secretary
shall initiate the pilot program under this section not later
than 180 days after the date of enactment of this Act.

(c) REPORT.—The Secretary shall, not later than 180
days following the completion of the pilot program, make
available on the website of the Food and Drug Administra-
tion a final report on the pilot program under this section,
including—

(1) findings and any associated recommenda-
tions with respect to the evaluation under subsection
(a), including any recommendations to address identified barriers to conducting unannounced inspections of foreign human drug facilities;

(2) findings and any associated recommendations regarding how the Secretary may achieve parity between domestic and foreign human drug inspections; and

(3) the number of unannounced inspections during the pilot that would not be unannounced under existing practices.

SEC. 514. COMBATING COUNTERFEIT DEVICES.

(a) PROHIBITED ACTS.—Section 301 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331) is amended by adding at the end the following:

“(fff)(1) Forging, counterfeiting, simulating, or falsely representing, or without proper authority using any mark, stamp, tag, label, or other identification upon any device or container, packaging, or labeling thereof so as to render such device a counterfeit device.

“(2) Making, selling, disposing of, or keeping in possession, control, or custody, or concealing any punch, die, plate, stone, or other thing designed to print, imprint, or reproduce the trademark, trade name, or other identifying mark or imprint of another or any likeness of any of the foregoing upon any device or container, packaging, or la-
belonging thereof so as to render such device a counterfeit
device.

“(3) The doing of any act which causes a device to
be a counterfeit device, or the sale or dispensing, or the
holding for sale or dispensing, of a counterfeit device.”.

(b) PENALTIES.—Section 303 of the Federal Food,
Drug, and Cosmetic Act (21 U.S.C. 333) is amended—

(1) in subsection (b)(8), by inserting “, or who
violates section 301(fff)(3) by knowingly making,
selling or dispensing, or holding for sale or dis-

dispensing, a counterfeit device,” after “a counterfeit
drug”; and

(2) in subsection (c), by inserting “; or (6) for
having violated section 301(fff)(2) if such person
acted in good faith and had no reason to believe that
use of the punch, die, plate, stone, or other thing in-
volved would result in a device being a counterfeit
device, or for having violated section 301(fff)(3) if
the person doing the act or causing it to be done
acted in good faith and had no reason to believe that
the device was a counterfeit device” before the pe-

(c) SEIZURE.—Section 304(a)(2) of the Federal
Food, Drug, and Cosmetic Act (21 U.S.C. 334(a)(2)) is
amended—
(1) by striking “, and (E)” and inserting “,
(E)”; and

(2) by inserting “, (F) Any device that is a
counterfeit device, (G) Any container, packaging, or
labeling of a counterfeit device, and (H) Any punch,
die, plate, stone, labeling, container, or other thing
used or designed for use in making a counterfeit de-
vice or devices” before the period.

SEC. 515. STRENGTHENING MEDICAL DEVICE SUPPLY
CHAINS.

(a) IN GENERAL.—Section 506J of the Federal
Food, Drug, and Cosmetic Act (21 U.S.C. 356j) is amend-
ed—

(1) by redesignating subsections (h) and (i) as
subsections (j) and (k), respectively;

(2) by inserting after subsection (g) the fol-
lowing:

“(h) RISK MANAGEMENT PLANS.—Each manufac-
turer of a device that is critical to public health, including
devices that are life-supporting, life-sustaining, or in-
tended for use in emergency medical care, shall develop,
maintain, and, as appropriate, implement a redundancy
risk management plan that identifies and evaluates risks
to the supply of the device, as applicable, for each estab-
lishment in which such device is manufactured. A risk management plan under this subsection—

“(1) may identify and evaluate risks to the supply of more than one device, or device category, manufactured at the same establishment; and

“(2) shall be subject to inspection and copying by the Secretary pursuant to section 704 or at the request of the Secretary.”; and

(3) in subsection (j) as so redesignated, by adding at the end the following: “Nothing in this section shall be construed to affect the authority of the Secretary to require additional information to be included in a risk management plan pursuant to subsection (h) other than the information that is otherwise required to be included under such subsection.”.

(b) REPORT.—Not later than 2 years after the date of enactment of this Act, and annually thereafter, the Secretary of Health and Human Services shall prepare and submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report on the use of information manufacturers submit pursuant to section 506J of the Federal Food, Drug, and Cosmetic
Act (21 U.S.C. 356j) and applicable guidance issued with respect to such section.

SEC. 516. PREVENTING MEDICAL DEVICE SHORTAGES.

(a) NOTIFICATIONS.—Section 506J of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 356j), as amended by section 515, is further amended—

(1) in the flush text at the end of subsection (a)—

(A) by inserting “or any other circumstance” before “that is likely to lead”;

(B) by striking “or interruption.” and inserting “, interruption, or other circumstance.”;

(2) in subsection (b)(1), by striking “or interruption.” and inserting “, interruption, or other circumstance.”;

(3) in subsection (c)(1), by inserting “, or other circumstance,” after “manufacture of devices”;

(4) in subsection (f), by inserting “or (i)” after “subsection (a)”;

(5) by inserting after subsection (h), as added by section 515, the following:

“(i) ADDITIONAL NOTIFICATIONS.—The Secretary may receive voluntary notifications from a manufacturer of a device that is life-supporting, life-sustaining, or intended for use in emergency medical care or during sur-
gery, or any other device the Secretary determines to be critical to the public health, pertaining to a permanent discontinuance in the manufacture of the device (except for any discontinuance as a result of an approved modification of the device) or an interruption of the manufacture of the device that is likely to lead to a meaningful disruption in the supply of that device in the United States, and the reasons for such discontinuance or interruption.”.

(b) **Guidance on Voluntary Notifications of Discontinuance or Interruption of Device Manufacture.**—Not later than 1 year after the date of enactment of this Act, the Secretary shall issue draft guidance to facilitate voluntary notifications under subsection (i) of section 506J of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 356j), as added by subsection (a). Such guidance shall include a description of circumstances in which a voluntary notification under such subsection (i) may be appropriate, recommended timeframes for such a notification, the process for receiving such notifications, and actions the Secretary may take to mitigate or prevent a shortage resulting from a discontinuance or interruption in the manufacture of a device for which such notification is received. The Secretary shall issue final guidance not later than 1 year after the close of the comment period for the draft guidance.
(c) GUIDANCE ON DEVICE SHORTAGE NOTIFICATION REQUIREMENT.—Not later than 1 year after the date of enactment of this Act, the Secretary shall issue or revise draft guidance regarding requirements under section 506J of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 356j), as amended by this section and section 515. Such guidance shall include a list of each device product code for which a manufacturer of such device is required to notify the Secretary in accordance with section 506J.

SEC. 517. REMOTE RECORDS ASSESSMENTS FOR MEDICAL DEVICES.

(a) FACTORY INSPECTION.—Section 704(a)(4)(A) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 374(a)(4)(A)) is amended—

(1) in the first sentence, by inserting “or device” after “processing of a drug”; and

(2) in the second sentence, by striking “shall include” and all that follows through the period at the end and inserting the following: “shall include—

“(A) a description of the records requested; and

“(B) a rationale for requesting such information in advance of, or in lieu of, an inspection.”.
(b) Guidance.—Not later than 1 year after the date of enactment of this Act, the Secretary shall issue draft guidance describing circumstances in which the Secretary intends to issue requests for records or other information in advance of, or in lieu of, an inspection, processes for responding to such requests electronically or in physical form, and factors the Secretary intends to consider in evaluating whether such records are provided within a reasonable timeframe, within reasonable limits, and in a reasonable manner, accounting for resource and other limitations that may exist, including for small businesses. The Secretary shall issue final guidance not later than 1 year after the close of the comment period for the draft guidance.

SEC. 518. ADVANCED MANUFACTURING TECHNOLOGIES DESIGNATION PILOT PROGRAM.

Subchapter A of chapter V of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 351 et seq.), as amended by section 506, is further amended by inserting after section 506K the following:

“SEC. 506L. ADVANCED MANUFACTURING TECHNOLOGIES DESIGNATION PILOT PROGRAM.

“(a) In General.—Not later than 1 year after the date of enactment of this section, the Secretary shall initiate a pilot program under which persons may request
designation of an advanced manufacturing technology as
described in subsection (b).

“(b) DESIGNATION PROCESS.—The Secretary shall
establish a process for the designation under this section
of methods of manufacturing drugs, including biological
products, and active pharmaceutical ingredients of such
drugs, as advanced manufacturing technologies. A method
of manufacturing, or a combination of manufacturing
methods, is eligible for designation as an advanced manu-
facturing technology if such method or combination of
methods incorporates a novel technology, or uses an estab-
lished technique or technology in a novel way, that will
substantially—

“(1) enhance drug quality; or

“(2) improve the manufacturing process for a
drug and maintain drug quality, including by—

“(A) reducing development time for a drug
using the designated manufacturing method; or

“(B) increasing or maintaining the supply
of—

“(i) a drug that is life-supporting,
life-sustaining, or of critical importance to
providing health care; or

“(ii) a drug that is on the drug short-
age list under section 506E.
“(c) Evaluation and Designation of an Advanced Manufacturing Technology.—

“(1) Submission.—A person who requests designation of a method of manufacturing as an advanced manufacturing technology under this section shall submit to the Secretary data or information demonstrating that the method of manufacturing meets the criteria described in subsection (b) in a particular context of use. The Secretary may facilitate the development and review of such data or information by—

“(A) providing timely advice to, and interactive communication with, such person regarding the development of the method of manufacturing; and

“(B) involving senior managers and experienced staff of the Food and Drug Administration, as appropriate, in a collaborative, cross-disciplinary review of the method of manufacturing, as applicable.

“(2) Evaluation and Designation.—Not later than 180 calendar days after the receipt of a request under paragraph (1), the Secretary shall determine whether to designate such method of manufacturing as an advanced manufacturing technology,
in a particular context of use, based on the data and
information submitted under paragraph (1) and the
criteria described in subsection (b).

“(d) Review of Advanced Manufacturing
Technologies.—If the Secretary designates a method of
manufacturing as an advanced manufacturing technology,
the Secretary shall—

“(1) expedite the development and review of an
application submitted under section 505 of this Act
or section 351 of the Public Health Service Act, in-
cluding supplemental applications, for drugs that are
manufactured using a designated advanced manufac-
turing technology; and

“(2) allow the holder of an advanced technology
designation, or a person authorized by the advanced
manufacturing technology designation holder, to ref-
ference or rely upon, in an application submitted
under section 505 of this Act or section 351 of the
Public Health Service Act, including a supplemental
application, data and information about the des-
ignated advanced manufacturing technology for use
in manufacturing drugs in the same context of use
for which the designation was granted.

“(e) Implementation and Evaluation of Ad-
vanced Manufacturing Technologies Pilot.—
“(1) PUBLIC MEETING.—The Secretary shall publish in the Federal Register a notice of a public meeting, to be held not later than 180 days after the date of enactment of this section, to discuss, and obtain input and recommendations from relevant stakeholders regarding—

“(A) the goals and scope of the pilot program, and a suitable framework, procedures, and requirements for such program; and

“(B) ways in which the Food and Drug Administration will support the use of advanced manufacturing technologies and other innovative manufacturing approaches for drugs.

“(2) PILOT PROGRAM GUIDANCE.—

“(A) IN GENERAL.—The Secretary shall—

“(i) not later than 180 days after the public meeting under paragraph (1), issue draft guidance regarding the goals and implementation of the pilot program under this section; and

“(ii) not later than 2 years after the date of enactment of this section, issue final guidance regarding the implementation of such program.
“(B) CONTENT.—The guidance described in subparagraph (A) shall address—

“(i) the process by which a person may request a designation under subsection (b);

“(ii) the data and information that a person requesting such a designation is required to submit under subsection (c), and how the Secretary intends to evaluate such submissions;

“(iii) the process to expedite the development and review of applications under subsection (d); and

“(iv) the criteria described in subsection (b) for eligibility for such a designation.

“(3) REPORT.—Not later than 3 years after the date of enactment of this section and annually thereafter, the Secretary shall publish on the website of the Food and Drug Administration and submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report containing a description and evaluation of the pilot program being conducted under this sec-
tion, including the types of innovative manufacturing approaches supported under the program. Such report shall include the following:

“(A) The number of persons that have requested designations and that have been granted designations.

“(B) The number of methods of manufacturing that have been the subject of designation requests and that have been granted designations.

“(C) The average number of calendar days for completion of evaluations under subsection (c)(2).

“(D) An analysis of the factors in data submissions that result in determinations to designate and not to designate after evaluation under subsection (c)(2).

“(E) The number of applications received under section 505 of this Act or section 351 of the Public Health Service Act, including supplemental applications, that have included an advanced manufacturing technology designated under this section, and the number of such applications approved.

“(f) SUNSET.—The Secretary—
“(1) may not consider any requests for designation submitted under subsection (e) after October 1, 2029; and

“(2) may continue all activities under this section with respect to advanced manufacturing technologies that were designated pursuant to subsection (d) prior to such date, if the Secretary determines such activities are in the interest of the public health.”.

SEC. 519. TECHNICAL CORRECTIONS.

(a) Technical Corrections to the CARES Act.—Division A of the CARES Act (Public Law 116–136) is amended—

(1) in section 3111(1), by striking “in paragraph (1)” and inserting “in the matter preceding paragraph (1)”;

(2) in section 3112(d)(1), by striking “and subparagraphs (A) and (B)” and inserting “as subparagraphs (A) and (B)”;

(3) in section 3112(e), by striking “Federal Food, Drug, Cosmetic Act” and inserting “Federal Food, Drug, and Cosmetic Act”.

(b) Technical Corrections to the Federal Food, Drug, and Cosmetic Act Related to the CARES Act.—
(1) **SECTION 506C.**—Section 506C(a) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 356c(a)) is amended, in the flush text at the end, by striking the second comma after “in the United States”.

(2) **EFFECTIVE DATE.**—The amendment made by paragraph (1) shall take effect as if included in section 3112 of division A of the CARES Act (Public Law 116–136).